<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0409234121
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XELJANZ 5 mg film-coated tablet 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TOFACITINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3485.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AA29 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>XELJANZ is a medicine that contains the active substance tofacitinib.</p><p>&nbsp;</p><p>XELJANZ is used for the treatment of the following inflammatory diseases:</p><p>&middot;&nbsp; rheumatoid arthritis</p><p>&middot;&nbsp; psoriatic arthritis</p><p>&middot;&nbsp; ulcerative colitis</p><p>&middot;&nbsp; ankylosing spondylitis</p><p>&middot;&nbsp; polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis</p><p>&nbsp;</p><p><strong>Rheumatoid arthritis</strong></p><p>XELJANZ is used to treat adult patients with moderate to severe active rheumatoid arthritis, a long‑term disease that mainly causes pain and swelling of your joints.</p><p>&nbsp;</p><p>XELJANZ is used together with methotrexate when previous rheumatoid arthritis treatment was not sufficient or was not well tolerated. XELJANZ can also be taken on its own in those cases where methotrexate treatment is not tolerated or treatment with methotrexate is not advised.</p><p>&nbsp;</p><p>XELJANZ has been shown to reduce pain and swelling of the joints and improve the ability to perform daily activities, when given on its own or together with methotrexate.</p><p>&nbsp;</p><p><strong>Psoriatic arthritis</strong></p><p>XELJANZ is used to treat adult patients with a condition called psoriatic arthritis. This condition is an inflammatory disease of the joints, often accompanied by psoriasis. If you have active psoriatic arthritis you will be first given another medicine to treat your psoriatic arthritis. If you do not respond well enough or the medicine is not tolerated, you may be given XELJANZ to reduce the sign and symptoms of active psoriatic arthritis and improve the ability to perform daily activities.</p><p>&nbsp;</p><p>XELJANZ is used together with methotrexate to treat adult patients with active psoriatic arthritis.</p><p><u>&nbsp;</u></p><p><strong>Ankylosing spondylitis</strong></p><p>XELJANZ is used to treat a condition called ankylosing spondylitis. This condition is an inflammatory disease of the spine.</p><p>&nbsp;</p><p>If you have ankylosing spondylitis, you may first be given other medicines. If you do not respond well enough to these medicines, you will be given XELJANZ. XELJANZ can help to reduce back pain, and improve physical function. These effects can ease your normal daily activities and so improve your quality of life.</p><p>&nbsp;</p><p><strong>Ulcerative colitis</strong></p><p>Ulcerative colitis is an inflammatory disease of the large bowel. XELJANZ is used in adult patients to reduce the signs and symptoms of ulcerative colitis when you did not respond well enough or were intolerant to previous ulcerative colitis treatment.</p><p>&nbsp;</p><p><strong>Polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis</strong></p><p>XELJANZ is used for the treatment of active polyarticular juvenile idiopathic arthritis a long‑term disease that mainly causes pain and swelling of your joints, in patients 2 years of age and older.</p><p>&nbsp;</p><p>XELJANZ is also used for the treatment of juvenile psoriatic arthritis, a condition that is an inflammatory disease of the joints often accompanied by psoriasis, in patients 2 years of age and older.</p><p>&nbsp;</p><p>XELJANZ can be used together with methotrexate when previous treatment for polyarticular juvenile idiopathic arthritis or juvenile psoriatic arthritis was not sufficient or was not well tolerated. XELJANZ can also be taken on its own in those cases where methotrexate treatment is not tolerated or treatment with methotrexate is not advised.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>&nbsp;</em></p><p><strong>Do not take XELJANZ</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to tofacitinib or any of the other ingredients of this medicine (listed in section&nbsp;6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe infection such as bloodstream infection or active tuberculosis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have been informed that you have severe liver problems, including cirrhosis (scarring of the liver)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant or breast‑feeding</p><p>&nbsp;</p><p>If you are not sure regarding any of the information provided above, please contact your doctor.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking XELJANZ:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you think you have an infection or have symptoms of an infection such as fever, sweating, chills, muscle aches, cough, shortness of breath, new phlegm or change in phlegm, weight loss, warm or red or painful skin or sores on your body, difficulty or pain when swallowing, diarrhoea or stomach pain, burning when you urinate or urinating more often than normal, feeling very tired</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any condition that increases your chance of infection (e.g., diabetes, HIV/AIDS, or a weak immune system)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any kind of infection, are being treated for any infection, or if you have infections that keep coming back. Tell your doctor immediately if you feel unwell. XELJANZ can reduce your body&rsquo;s ability to respond to infections and may make an existing infection worse or increase the chance of getting a new infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or have a history of tuberculosis or have been in close contact with someone with tuberculosis. Your doctor will test you for tuberculosis before starting XELJANZ and may retest during treatment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have any chronic lung disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or had hepatitis B or hepatitis C (viruses that affect the liver). The virus may become active while you are taking XELJANZ. Your doctor may do blood tests for hepatitis before you start treatment with XELJANZ and while you are taking XELJANZ</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are 65&nbsp;years of age and older, if you have ever had any type of cancer, and also if you are a current or past smoker. XELJANZ may increase your risk of certain cancers. White blood cell cancer, lung cancer and other cancers (such as breast, skin, prostate and pancreatic) have been reported in patients treated with XELJANZ. If you develop cancer while taking XELJANZ your doctor will review whether to stop XELJANZ treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are at known risk of fractures, e.g., if you are 65&nbsp;years of age and older, you are a female, or take corticosteroids (e.g., prednisone).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cases of non-melanoma skin cancer have been observed in patients taking XELJANZ. Your doctor may recommend that you have regular skin examinations while taking XELJANZ. If new skin lesions appear during or after therapy or if existing lesions change appearance, tell your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had diverticulitis (a type of inflammation of the large intestine) or ulcers in stomach or intestines (see section 4)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have kidney problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are planning to get vaccinated, tell your doctor. Certain types of vaccines should not be given when taking XELJANZ. Before you start XELJANZ, you should be up to date with all recommended vaccinations. Your doctor will decide whether you need to have herpes zoster vaccination.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have heart problems, high blood pressure, high cholesterol, and also if you are a current or past smoker</p><p>&nbsp;</p><p>There have been reports of patients treated with XELJANZ who have developed blood clots in the lungs or veins. Your doctor will evaluate your risk to develop blood clots in the lungs or veins and determine if XELJANZ is appropriate for you. If you have already had problems on developing blood clots in lungs and veins or have an increased risk for developing this (for example: if you are seriously overweight, if you have cancer, heart problems, diabetes, experienced a heart attack (within previous 3 months), recent major surgery, if you use hormonal contraceptives\hormonal replacement therapy, if a coagulation defect is identified in you or your close relatives), if you are of older age, or if you smoke currently or in the past, your doctor may decide that XELJANZ is not suitable for you.</p><p>&nbsp;</p><p>Talk to your doctor straight away if you develop sudden shortness of breath or difficulty breathing, chest pain or pain in upper back, swelling of the leg or arm, leg pain or tenderness, or redness or discoloration in the leg or arm while taking XELJANZ, as these may be signs of a clot in the lungs or veins.</p><p>&nbsp;</p><p>Talk to your doctor straight away if you experience acute changes to your eyesight (blurry vision, partial or complete loss of vision), as this may be a sign of blood clots in the eyes.</p><p>&nbsp;</p><p>There have been reports of patients treated with XELJANZ who have had a heart problem, including heart attack. Your doctor will evaluate your risk to develop a heart problem and determine if XELJANZ is appropriate for you. Talk to your doctor straight away if you develop signs and symptoms of a heart attack including severe chest pain or tightness (that may spread to arms, jaw, neck, back), shortness of breath, cold sweat, light headedness or sudden dizziness.</p><p>&nbsp;</p><p><u>Additional monitoring tests</u></p><p>Your doctor should perform blood tests before you start taking XELJANZ, and after 4 to 8 weeks of treatment and then every 3 months, to determine if you have a low white blood cell (neutrophil or lymphocyte) count, or a low red blood cell count (anaemia).</p><p>&nbsp;</p><p>You should not receive XELJANZ if your white blood cell (neutrophil or lymphocyte) count or red blood cell count is too low. If needed, your doctor may interrupt your XELJANZ treatment to reduce the risk of infection (white blood cell counts) or anaemia (red blood cell counts).</p><p>&nbsp;</p><p>Your doctor may also perform other tests, for example to check your blood cholesterol levels or monitor the health of your liver. Your doctor should test your cholesterol levels 8 weeks after you start receiving XELJANZ. Your doctor should perform liver tests periodically.</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p>There is a higher rate of infections, some of which may be serious, in patients 65 years of age and older. Tell your doctor as soon as you notice any signs or symptoms of infections.</p><p>&nbsp;</p><p>Patients 65 years of age and older may be at increased risk of infections, heart attack and some types of cancer. Your doctor may decide that XELJANZ is not suitable for you.</p><p><strong>&nbsp;</strong></p><p><strong>Asian patients</strong></p><p>There is a higher rate of shingles in Japanese and Korean patients. Tell your doctor if you notice any painful blisters on your skin.</p><p>&nbsp;</p><p>You may also be at higher risk of certain lung problems. Tell your doctor if you notice any breathing difficulties.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>The safety and benefits of XELJANZ in children have not yet been established in patients less than 2&nbsp;years of age.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and XELJANZ</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Tell your doctor if you have diabetes or are taking medicines to treat diabetes. Your doctor may decide if you need less anti-diabetic medicine while taking tofacitinib.</p><p>&nbsp;</p><p>Some medicines should not be taken with XELJANZ. If taken with XELJANZ, they could alter the level of XELJANZ in your body, and the dose of XELJANZ may require adjustment. You should tell your doctor if you are using medicines that contain any of the following active substances:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics such as rifampicin, used to treat bacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fluconazole, ketoconazole, used to treat fungal infections</p><p>&nbsp;</p><p>XELJANZ is not recommended for use with medicines that depress the immune system, including so‑called targeted biologic (antibody) therapies, such as those that inhibit tumour necrosis factor, interleukin‑17, interleukin‑12/interleukin‑23, anti-integrins, and strong chemical immunosuppressants including azathioprine, mercaptopurine, ciclosporin, and tacrolimus. Taking XELJANZ with these medicines may increase your risk of side effects including infection.</p><p>&nbsp;</p><p>Serious infections and fractures may happen more often in people who also take corticosteroids (e.g., prednisone).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are a woman of childbearing age, you should use effective birth control during treatment with XELJANZ and for at least 4 weeks after the last dose.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. XELJANZ must not be used during pregnancy. Tell your doctor right away if you become pregnant while taking XELJANZ.</p><p>&nbsp;</p><p>If you are taking XELJANZ and breast-feeding, you must stop breast-feeding until you talk to your doctor about stopping treatment with XELJANZ.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>XELJANZ has no or limited effect on your ability to drive or use machines.</p><p>&nbsp;</p><p><strong>XELJANZ contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p><strong>XELJANZ contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine is provided to you and supervised by a specialised doctor who knows how to treat your condition.</p><p>&nbsp;</p><p>Always take this medicine exactly as your doctor has told you, the recommended dose should not be exceeded. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Rheumatoid arthritis</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 5&nbsp;mg twice a day.</p><p>&nbsp;</p><p><strong>Psoriatic arthritis</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 5&nbsp;mg twice a day.</p><p><strong>&nbsp;</strong></p><p>If you suffer from rheumatoid arthritis or psoriatic arthritis, your doctor may switch your tablets between XELJANZ 5&nbsp;mg film‑coated tablets twice daily and XELJANZ 11&nbsp;mg prolonged-release tablet once daily. You can start the XELJANZ prolonged‑release tablet once daily or XELJANZ film‑coated tablets twice daily on the day following the last dose of either tablet. You should not switch between XELJANZ film‑coated tablets and XELJANZ prolonged‑release tablet unless instructed by your doctor.</p><p>&nbsp;</p><p><strong>Ankylosing spondylitis</strong></p><ul><li>The recommended dose is 5&nbsp;mg twice a day.</li><li>Your doctor may decide to stop XELJANZ if XELJANZ does not work for you within 16&nbsp;weeks.</li></ul><p>&nbsp;</p><p><strong>Ulcerative colitis</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 10&nbsp;mg twice a day for 8&nbsp;weeks, followed by 5&nbsp;mg twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may decide to extend the initial 10&nbsp;mg twice a day treatment by an additional 8&nbsp;weeks (16 weeks in total), followed by 5&nbsp;mg twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may decide to stop XELJANZ if XELJANZ does not work for you within 16&nbsp;weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients, who have previously taken biologic medicines to treat ulcerative colitis (such as those that block the activity of tumour necrosis factor in the body) and these medicines did not work, the doctor may decide to increase your dose of XELJANZ to 10&nbsp;mg twice a day if you do not respond sufficiently to 5&nbsp;mg twice a day. Your doctor will consider the potential risks, including that of developing blood clots in the lungs or veins, and potential benefits to you. Your doctor will tell you if this applies to you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your treatment is interrupted, your doctor may decide to restart your treatment.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p><strong>&nbsp;</strong></p><p><strong>Polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is 5&nbsp;mg twice a day for patients &ge;40 kg.</p><p>&nbsp;</p><p>Try to take your tablet at the same time every day (one tablet in the morning and one tablet in the evening).</p><p>&nbsp;</p><p>Tofacitinib tablets may be crushed and taken with water.</p><p>&nbsp;</p><p>Your doctor may reduce the dose if you have liver or kidney problems or if you are prescribed certain other medicines. Your doctor may also stop treatment temporarily or permanently if blood tests show low white blood cell or red blood cell counts.</p><p>&nbsp;</p><p>XELJANZ is for oral use. You can take XELJANZ with or without food.</p><p>&nbsp;</p><p><strong>If you take more XELJANZ than you should</strong></p><p>If you take more tablets than you should, <strong>immediately </strong>tell your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take</strong> <strong>XELJANZ</strong></p><p>Do not take a double dose to make up for a forgotten tablet. Take your next tablet at the usual time and continue as before.</p><p>&nbsp;</p><p><strong>If you stop taking XELJANZ</strong></p><p>You should not stop taking XELJANZ without discussing this with your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Some may be serious and need medical attention.</p><p>&nbsp;</p><p>Side effects in patients with polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis were consistent with those seen in adult rheumatoid arthritis patients with the exception of some infections (influenza, pharyngitis, sinusitis, viral infection) and gastrointestinal or general disorders (abdominal pain, nausea, vomiting, fever, headache, cough), which were more common in juvenile idiopathic arthritis paediatric population.</p><p>&nbsp;</p><p><strong>Possible serious side effects </strong></p><p>In rare cases, infection may be life-threatening. Lung cancer, white blood cell cancer and heart attack have also been reported.</p><p><strong>&nbsp;</strong></p><p><strong>If</strong><strong> you notice any of the following </strong><strong>serious side effects</strong> <strong>you need to tell</strong><strong> a doctor straight away.</strong></p><p>&nbsp;</p><p><strong>Signs</strong><strong> of serious infections (common) include</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever and chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin blisters</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach ache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; persistent headaches</p><p>&nbsp;</p><p><strong>Signs of ulcers or holes (perforations) in your stomach (uncommon) include</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach or abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in the stool</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexplained changes in bowel habits</p><p><strong>&nbsp;</strong></p><p>Holes in stomach or intestines happen most often in people who also take nonsteroidal anti‑inflammatory drugs or corticosteroids (e.g., prednisone).</p><p>&nbsp;</p><p><strong>Signs of allergic reactions (unknown) include</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest tightness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wheezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe dizziness or light‑headedness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the lips, tongue or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hives (itching or skin rash)</p><p>&nbsp;</p><p><strong>Signs of blood clots in lungs or veins or eyes (uncommon: venous thromboembolism) include</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden shortness of breath or difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain or pain in upper back</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the leg or arm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leg pain or tenderness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness or discoloration in the leg or arm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute changes in eyesight</p><p>&nbsp;</p><p><strong>Signs of a heart attack (uncommon) include</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe chest pain or tightness (that may spread to arms, jaw, neck, back)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cold sweat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; light headedness or sudden dizziness</p><p>&nbsp;</p><p><strong>Other side effects</strong> which have been observed with XELJANZ are listed below.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people): lung infection (pneumonia and bronchitis), shingles (herpes zoster), infections of nose, throat or the windpipe (nasopharyngitis), influenza, sinusitis, urinary bladder infection (cystitis), sore throat (pharyngitis), increased muscle enzymes in the blood (sign of muscle problems), stomach (belly) pain (which may be from inflammation of the stomach lining), vomiting, diarrhoea, feeling sick (nausea), indigestion, low white blood cell counts, low red blood cell count (anaemia), swelling of the feet and hands, headache, high blood pressure (hypertension), cough, rash.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people): lung cancer, tuberculosis, kidney infection, skin infection, herpes simplex or cold sores (oral herpes), blood creatinine increased (a possible sign of kidney problems), increased cholesterol (including increased LDL), fever, fatigue (tiredness), weight gain, dehydration, muscle strain, tendonitis, joint swelling, joint sprain, abnormal sensations, poor sleep, sinus congestion, shortness of breath or difficulty breathing, skin redness, itching, fatty liver, painful inflammation of small pockets in the lining of your intestine (diverticulitis), viral infections, viral infections affecting the gut, some types of skin cancers (non-melanoma-types).</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people): blood infection (sepsis), lymphoma (white blood cell cancer), disseminated tuberculosis involving bones and other organs, other unusual infections, joint infections, increased liver enzymes in the blood (sign of liver problems), pain in the muscles and joints.</p><p>&nbsp;</p><p><strong>Very rare</strong> (may affect up to 1 in 10,000 people): tuberculosis involving the brain and spinal cord, meningitis, infection of the soft tissue and fascia.</p><p><strong>&nbsp;</strong></p><p>In general, fewer side effects were seen when XELJANZ was used alone than in combination with methotrexate in rheumatoid arthritis.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the bottle or carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in the original package in order to protect from moisture.</p><p>&nbsp;</p><p>Do not use this medicine if you notice the tablets show visible signs of deterioration (for example, are broken or discoloured).</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>XELJANZ 5&nbsp;mg film-coated tablet</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is tofacitinib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each 5&nbsp;mg film-coated tablet contains 5&nbsp;mg of tofacitinib (as tofacitinib citrate).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are microcrystalline cellulose, lactose monohydrate (see section 2 &ldquo;XELJANZ contains lactose&rdquo;), croscarmellose sodium (see section 2 &ldquo;XELJANZ contains sodium&rdquo;), magnesium stearate, hypromellose (E464), titanium dioxide (E171), macrogol, and triacetin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                XELJANZ 5 mg film-coated tablets
	XELJANZ 5 mg film-coated tablet is white and round in appearance.
	
The tablets are provided in bottles contain 60 tablets.
	
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Pfizer Inc. USA</p><p><strong>&nbsp;</strong></p><p><strong>Manufactured by </strong></p><p>Pfizer Manufacturing Deutschland GmbH</p><p>(Betriebsst&auml;tte Freiburg)</p><p>Freiburg, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                March 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">زيلجانز هو دواء يحتوي على المادة الفعالة توفاسيتينيب.</p><p>&nbsp;</p><p dir="RTL">يُستخدم زيلجانز لعلاج الأمراض الالتهابية التالية:</p><p dir="RTL">&middot;&nbsp; التهاب المفاصل الروماتويدي</p><p dir="RTL">&middot;&nbsp; التهاب المفاصل الصدفي</p><p dir="RTL">&middot;&nbsp; التهاب القولون التقرحي</p><p dir="RTL">&middot;&nbsp; التهاب الفقار المقسط</p><p dir="RTL">&middot;&nbsp; التهاب المفاصل اليفعي المتعدد مجهول السبب والتهاب المفاصل الصدفي اليفعي</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل الروماتويدي</strong></p><p dir="RTL">يُستخدم زيلجانز لعلاج المرضى البالغين المصابين بالتهاب المفاصل الروماتويدي النشط المتوسط إلى شديد الحدة، وهو مرض طويل الأمد يسبب بشكل رئيسي ألمًا وتورمًا في مفاصلك.</p><p>&nbsp;</p><p dir="RTL">يُستخدم زيلجانز مع ميثوتريكسات عندما يتضح أن العلاج السابق لالتهاب المفاصل الروماتويدي لم يكن كافيًا أو لم يتم تحمله بشكل جيد. يمكن أيضًا تناول زيلجانز بمفرده في تلك الحالات التي لا يتم فيها تحمل العلاج بميثوتريكسات أو التي لا ينصح فيها بالعلاج بميثوتريكسات.</p><p>&nbsp;</p><p dir="RTL">لقد ثبت أن زيلجانز يخفف ألم وتورم المفاصل ويحسن القدرة على أداء الأنشطة اليومية، عندما يُعطى بمفرده أو مع ميثوتريكسات.</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل الصدفي</strong></p><p dir="RTL">يُستخدم زيلجانز لعلاج المرضى البالغين المصابين بحالة تُسمى التهاب المفاصل الصدفي. وهذه الحالة هي مرض التهابي يصيب المفاصل، وعادةً ما يكون مصحوبًا بالصدفية. إذا كنت مصابًا بالتهاب المفاصل الصدفي النشط، فسيتم أولًا إعطاؤك دواءً آخر لعلاج التهاب المفاصل الصدفي. إذا لم تستجب بشكل كاف أو لم يتم تحمل الدواء، فقد يتم إعطاؤك زيلجانز لتقليل علامات وأعراض التهاب المفاصل الصدفي النشط ولتحسين القدرة على أداء الأنشطة اليومية.</p><p>&nbsp;</p><p dir="RTL">يُستخدم زيلجانز مع ميثوتريكسات لعلاج المرضى البالغين المصابين بالتهاب المفاصل الصدفي النشط.</p><p><u>&nbsp;</u></p><p dir="RTL"><strong>التهاب الفقار المقسط</strong></p><p dir="RTL">يُستخدم زيلجانز لعلاج حالة تُسمى التهاب الفقار المقسط. هذه الحالة هي مرض التهابي يصيب العمود الفقري.</p><p>&nbsp;</p><p dir="RTL">إذا كنت تعاني من التهاب الفقار المقسط، فقد تُعطى أدوية أخرى أولًا. إذا لم تستجب جيدًا بشكل كافٍ لتلك الأدوية، فستُعطى زيلجانز. قد يساعدك زيلجانز في تقليل ألم الظهر، ويحسن أداءك البدني. قد تسهل هذه الآثار القيام بالأنشطة اليومية المعتادة، وبذلك تحسن من نوعية الحياة.</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب القولون التقرحي</strong></p><p dir="RTL">التهاب القولون التقرحي هو مرض التهابي يصيب الأمعاء الغليظة. يستخدم زيلجانز مع المرضى البالغين لتقليل علامات وأعراض التهاب القولون التقرحي عندما لا تستجيب بشكل كاف للعلاج السابق لالتهاب القولون التقرحي أو لا تتحمله.</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل اليفعي المتعدد مجهول السبب والتهاب المفاصل الصدفي اليفعي</strong></p><p dir="RTL">يُستخدم زيلجانز لعلاج التهاب المفاصل اليفعي المتعدد مجهول السبب النشط، وهو مرض طويل الأمد يسبب بشكل رئيسي ألمًا وتورمًا في المفاصل في المرضى الذين يبلغون من العمر عامين وأكبر.</p><p>&nbsp;</p><p dir="RTL">يُستخدم زيلجانز أيضًا في علاج التهاب المفاصل الصدفي اليفعي، وهي حالة تُصاب فيها المفاصل بمرض التهابي يكون في الأغلب مصحوبًا بالصدفية لدى المرضى الذين يبلغون من العمر عامين وأكبر.</p><p>&nbsp;</p><p dir="RTL">يمكن استخدام زيلجانز مع ميثوتريكسات عندما يتضح أن العلاج السابق لالتهاب المفاصل اليفعي المتعدد مجهول السبب أو التهاب المفاصل الصدفي اليفعي لم يكن كافيًا أو لم يتم تحمله بشكل جيد. يمكن أيضًا تناول زيلجانز بمفرده في تلك الحالات التي لا يتم فيها تحمل العلاج بميثوتريكسات أو التي لا ينصح فيها بالعلاج بميثوتريكسات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><em>&nbsp;</em></p><p dir="RTL"><strong>موانع استعمال زيلجانز</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه توفاسيتينيب أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم ٦)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بعدوى شديدة مثل عدوى مجرى الدم أو مرض السل النشط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم إخبارك أنك مصاب بمشكلات شديدة في الكبد، بما في ذلك تليف الكبد (تندب الكبد)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من أي معلومة من المعلومات المقدمة أعلاه، يُرجى التواصل مع طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال زيلجانز</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول زيلجانز:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تظن أنك مصاب بعدوى أو لديك أعراض الإصابة بعدوى مثل الحمى، العرق، القشعريرة، آلام العضلات، السعال، ضيق التنفس، الإصابة حديثًا بالبلغم أو التغير في البلغم، فقدان الوزن، سخونة أو احمرار الجلد أو الشعور بألم فيه أو وجود قرح على جسمك، وجود صعوبة أو ألم عند البلع، الإسهال أو ألم البطن، الشعور بحرقة عند التبول أو التبول بمعدل أكثر من المعتاد، الشعور بالتعب الشديد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بأي حالة تزيد من فرصة إصابتك بعدوى (على سبيل المثال، داء السكري، أو فيروس نقص المناعة البشرية/الإيدز، أو ضعف جهاز المناعة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بأي نوع من أنواع العدوى، أو كنت تتلقى علاجًا لأي عدوى، أو كنت تعاني من تكرار الإصابة بالعدوى. أخبر طبيبك على الفور إذا شعرت بأنك لست على ما يرام. يمكن أن يقلل زيلجانز من قدرة جسمك على الاستجابة إلى حالات العدوى وقد يؤدي إلى تفاقم حالة عدوى موجودة بالفعل أو يزيد من فرصة الإصابة بعدوى جديدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض السل أو لديك تاريخ من الإصابة به أو خالطت عن كثب شخصًا مصابًا بمرض السل. سيخضعك طبيبك إلى اختبار للكشف عن إصابتك بمرض السل قبل البدء في العلاج بزيلجانز وقد يعيد إجراء الاختبار أثناء العلاج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بأي من أمراض الرئة المزمنة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أو سبق وأصبت بفيروس التهاب الكبد الوبائي B أو C (فيروسات تؤثر على الكبد). قد يصبح الفيروس نشطًا أثناء تناول زيلجانز. قد يُجري طبيبك فحوصات دم للتحقق من عدم الإصابة بالتهاب الكبد الوبائي قبل أن تبدأ العلاج بزيلجانز وأثناء تناول زيلجانز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تبلغ من العمر ٦٥ عامًا وأكثر، وإذا كنت مصابًا بأي نوع من أنواع السرطان، وأيضًا إذا كنت مدخنًا حاليًا أو فيما سبق. قد يزيد زيلجانز من خطر إصابتك بأنواع معينة من السرطانات. لقد تم الإبلاغ عن الإصابة بسرطان خلايا الدم البيضاء وسرطان الرئة وسرطانات أخرى (مثل سرطان الثدي، وسرطان الجلد، وسرطان البروستاتا، وسرطان البنكرياس) في المرضى الذين تم علاجهم بزيلجانز. إذا أصبت بسرطان أثناء تناول زيلجانز، فسيقوم طبيبك بالنظر فيما إذا كان ينبغي إيقاف العلاج به.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان معروفًا أنك معرض لخطر الكسور، أي إذا كنت ٦٥ عامًا وأكثر أو إذا كنتِ امرأة أو كنت تتناول الستيرويدات القشرية (مثل، بريدنيزون).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لوحظت حالات من سرطان جلد اللاميلانوما لدى مرضى يتناولون زيلجانز. قد يوصي طبيبك بإجراء فحوصات على الجلد بصورة منتظمة أثناء تناول زيلجانز. إذا ظهرت آفات جلدية جديدة أثناء العلاج أو بعده أو إذا تغير مظهر الآفات الموجودة، فأخبر طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بالتهاب الرتج (أحد أنواع الالتهابات التي تصيب الأمعاء الغليظة) أو بقرح في البطن أو الأمعاء (انظر القسم ٤)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في الكلى</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخطط لتلقي لقاح، فأخبر طبيبك.&nbsp; هناك أنواع معينة من اللقاحات ينبغي عدم إعطائها أثناء تناول زيلجانز. قبل أن تبدأ في تناول زيلجانز، ينبغي أن تكون قد تلقيت جميع اللقاحات الموصى بها حتى الوقت الحالي. سيقرر طبيبك ما إذا كنت بحاجة إلى أخذ لقاح الحزام الناري أم لا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في القلب، وضغط الدم المرتفع، وارتفاع الكوليسترول، وأيضًا إذا كنت مدخنًا حاليًا أو فيما سبق</p><p>&nbsp;</p><p dir="RTL">كانت هناك تقارير عن مرضى تم علاجهم بزيلجانز وأصيبوا بجلطات دموية في الرئتين أو الأوردة. سيقوم طبيبك بتقييم مخاطر إصابتك بجلطات دموية في الرئتين أو الأوردة وتحديد ما إذا كان زيلجانز مناسبًا لك. إذا كنت قد عانيت مسبقًا من مشكلات في تكوّن جلطات دموية في الرئتين والأوردة أو كنت معرضًا لخطر متزايد للإصابة بذلك (على سبيل المثال: إذا كنت تعاني من زيادة الوزن بشكل خطير، إذا كنت مصابًا بالسرطان، مشكلات في القلب، داء السكري، أو تعرضت لنوبة قلبية (خلال الثلاثة أشهر الماضية)، خضعت لعملية جراحية كبرى مؤخرًا، إذا كنتِ تستخدمين وسائل منع الحمل الهرمونية/العلاج بالهرمونات البديلة، إذا تم تحديد عيب في التخثر لديك أو لدى أقربائك المقربين)، أو إذا كنت كبيرًا في السن، أو إذا كنت تدخن حاليًا أو في الماضي، فإن طبيبك قد يقرر أن زيلجانز غير مناسب لك.</p><p>&nbsp;</p><p dir="RTL">تحدث إلى طبيبك على الفور إذا كنت تعاني من ضيق تنفس أو صعوبة في التنفس بشكل مفاجئ، أو ألم في الصدر أو ألم في أعلى الظهر، أو تورم في الساق أو الذراع، أو ألم أو إيلام في الساق، أو احمرار أو تغير لون الساق أو الذراع أثناء تناول زيلجانز، لأن هذه الأعراض قد تكون علامات على الإصابة بجلطة في الرئتين أو الأوردة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك على الفور إذا كنت تعاني من تغيرات حادة في إبصارك (رؤية ضبابية، فقدان رؤية جزئي أو كلي)، فقد يكون ذلك علامة على وجود جلطات دموية في العين.</p><p>&nbsp;</p><p dir="RTL">كانت هناك تقارير عن مرضى تم علاجهم بزيلجانز يعانون من مشكلات في القلب، بما في ذلك النوبة القلبية. سيقوم طبيبك بتقييم مخاطر إصابتك بمشكلة في القلب وتحديد ما إذا كان زيلجانز مناسبًا لك. تحدث إلى طبيبك على الفور إذا ظهرت عليك علامات وأعراض النوبة القلبية بما في ذلك ألم أو ضيق شديدين في الصدر (قد ينتشرا إلى الذراعين أو الفك أو الرقبة أو الظهر)، أو ضيق التنفس، أو العرق البارد، أو الدوخة، أو الدوار المفاجئ.</p><p>&nbsp;</p><p dir="RTL"><u>اختبارات المراقبة الإضافية</u></p><p dir="RTL">ينبغي أن يقوم طبيبك بإجراء فحوصات دم قبل أن تبدأ في تناول زيلجانز، وبعد مدة تتراوح بين ٤ و۸ أسابيع من العلاج ثم كل ۳ شهور، لتحديد ما إذا كنت تعاني من انخفاض تعداد خلايا الدم البيضاء (العدلات أو الليمفاويات)، أو انخفاض تعداد خلايا الدم الحمراء (فقر الدم).</p><p>&nbsp;</p><p dir="RTL">ينبغي ألا تتلقى زيلجانز إذا كان تعداد خلايا الدم البيضاء (العدلات أو الليمفاويات) أو تعداد خلايا الدم الحمراء لديك منخفضًا بشدة. إذا لزم الأمر، قد يوقف طبيبك علاجك بزيلجانز لتقليل خطر الإصابة بالعدوى (تعداد خلايا الدم البيضاء) أو فقر الدم (تعداد خلايا الدم الحمراء).</p><p>&nbsp;</p><p dir="RTL">قد يقوم طبيبك أيضًا بإجراء اختبارات أخرى، على سبيل المثال لتفقد مستويات الكوليسترول في دمك أو لمراقبة صحة كبدك. ينبغي أن يقوم طبيبك بإجراء اختبار لقياس مستويات الكوليسترول لديك بعد ۸ أسابيع من بدء تلقي زيلجانز. ينبغي أن يقوم طبيبك بإجراء اختبارات على الكبد بصورة دورية.</p><p>&nbsp;</p><p dir="RTL"><strong>المسنون</strong></p><p dir="RTL">يرتفع معدل الإصابة بالعدوى، وقد يكون بعضها خطيرًا، في المرضى الذين يبلغون من العمر ٦٥ عامًا وأكبر. أخبر طبيبك في أقرب وقت ممكن عندما تلاحظ أيًا من علامات أو أعراض العدوى.</p><p>&nbsp;</p><p dir="RTL">قد يكون المرضى الذين يبلغون من العمر ٦٥ عامًا فأكبر هم الأكثر عرضة للإصابة بالعدوى والنوبات القلبية وبعض أنواع السرطانات. قد يقرر طبيبك أن زيلجانز غير مناسب لك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>المرضي الآسيويون</strong></p><p dir="RTL">يرتفع معدل الإصابة بالهربس النطاقي في المرضى اليابانيين والكوريين. أخبر طبيبك إذا لاحظت أي بثور مؤلمة على جلدك.</p><p>&nbsp;</p><p dir="RTL">&nbsp;قد تكون أيضًا أكثر عرضة لخطر الإصابة بمشكلات رئوية معينة. أخبر طبيبك إذا لاحظت أي صعوبات في التنفس.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لم يتم إثبات سلامة وفوائد زيلجانز بعد في الأطفال المرضى الذين يبلغون من العمر أقل من عامين.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تعاني من داء السكري أو تتناول أدوية لعلاج داء السكري. قد يقرر طبيبك ما إذا كنت بحاجة إلى تناول جرعة أقل من الدواء المضاد لداء السكري أثناء تناول توفاسيتينيب.</p><p>&nbsp;</p><p dir="RTL">توجد بعض الأدوية التي ينبغي عدم تناولها مع زيلجانز. وإذا تم تناولها مع زيلجانز، فقد تغير من مستوى زيلجانز في جسمك، وقد يلزم تعديل جرعة زيلجانز. ينبغي أن تخبر طبيبك إذا كنت تستخدم أدوية تحتوي على أي من المواد الفعالة التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية مثل ريفامبيسين، المستخدم لعلاج حالات العدوى البكتيرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول، كيتوكونازول، المستخدمان لعلاج حالات العدوى الفطرية</p><p>&nbsp;</p><p dir="RTL">لا يوصى باستخدام زيلجانز مع الأدوية التي تثبط جهاز المناعة، بما في ذلك ما يسمى بالعلاجات الحيوية المستهدِفة (الأجسام المضادة)، مثل تلك العلاجات التي تثبط عامل نخر الورم، وإنترلوكين‑۱٧، وإنترلوكين‑۱۲/إنترلوكين‑۲۳، ومضادات إنتجرين، ومثبطات المناعة الكيميائية القوية بما في ذلك آزاثيوبرين، ومركابتوبورين وسيكلوسبورين، وتاكروليموس. قد يؤدي تناول زيلجانز مع هذه الأدوية إلى زيادة خطر إصابتك بالأعراض الجانبية بما في ذلك العدوى.</p><p>&nbsp;</p><p dir="RTL">قد تقع حالات العدوى الخطيرة والكسور بصورة أكثر من المعتاد في الأشخاص الذين يتناولون الستيرويدات القشرية أيضًا (مثل، بريدنيزون).</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ امرأة في سن الإنجاب، ينبغي أن تستخدمي وسيلة فعالة لمنع الحمل أثناء العلاج بزيلجانز ولمدة ٤ أسابيع على الأقل بعد آخر جرعة.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ قبل تناول هذا الدواء. يجب عدم استخدام زيلجانز أثناء الحمل. أخبري طبيبكِ فورًا إذا أصبحتِ حاملًا أثناء تناول زيلجانز.</p><p>&nbsp;</p><p dir="RTL">إذا كنتِ تتناولين زيلجانز وترضعين رضاعة طبيعية، يجب عليكِ التوقف عن الرضاعة الطبيعية حتى تتحدثي مع طبيبكِ بشأن إيقاف العلاج بزيلجانز.</p><p>&nbsp;</p><p dir="RTL"><strong>تأثير زيلجانز على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يوجد تأثير لزيلجانز أو له تأثير طفيف للغاية على قدرتك على القيادة أو استخدام الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي زيلجانز على اللاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك بأنك لا تتحمل بعض أنواع السكريات، فتواصل معه قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي زيلجانز على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من ۱ مليمول من الصوديوم (۲۳ ملجم) لكل قرص، أي أنه يعد &quot;خاليًا من الصوديوم&quot; تقريبًا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم توفير هذا الدواء لك تحت إشراف طبيب متخصص يعرف كيفية علاج حالتك.</p><p>&nbsp;</p><p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك، ولا تتجاوز الجرعة الموصى بها. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا مما ينبغي لك فعله.</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل الروماتويدي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي ٥ ملجم مرتين في اليوم.</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب المفاصل الصدفي</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الجرعة الموصى بها هي ٥ ملجم مرتين في اليوم.</p><p><strong>&nbsp;</strong></p><p dir="RTL">إذا كنت تعاني من التهاب المفاصل الروماتويدي أو التهاب المفاصل الصدفي، فقد يبدّل طبيبك بين أقراص زيلجانز ٥ ملجم المغلفة بطبقة رقيقة مرتين يوميًا وأقراص زيلجانز ۱۱ ملجم ممتدة المفعول مرة واحدة يوميًا. يمكنك بدء تناول قرص زيلجانز ممتد المفعول مرة واحدة يوميًا أو قرصي زيلجانز المغلفين بطبقة رقيقة مرتين يوميًا في اليوم التالي للجرعة الأخيرة من أي من الدواءين. ينبغي ألا تُبدل بين قرصي زيلجانز المغلفين بطبقة رقيقة وقرص زيلجانز ممتد المفعول إلا بتعليمات من طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>التهاب الفقار المقسط</strong></p><ul><li dir="RTL">الجرعة الموصى بها هي ٥ ملجم مرتين في اليوم.</li><li dir="RTL">قد يقرر طبيبك إيقاف زيلجانز إذا لم ينجح زيلجانز معك خلال ۱٦ أسبوعًا.</li></ul><p>&nbsp;</p><p dir="RTL"><strong>التهاب القولون التقرحي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي ۱۰ ملجم مرتين في اليوم لمدة ۸ أسابيع، يليها ٥ ملجم مرتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقرر طبيبك تمديد فترة العلاج المبدئي، التي يتم فيها تناول ۱۰ ملجم مرتين في اليوم، لـ۸ أسابيع إضافية (۱٦ أسبوعًا في المجمل)، يليها ٥ ملجم مرتين اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يقرر طبيبك إيقاف زيلجانز إذا لم ينجح زيلجانز معك خلال ۱٦ أسبوعًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالنسبة للمرضى، الذين تناولوا في السابق أدوية حيوية لعلاج التهاب القولون التقرحي (مثل تلك التي تمنع نشاط عامل نخر الورم في الجسم) ولم تنجح هذه الأدوية، فقد يقرر الطبيب زيادة جرعتك من زيلجانز إلى ۱۰ ملجم مرتين في اليوم إذا لم تستجب بشكل كافٍ إلى العلاج بتناول ٥ ملجم مرتين في اليوم. سيأخذ طبيبك الفوائد والمخاطر المحتملة بعين الاعتبار، بما في ذلك الإصابة بجلطات دموية في الرئتين أو الأوردة. سيخبرك طبيبك إذا كان هذا ينطبق عليك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة إيقاف العلاج، قد يقرر طبيبك بدء العلاج من جديد.</p><p>&nbsp;</p><p dir="RTL"><strong>الاستخدام مع الأطفال والمراهقين</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>التهاب المفاصل اليفعي المتعدد مجهول السبب والتهاب المفاصل الصدفي اليفعي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي ٥ ملجم مرتين في اليوم للمرضى الذين يزنون ٤۰ كلجم أو أكثر.</p><p>&nbsp;</p><p dir="RTL">حاول أن تتناول قرصك في الوقت نفسه كل يوم (قرص واحد في الصباح وقرص واحد في المساء).</p><p>&nbsp;</p><p dir="RTL">يمكن سحق أقراص توفاسيتينيب وتناولها مع الماء.</p><p>&nbsp;</p><p dir="RTL">قد يقلل طبيبك الجرعة إذا كنت تعاني من مشكلات في الكبد أو الكلى أو إذا تم وصف بعض الأدوية الأخرى لك. وأيضًا، قد يقوم طبيبك بإيقاف العلاج بشكل مؤقت أو دائم إذا أظهرت فحوصات الدم انخفاض تعداد خلايا الدم البيضاء أو خلايا الدم الحمراء.</p><p>&nbsp;</p><p dir="RTL">يؤخذ زيلجانز عن طريق الفم. ويمكنك تناول زيلجانز مع الطعام أو دونه.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من زيلجانز</strong></p><p dir="RTL">إذا أخذت عدد أقراص أكثر مما ينبغي، فأخبر طبيبك أو الصيدلي فورًا.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>نسيان تناول جرعة زيلجانز</strong></p><p dir="RTL">لا تتناول جرعة مزدوجة لتعويض القرص الذي نسيته. تناول القرص التالي في الوقت المعتاد ثم استمر كما سبق.</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول زيلجانز</strong></p><p dir="RTL">ينبغي ألا تتوقف عن تناول زيلجانز دون مناقشة ذلك مع طبيبك.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، قد يسبب هذا الدواء أعراضًا جانبية، غير أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL">وقد يكون بعضها خطيرًا ويستلزم رعاية طبية.</p><p>&nbsp;</p><p dir="RTL">كانت الأعراض الجانبية في المرضى المصابين بالتهاب المفاصل اليفعي المتعدد مجهول السبب والتهاب المفاصل الصدفي اليفعي متسقة مع تلك التي ظهرت في مرضى التهاب المفاصل الروماتويدي من البالغين، باستثناء بعض حالات العدوى (الإنفلونزا، التهاب البلعوم، التهاب الجيوب الأنفية، العدوى الفيروسية) والاضطرابات المعدية المعوية أو الاضطرابات العامة (آلام البطن، الغثيان، القيء، الحمى، الصداع، السعال)، التي كانت أكثر شيوعًا عند الأطفال المصابين بالتهاب المفاصل اليفعي مجهول السبب.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة المحتملة</strong></p><p dir="RTL">في حالات نادرة، قد تكون العدوى مهددة للحياة.</p><p>&nbsp;</p><p dir="RTL">تم الإبلاغ أيضًا عن الإصابة بسرطان الرئة وسرطان خلايا الدم البيضاء والنوبات القلبية.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا لاحظت أيًا مما يلي من الأعراض الجانبية الخطيرة، يجب أن تخبر طبيبًا فورًا.</strong></p><p>&nbsp;</p><p dir="RTL"><strong>تتضمن علامات العدوى الخطيرة (شائعة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى والقشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بثور الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع المستمر</p><p>&nbsp;</p><p dir="RTL"><strong>تتضمن علامات القرح أو الثقوب (الانثقاب) في بطنك (غير شائعة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ألم في المعدة أو البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;وجود دم في البراز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات غير مبررة في عادات التبرز لديك</p><p><strong>&nbsp;</strong></p><p dir="RTL">تحدث الثقوب في البطن أو الأمعاء في معظم الأحيان في الأشخاص الذين يتناولون أيضًا مضادات الالتهاب غير الستيرويدية أو الستيرويدات القشرية (مثل، بريدنيزون).</p><p>&nbsp;</p><p dir="RTL"><strong>تتضمن علامات تفاعلات الحساسية (غير شائعة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأزيز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الدوار أو الدوخة الشديدان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الشفتين، أو اللسان، أو الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى (الحكة أو الطفح جلدي)</p><p>&nbsp;</p><p dir="RTL"><strong>تتضمن علامات وجود جلطات دموية في الرئتين أو الأوردة أو العينين (غير شائعة: الانصمام الخثاري الوريدي)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس أو صعوبة في التنفس بشكل مفاجئ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر أو في أعلى الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الساقين أو الذراعين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو إيلام الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الساق أو الذراع أو تغير لونهما</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات حادة في الإبصار</p><p>&nbsp;</p><p dir="RTL"><strong>تتضمن علامات النوبة القلبية (غير شائعة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق أو ألم شديدان في الصدر (قد ينتشرا إلى الذراعين أو الفك أو الرقبة أو الظهر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق البارد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة أو الدوار المفاجئ</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong> التي تمت ملاحظتها مع زيلجانز مذكورة أدناه.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص): العدوى الرئوية (الالتهاب الرئوي والالتهاب الشعبي)، الهربس النطاقي (الحزام الناري)، حالات العدوى التي تصيب الأنف أو الحلق أو القصبة الهوائية (التهاب الأنف والبلعوم)، الإنفلونزا، التهاب الجيوب الأنفية، عدوى المثانة البولية (التهاب المثانة)، التهاب الحلق (التهاب البلعوم)، زيادة إنزيمات العضلات في الدم (علامة تدل على وجود مشكلات في العضلات)، ألم المعدة (البطن) (الذي قد يكون بسبب التهاب بطانة المعدة)، القيء، الإسهال، الشعور برغبة في التقيؤ (الغثيان)، سوء الهضم، انخفاض تعداد خلايا الدم البيضاء، انخفاض تعداد خلايا الدم الحمراء (فقر الدم)، تورم القدمين واليدين، الصداع، ضغط الدم المرتفع، السعال، الطفح الجلدي.</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰ شخص): سرطان الرئة، السل، عدوى الكلى، عدوى الجلد، الهربس البسيط أو قرح البرد (الهربس الفموي)، زيادة الكرياتينين في الدم (علامة محتملة على الإصابة بمشكلات في الكلى)، زيادة الكوليسترول (بما في ذلك زيادة البروتين الشحمي منخفض الكثافة( (LDL)، الحمى، الإرهاق (التعب)، زيادة الوزن، الجفاف، الإجهاد العضلي، التهاب الأوتار، تورم المفاصل، التواء المفاصل، أحاسيس غير طبيعية، سوء جودة النوم، التهاب الجيوب الأنفية، ضيق التنفس أو صعوبات في التنفس، احمرار الجلد، الحكة، الكبد الدهني، التهاب مؤلم في الجيوب الصغيرة في بطانة أمعائك (التهاب الرتج)، حالات العدوى الفيروسية، حالات العدوى الفيروسية التي تؤثر على الأمعاء، بعض أنواع سرطانات الجلد (أنواع السرطان غير الميلانيني).</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰ شخص): عدوى الدم (الإنتان)، سرطان الغدد الليمفاوية (سرطان خلايا الدم البيضاء)، السل المنتشر في العظام والأعضاء الأخرى، حالات العدوى الأخرى غير المعتادة، عدوى المفاصل، زيادة إنزيمات الكبد في الدم (علامة على وجود مشكلات في الكبد)، ألم في العضلات والمفاصل.</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة جدًا</strong> (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰۰ شخص): السل المنتشر في الدماغ والحبل الشوكي، التهاب السحايا، عدوى النسيج الرخو واللفافة.</p><p><strong>&nbsp;</strong></p><p dir="RTL">بشكل عام، كانت الأعراض الجانبية التي تم رصدها عند استخدام زيلجانز بمفرده أقل من تلك التي تم رصدها عند استخدامه بالتزامن مع ميثوتريكسات في علاج التهاب المفاصل الروماتويدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أُصبت بأي أعراض جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الأعراض الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><ul><li dir="RTL"><strong>المملكة العربية السعودية</strong></li></ul><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL">مركز الاتصال الموحد: ۱۹۹۹۹</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><ul><li dir="RTL"><strong>دول الخليج الأخرى</strong></li></ul><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp; </em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">يتم تخزينه في درجة حرارة أقل من ۳۰ درجة مئوية.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على القنينة أو العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">خزّنه في عبوته الأصلية لحمايته من الرطوبة.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أن الأقراص بها علامات تلف واضحة (على سبيل المثال، مكسورة أو تغير لونها).</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>أقراص زيلجانز ٥ ملجم المغلفة بطبقة رقيقة</u></p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي توفاسيتينيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل قرص <u>٥</u> ملجم مغلف بطبقة رقيقة على <u>٥</u> ملجم توفاسيتينيب (في صورة توفاسيتينيب سيتريت).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي السليلوز دقيق التبلور، واللاكتوز أحادي الهيدرات (انظر القسم ۲ &quot;يحتوي زيلجانز على اللاكتوز&quot;)، وكروسكارميلوز الصوديوم (انظر القسم ۲ &quot;يحتوي زيلجانز على الصوديوم&quot;)، وسترات المغنيسيوم، وهيبروميلوز (E464)، وثاني أكسيد التيتانيوم (E171)، وماكروجول، وثلاثي الأستين.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>أقراص زيلجانز ٥ ملجم المغلفة بطبقة رقيقة</u></p><p dir="RTL">أقراص زيلجانز ٥ ملجم المغلفة بطبقة رقيقة هي أقراص بيضاء اللون دائرية الشكل.</p><p>&nbsp;</p><p dir="RTL">يتم توفير الأقراص في عبوات بلاستيكية تحتوي على ٦۰ &nbsp;قرصًا.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك تصريح التسويق</strong></p><p dir="RTL">Pfizer Inc. USA، الولايات المتحدة الأمريكية</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>&rlm;الشركة الصانعة</strong></p><p>&rlm;Pfizer Manufacturing Deutschland GmbH</p><p>(Betriebsst&auml;tte Freiburg)</p><p>، ألمانيا Freiburg</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مارس 2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XELJANZ 5 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XELJANZ 5 mg film coated tablets

Each film-coated tablet contains tofacitinib citrate, equivalent to 5 mg tofacitinib.

Excipient with known effect
Each film coated tablet contains 59.44 mg of lactose.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)

XELJANZ 5 mg film coated tablets

White, round tablet of 7.9 mm diameter, debossed “Pfizer” on one side and “JKI 5” on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Rheumatoid arthritis</u></p><p>Tofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section&nbsp;5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections&nbsp;4.4 and 4.5).</p><p>&nbsp;</p><p><u>Psoriatic arthritis</u></p><p>Tofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease‑modifying antirheumatic drug (DMARD) therapy (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Ankylosing spondylitis</u></p><p>Tofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy.</p><p>&nbsp;</p><p><u>Ulcerative colitis</u></p><p>Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).</p><p>&nbsp;</p><p><u>Juvenile idiopathic arthritis (JIA)</u></p><p>Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with DMARDs.</p><p>&nbsp;</p><p>Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditions for which tofacitinib is indicated.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Rheumatoid arthritis and psoriatic arthritis</u></em></p><p>&nbsp;</p><p>The recommended dose is 5&nbsp;mg film-coated tablets administered twice daily, which should not be exceeded.</p><p>&nbsp;</p><p>No dose adjustment is required when used in combination with MTX.</p><p><u>&nbsp;</u></p><p>For information on switching between tofacitinib film-coated tablets and tofacitinib prolonged‑release tablets see Table 1.</p><p>&nbsp;</p><p><strong>Table 1: Switching between tofacitinib film-coated tablets and tofacitinib prolonged‑release tablets</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td style="vertical-align:top"><p>Switching between tofacitinib 5&nbsp;mg film‑coated tablets and tofacitinib 11&nbsp;mg prolonged‑release tablet<sup>a</sup></p></td><td style="vertical-align:top"><p>Treatment with tofacitinib 5&nbsp;mg film‑coated tablets twice daily and tofacitinib 11&nbsp;mg prolonged‑release tablet once daily may be switched between each other on the day following the last dose of either tablet.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>a</sup> See section 5.2 for comparison of pharmacokinetics of prolonged-release and film-coated formulations.</p></td></tr></tbody></table><p><em><u>&nbsp;</u></em></p><p><em><u>Ankylosing spondylitis</u></em></p><p><strong>&nbsp;</strong></p><p>The recommended dose of tofacitinib is 5&nbsp;mg administered twice daily.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Ulcerative colitis</u></em></p><p><u>&nbsp;</u></p><p><em>Induction treatment</em></p><p>The recommended dose is 10&nbsp;mg given orally twice daily for induction for 8&nbsp;weeks.</p><p>&nbsp;</p><p>For patients who do not achieve adequate therapeutic benefit by week 8, the induction dose of 10&nbsp;mg twice daily can be extended for an additional 8 weeks (16 weeks total), followed by 5 mg twice daily for maintenance. Tofacitinib induction therapy should be discontinued in any patient who shows no evidence of therapeutic benefit by week&nbsp;16.</p><p>&nbsp;</p><p><em>Maintenance treatment</em></p><p>The recommended dose for maintenance treatment is tofacitinib 5&nbsp;mg given orally twice daily.</p><p>&nbsp;</p><p>Tofacitinib 10&nbsp;mg twice daily for maintenance treatment is not recommended in patients with UC who have known venous thromboembolism (VTE), major adverse cardiovascular events&nbsp;(MACE) and malignancy risk factors, unless there is no suitable alternative treatment available (see section 4.4 and 4.8).</p><p>&nbsp;</p><p>For patients with UC who are not at increased risk for VTE, MACE and malignancy (see section 4.4), tofacitinib 10&nbsp;mg orally twice daily may be considered if the patient experiences a decrease in response on tofacitinib 5&nbsp;mg twice daily and failed to respond to alternative treatment options for ulcerative colitis such as tumour necrosis factor inhibitor (TNF inhibitor) treatment. Tofacitinib 10 mg twice daily for maintenance treatment should be used for the shortest duration possible. The lowest effective dose needed to maintain response should be used.</p><p>&nbsp;</p><p>In patients who have responded to treatment with tofacitinib, corticosteroids may be reduced and/or discontinued in accordance with standard of care.</p><p>&nbsp;</p><p><em>Retreatment in UC</em></p><p>If therapy is interrupted, restarting treatment with tofacitinib can be considered. If there has been a loss of response, reinduction with tofacitinib 10&nbsp;mg twice daily may be considered. The treatment interruption period in clinical studies extended up to 1 year. Efficacy may be regained by 8&nbsp;weeks of 10&nbsp;mg twice daily therapy (see section 5.1).</p><p>&nbsp;</p><p><em><u>Polyarticular JIA and juvenile PsA (children between 2 and 18 years of age)</u></em></p><p>&nbsp;</p><p>Tofacitinib may be used as monotherapy or in combination with MTX.</p><p>&nbsp;</p><p>The recommended dose in patients 2 years of age and older is based upon the following weight categories:</p><p>&nbsp;</p><p><strong>Table 2: Tofacitinib dose for patients with polyarticular juvenile idiopathic arthritis and juvenile PsA two years of age and older</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Body weight (kg)</strong></p></td><td><p><strong>Dose regimen</strong></p></td></tr><tr><td><p>10 ‑ &lt;&nbsp;20</p></td><td><p>3.2 mg (3.2 mL of oral solution) twice daily</p></td></tr><tr><td><p>20 ‑ &lt;&nbsp;40</p></td><td><p>4 mg (4 mL of oral solution) twice daily</p></td></tr><tr><td><p>&ge;&nbsp;40</p></td><td><p>5 mg (5 mL of oral solution or 5 mg film-coated tablet) twice daily</p></td></tr></tbody></table><p>&nbsp;</p><p>Patients &nbsp;40 kg treated with tofacitinib 5 mL oral solution twice daily may be switched to tofacitinib 5&nbsp;mg film‑coated<em> </em>tablets twice daily. Patients &lt;&nbsp;40 kg cannot be switched from tofacitinib oral solution.</p><p>&nbsp;</p><p><u>Dose interruption and discontinuation</u><u> in adults and paediatric patients</u><u> </u></p><p><u>&nbsp;</u></p><p>Tofacitinib treatment should be interrupted if a patient develops a serious infection until the infection is controlled.</p><p>&nbsp;</p><p>Interruption of dosing may be needed for management of dose-related laboratory abnormalities including lymphopenia, neutropenia, and anaemia. As described in Tables&nbsp;3, 4 and 5 below, recommendations for temporary dose interruption or permanent discontinuation of treatment are made according to the severity of laboratory abnormalities (see section&nbsp;4.4).</p><p>&nbsp;</p><p>It is recommended not to initiate dosing in patients with an absolute lymphocyte count (ALC) less than 750&nbsp;cells/mm<sup>3</sup>.</p><p>&nbsp;</p><p><strong>Table&nbsp;3:&nbsp;&nbsp; Low absolute lymphocyte count</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Low absolute lymphocyte count (ALC) (see section&nbsp;4.4)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory value</strong></p><p><strong>(cells/mm<sup>3</sup>)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendation</strong></p></td></tr><tr><td style="vertical-align:top"><p>ALC greater than or equal to&nbsp;750</p></td><td style="vertical-align:top"><p>Dose should be maintained.</p></td></tr><tr><td style="vertical-align:top"><p>ALC 500-750</p></td><td style="vertical-align:top"><p>For persistent (2&nbsp;sequential values in this range on routine testing) decrease in this range, dosing should be reduced or interrupted.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>For patients receiving tofacitinib 10&nbsp;mg twice daily, dosing should be reduced to tofacitinib 5&nbsp;mg twice daily.</p><p>&nbsp;</p><p>For patients receiving tofacitinib 5&nbsp;mg twice daily, dosing should be interrupted.</p><p>&nbsp;</p><p>When ALC is greater than&nbsp;750, treatment should be resumed as clinically appropriate.</p></td></tr><tr><td style="vertical-align:top"><p>ALC less than 500</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>If laboratory value confirmed by repeat testing within 7&nbsp;days, dosing should be discontinued.</p></td></tr></tbody></table><p>&nbsp;</p><p>It is recommended not to initiate dosing in adult patients with an absolute neutrophil count (ANC) less than 1,000&nbsp;cells/mm<sup>3</sup>. It is recommended not to initiate dosing in paediatric patients with an absolute neutrophil count (ANC) less than 1,200&nbsp;cells/mm<sup>3</sup>.</p><p>&nbsp;</p><p><strong>Table&nbsp;4:&nbsp;&nbsp; Low absolute neutrophil count</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Low absolute neutrophil count (ANC) (see section&nbsp;4.4)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory Value</strong></p><p><strong>(cells/mm<sup>3</sup>)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendation</strong></p></td></tr><tr><td style="vertical-align:top"><p>ANC greater than&nbsp;1,000</p></td><td style="vertical-align:top"><p>Dose should be maintained.</p></td></tr><tr><td style="vertical-align:top"><p>ANC&nbsp;500-1,000</p></td><td style="vertical-align:top"><p>For persistent (2&nbsp;sequential values in this range on routine testing) decreases in this range, dosing should be reduced or interrupted.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>For patients receiving tofacitinib 10&nbsp;mg twice daily, dosing should be reduced to tofacitinib 5&nbsp;mg twice daily.</p><p>&nbsp;</p><p>For patients receiving tofacitinib 5&nbsp;mg twice daily, dosing should be interrupted.</p><p>&nbsp;</p><p>When ANC is greater than&nbsp;1,000, treatment should be resumed as clinically appropriate.</p></td></tr><tr><td style="vertical-align:top"><p>ANC less than&nbsp;500</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>If laboratory value confirmed by repeat testing within 7&nbsp;days, dosing should be discontinued.</p></td></tr></tbody></table><p>&nbsp;</p><p>It is recommended not to initiate dosing in adult patients with haemoglobin less than 9&nbsp;g/dL. It is recommended not to initiate dosing in paediatric patients with haemoglobin less than 10&nbsp;g/dL.</p><p>&nbsp;</p><p><strong>Table&nbsp;5:&nbsp;&nbsp; Low haemoglobin value</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Low haemoglobin value (see section&nbsp;4.4)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory value</strong></p><p><strong>(g/dL)</strong></p></td><td style="vertical-align:top"><p><strong>Recommendation</strong></p></td></tr><tr><td style="vertical-align:top"><p>Less than or equal to 2&nbsp;g/dL decrease and greater than or equal to 9.0&nbsp;g/dL</p></td><td style="vertical-align:top"><p>Dose should be maintained.</p></td></tr><tr><td style="vertical-align:top"><p>Greater than 2&nbsp;g/dL decrease or less than 8.0&nbsp;g/dL</p><p>(confirmed by repeat testing)</p></td><td style="vertical-align:top"><p>Dosing should be interrupted until haemoglobin values have normalised.</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Interactions</u></em></p><p><em><u>&nbsp;</u></em></p><p>Tofacitinib total daily dose should be reduced by half in patients receiving potent inhibitors of cytochrome P450 (CYP) 3A4 (e.g., ketoconazole) and in patients receiving 1 or more concomitant medicinal products that result in both moderate inhibition of CYP3A4 as well as potent inhibition of CYP2C19 (e.g., fluconazole) (see section&nbsp;4.5) as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tofacitinib dose should be reduced to 5&nbsp;mg once daily in patients receiving 5&nbsp;mg twice daily (adult and paediatric patients).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tofacitinib dose should be reduced to 5&nbsp;mg twice daily in patients receiving 10&nbsp;mg twice daily (adult patients).</p><p>&nbsp;</p><p>Only in paediatric patients: available data suggest that clinical improvement is observed within 18 weeks of initiation of treatment with tofacitinib. Continued therapy should be carefully reconsidered in a patient exhibiting no clinical improvement within this timeframe.</p><p>&nbsp;</p><p><u>Dose discontinuation in AS </u></p><p><u>&nbsp;</u></p><p>Available data suggest that clinical improvement in AS is observed within 16&nbsp;weeks of initiation of treatment with tofacitinib. Continued therapy should be carefully reconsidered in a patient exhibiting no clinical improvement within this timeframe.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Elderly</em></p><p>&nbsp;</p><p>No dose adjustment is required in patients 65&nbsp;years of age and older. There are limited data in patients aged 75&nbsp;years and older. See section 4.4 for Use in patients 65 years of age and older.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>&nbsp;</p><p><strong>Table 6: &nbsp;&nbsp; Dose adjustment for hepatic impairment </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td style="vertical-align:top"><p><strong>Hepatic impairment category</strong></p></td><td style="vertical-align:top"><p><strong>Classification</strong></p></td><td style="vertical-align:top"><p><strong>Dose adjustment in hepatic impairment for different strength tablets</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>Child Pugh A</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>Child Pugh B</p></td><td style="vertical-align:top"><p>Dose should be reduced to 5&nbsp;mg once daily when the indicated dose in the presence of normal hepatic function is 5&nbsp;mg twice daily.</p><p>&nbsp;</p><p>Dose should be reduced to 5&nbsp;mg twice daily when the indicated dose in the presence of normal hepatic function is 10&nbsp;mg twice daily (see section&nbsp;5.2).</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>Child Pugh C</p></td><td style="vertical-align:top"><p>Tofacitinib should not be used in patients with severe hepatic impairment (see section 4.3).</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Renal impairment</em></p><p>&nbsp;</p><p><strong>Table 7: &nbsp;&nbsp; Dose adjustment for renal impairment </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><thead><tr><td style="vertical-align:top"><p><strong>Renal impairment category</strong></p></td><td style="vertical-align:top"><p><strong>Creatinine clearance</strong></p></td><td style="vertical-align:top"><p><strong>Dose adjustment in renal impairment for different strength tablets</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50-80&nbsp;mL/min</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30-49&nbsp;mL/min</p></td><td style="vertical-align:top"><p>No dose adjustment required.</p></td></tr><tr><td style="vertical-align:top"><p>Severe (including patients undergoing haemodialysis)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;30&nbsp;mL/min</p></td><td style="vertical-align:top"><p>Dose should be reduced to 5&nbsp;mg once daily when the indicated dose in the presence of normal renal function is 5&nbsp;mg twice daily.</p><p>&nbsp;</p><p>Dose should be reduced to 5&nbsp;mg twice daily when the indicated dose in the presence of normal renal function is 10&nbsp;mg twice daily.</p><p>&nbsp;</p><p>Patients with severe renal impairment should remain on a reduced dose even after haemodialysis (see section&nbsp;5.2).</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Pediatric population</em></p><p>&nbsp;</p><p>The safety and efficacy of tofacitinib in children less than 2 years of age with polyarticular JIA and juvenile PsA has not been established. No data are available.</p><p>&nbsp;</p><p>The safety and efficacy of tofacitinib in children less than 18 years of age with other indications (e.g., ulcerative colitis) has not been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral use.</p><p>&nbsp;</p><p>Tofacitinib is given orally with or without food.</p><p>&nbsp;</p><p>For patients who have difficulties swallowing, tofacitinib tablets may be crushed and taken with water.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Active tuberculosis (TB), serious infections such as sepsis, or opportunistic infections (see section 4.4).
•	Severe hepatic impairment (see section 4.2).
•	Pregnancy and lactation (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td style="vertical-align:top"><p>Tofacitinib should only be used if no suitable treatment alternatives are available in patients:</p><p>-65 years of age and older;</p><p>-patients with history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as current or past long-time smokers);</p><p>-patients with malignancy risk factors (e.g. current malignancy or history of malignancy)</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Use in patients 65&nbsp;years of age and older</u></p><p>&nbsp;</p><p>Considering the increased risk of serious infections, myocardial infarction, malignancies and all cause mortality with tofacitinib in patients 65&nbsp;years of age and older, tofacitinib should only be used in these patients if no suitable treatment alternatives are available (see further details below in section 4.4 and section 5.1).</p><p><u>&nbsp;</u></p><p><u>Combination with other therapies</u></p><p>&nbsp;</p><p>Tofacitinib has not been studied and its use should be avoided in combination with biologics such as TNF antagonists, interleukin (IL)-1R antagonists, IL-6R antagonists, anti-CD20 monoclonal antibodies, IL‑17 antagonists, IL‑12/IL‑23 antagonists, anti-integrins, selective co-stimulation modulators and potent immunosuppressants such as azathioprine, 6-mercaptopurine, ciclosporin and tacrolimus because of the possibility of increased immunosuppression and increased risk of infection.</p><p>&nbsp;</p><p>There was a higher incidence of adverse events for the combination of tofacitinib with MTX versus tofacitinib as monotherapy in RA clinical studies.</p><p>&nbsp;</p><p>The use of tofacitinib in combination with phosphodiesterase 4 inhibitors has not been studied in tofacitinib clinical studies.</p><p>&nbsp;</p><p><u>Venous thromboembolism (VTE) </u></p><p>&nbsp;</p><p>Serious VTE events including pulmonary embolism (PE), some of which were fatal, and deep vein thrombosis (DVT), have been observed in patients taking tofacitinib. In a randomised post‑authorisation safety study in patients with rheumatoid arthritis who were 50&nbsp;years of age or older with at least one additional cardiovascular risk factor, a dose dependent increased risk for VTE was observed with tofacitinib compared to TNF inhibitors (see sections 4.8 and 5.1).</p><p>&nbsp;</p><p>In a post hoc exploratory analysis within this study, in patients with known VTE risk factors, occurrences of subsequent VTEs were observed more frequently in tofacitinib-treated patients that, at 12 months treatment, had D-dimer level &ge;2&times; ULN versus those with D-dimer level &lt;2&times; ULN; this was not evident in TNF inhibitor‑treated patients. Interpretation is limited by the low number of VTE events and restricted D‑dimer test availability (only assessed at Baseline, Month 12, and at the end of the study). In patients who did not have a VTE during the study, mean D-dimer levels were significantly reduced at Month 12 relative to Baseline across all treatment arms. However, D-dimer levels &ge;2&times; ULN at Month 12 were observed in approximately 30% of patients&nbsp;without subsequent VTE events, indicating limited specificity of D‑Dimer testing in this study.</p><p>&nbsp;</p><p>Tofacitinib 10&nbsp;mg twice daily for maintenance treatment is not recommended in patients with UC who have known VTE, MACE and malignancy risk factors, unless there is no suitable alternative treatment available (see section 4.2).</p><p>&nbsp;</p><p>In patients with cardiovascular or malignancy risk factors (see also section 4.4 &ldquo;Major adverse cardiovascular events (MACE)&rdquo; and &ldquo;Malignancy&rdquo;) tofacitinib should only be used if no suitable treatment alternatives are available.</p><p>&nbsp;</p><p>In patients with VTE risk factors other than MACE or malignancy risk factors, tofacitinib should be used with caution. VTE risk factors other than MACE or malignancy risk factors include previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, inherited coagulation disorder. Patients should be re-evaluated periodically during tofacitinib treatment to assess for changes in VTE risk.</p><p>&nbsp;</p><p>For patients with RA with known risk factors for VTE, consider testing D-dimer levels after&nbsp;approximately 12 months of treatment. If D-dimer test result is &ge; 2&times; ULN, confirm that clinical benefits outweigh risks prior to a decision on treatment continuation with tofacitinib.</p><p>&nbsp;</p><p>Promptly evaluate patients with signs and symptoms of VTE and discontinue tofacitinib in patients with suspected VTE, regardless of dose or indication.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Retinal venous thrombosis</u></em></p><p>&nbsp;</p><p>Retinal venous thrombosis (RVT) has been reported in patients treated with tofacitinib (see section 4.8). The patients should be advised to promptly seek medical care in case they experience symptoms suggestive of RVT.</p><p>&nbsp;</p><p><u>Serious infections</u></p><p>&nbsp;</p><p>Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib (see section 4.8). The risk of opportunistic infections is higher in Asian geographic regions (see&nbsp;section&nbsp;4.8). Rheumatoid arthritis patients taking corticosteroids may be predisposed to infection.</p><p>&nbsp;</p><p>Tofacitinib should not be initiated in patients with active infections, including localised infections.</p><p><strong><u>&nbsp;</u></strong></p><p>The risks and benefits of treatment should be considered prior to initiating tofacitinib in patients:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with recurrent infections,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with a history of a serious or an opportunistic infection,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have resided or travelled in areas of endemic mycoses,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have underlying conditions that may predispose them to infection.</p><p>&nbsp;</p><p>Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with tofacitinib. Treatment should be interrupted if a patient develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new infection during treatment with tofacitinib should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient, appropriate antimicrobial therapy should be initiated, and the patient should be closely monitored.</p><p>&nbsp;</p><p>As there is a higher incidence of infections in the elderly and in the diabetic populations in general, caution should be used when treating the elderly and patients with diabetes (see section&nbsp;4.8). In patients 65&nbsp;years of age and older, tofacitinib should only be used if no suitable treatment alternatives are available (see section 5.1).</p><p><u>&nbsp;</u></p><p>Risk of infection may be higher with increasing degrees of lymphopenia and consideration should be given to lymphocyte counts when assessing individual patient risk of infection. Discontinuation and monitoring criteria for lymphopenia are discussed in section&nbsp;4.2.</p><p><u>&nbsp;</u></p><p><u>Tuberculosis</u></p><p>&nbsp;</p><p>The risks and benefits of treatment should be considered prior to initiating tofacitinib in patients:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have been exposed to TB,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who have resided or travelled in areas of endemic TB.</p><p>&nbsp;</p><p>Patients should be evaluated and tested for latent or active infection prior to and per applicable guidelines during administration of tofacitinib.</p><p>&nbsp;</p><p>Patients with latent TB, who test positive, should be treated with standard antimycobacterial therapy before administering tofacitinib.</p><p>&nbsp;</p><p>Antituberculosis therapy should also be considered prior to administration of tofacitinib in patients who test negative for TB but who have a past history of latent or active TB and where an adequate course of treatment cannot be confirmed; or those who test negative but who have risk factors for TB infection. Consultation with a healthcare professional with expertise in the treatment of TB is recommended to aid in the decision about whether initiating antituberculosis therapy is appropriate for an individual patient. Patients should be closely monitored for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.</p><p>&nbsp;</p><p><u>Viral reactivation</u></p><p>&nbsp;</p><p>Viral reactivation and cases of herpes virus reactivation (e.g., herpes zoster) have been observed in patients receiving tofacitinib (see section 4.8).</p><p>&nbsp;</p><p>In patients treated with tofacitinib, the incidence of herpes zoster appears to be increased in:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japanese or Korean patients.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with an ALC less than 1,000&nbsp;cells/mm<sup>3</sup> (see section&nbsp;4.2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with long standing RA who have previously received two or more biological disease modifying antirheumatic drugs (DMARDs).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients treated with 10&nbsp;mg twice daily.</p><p>&nbsp;</p><p>The impact of tofacitinib on chronic viral hepatitis reactivation is unknown. Patients screened positive for hepatitis B or C were excluded from clinical studies. Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy with tofacitinib.</p><p><u>&nbsp;</u></p><p><u>Major adverse cardiovascular events (including myocardial infarction)</u></p><p>&nbsp;</p><p>Major adverse cardiovascular events (MACE) have been observed in patients taking tofacitinib.</p><p>&nbsp;</p><p>In a randomised post authorisation safety study in patients with RA who were 50&nbsp;years of age or older with at least one additional cardiovascular risk factor, an increased incidence of myocardial infarctions was observed with tofacitinib compared to TNF inhibitors (see sections 4.8 and 5.1). In patients 65&nbsp;years of age and older, patients who are current or past long-time smokers, and patients with history of atherosclerotic cardiovascular disease or<em> </em>other cardiovascular risk factors, tofacitinib should only be used if no suitable treatment alternatives are available (see section 5.1).</p><p>&nbsp;</p><p><u>Malignancies </u><u>and lymphoproliferative disorder</u></p><p>&nbsp;</p><p>Tofacitinib may affect host defences against malignancies.</p><p>&nbsp;</p><p>In a randomised post authorisation safety study in patients with RA who were 50&nbsp;years of age or older with at least one additional cardiovascular risk factor, an increased incidence of malignancies, particularly NMSC, lung cancer and lymphoma, was observed with tofacitinib compared to TNF inhibitors (see sections 4.8 and 5.1).</p><p>&nbsp;</p><p>NMSC lung cancers and lymphoma in patients treated with tofacitinib have also been observed in other clinical studies and in the post marketing setting.</p><p>&nbsp;</p><p>Other malignancies in patients treated with tofacitinib were observed in clinical studies and the post‑marketing setting, including, but not limited to, breast cancer, melanoma, prostate cancer, and pancreatic cancer.</p><p>&nbsp;</p><p>In patients 65&nbsp;years of age and older, patients who are current or past long-time smokers, and patients with other malignancy risk factors (e.g. current malignancy or history of malignancy other than a successfully treated non-melanoma skin cancer) tofacitinib should only be used if no suitable treatment alternatives are available (see section 5.1). Periodic skin examination is recommended for all patients, particularly those who are at increased risk for skin cancer (see Table&nbsp;8 in section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Interstitial lung disease </u></p><p>&nbsp;</p><p>Caution is also recommended in patients with a history of chronic lung disease as they may be more prone to infections. Events of interstitial lung disease (some of which had a fatal outcome) have been reported in patients treated with tofacitinib in RA clinical studies and in the post-marketing setting although the role of Janus kinase (JAK) inhibition in these events is not known. Asian RA patients are known to be at higher risk of interstitial lung disease, thus caution should be exercised in treating these patients.</p><p><u>&nbsp;</u></p><p><u>Gastrointestinal perforations</u></p><p>&nbsp;</p><p>Events of gastrointestinal perforation have been reported in clinical studies although the role of JAK inhibition in these events is not known. Tofacitinib should be used with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis, patients with concomitant use of corticosteroids and/or nonsteroidal anti-inflammatory drugs). Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of gastrointestinal perforation.</p><p><u>&nbsp;</u></p><p><u>Fractures </u></p><p>&nbsp;</p><p>Fractures have been observed in patients treated with tofacitinib.</p><p>&nbsp;</p><p>Tofacitinib should be used with caution in patients with known risk factors for fractures such as elderly patients, female patients and patients with corticosteroid use, regardless of indication and dosage.</p><p><u>&nbsp;</u></p><p><u>Liver enzymes</u></p><p>&nbsp;</p><p>Treatment with tofacitinib was associated with an increased incidence of liver enzyme elevation in some patients (see section 4.8 liver enzyme tests). Caution should be exercised when considering initiation of tofacitinib treatment in patients with elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST), particularly when initiated in combination with potentially hepatotoxic medicinal products such as MTX. Following initiation, routine monitoring of liver tests and prompt investigation of the causes of any observed liver enzyme elevations are recommended to identify potential cases of drug-induced liver injury. If drug-induced liver injury is suspected, the administration of tofacitinib should be interrupted until this diagnosis has been excluded.</p><p><u>&nbsp;</u></p><p><u>Hypersensitivity</u></p><p>&nbsp;</p><p>In post‑marketing experience, cases of hypersensitivity associated with tofacitinib administration have been reported. Allergic reactions included angioedema and urticaria; serious reactions have occurred. If any serious allergic or anaphylactic reaction occurs, tofacitinib should be discontinued immediately.</p><p><u>&nbsp;</u></p><p><u>Laboratory parameters</u></p><p><em>&nbsp;</em></p><p><em><u>Lymphocytes</u></em></p><p>Treatment with tofacitinib was associated with an increased incidence of lymphopenia compared to placebo. Lymphocyte counts less than 750&nbsp;cells/mm<sup>3</sup> were associated with an increased incidence of serious infections. It is not recommended to initiate or continue tofacitinib treatment in patients with a confirmed lymphocyte count less than 750&nbsp;cells/mm<sup>3</sup>. Lymphocytes should be monitored at baseline and every 3&nbsp;months thereafter. For recommended modifications based on lymphocyte counts, see section&nbsp;4.2.</p><p>&nbsp;</p><p><em><u>Neutrophils</u></em></p><p>Treatment with tofacitinib was associated with an increased incidence of neutropenia (less than 2,000&nbsp;cells/mm<sup>3</sup>) compared to placebo. It is not recommended to initiate tofacitinib treatment in adult patients with an ANC less than 1,000&nbsp;cells/mm<sup>3</sup> and in paediatric patients with an ANC less than 1,200&nbsp;cells/mm<sup>3</sup>. ANC should be monitored at baseline and after 4 to 8&nbsp;weeks of treatment and every 3&nbsp;months thereafter. For recommended modifications based on ANC, see section 4.2.</p><p>&nbsp;</p><p><em><u>Haemoglobin</u></em></p><p>Treatment with tofacitinib has been associated with decreases in haemoglobin levels. It is not recommended to initiate tofacitinib treatment in adult patients with a haemoglobin value less than 9&nbsp;g/dL and in paediatric patients with a haemoglobin value less than 10 g/dL. Haemoglobin should be monitored at baseline and after 4 to 8&nbsp;weeks of treatment and every 3&nbsp;months thereafter. For recommended modifications based on haemoglobin level, see section&nbsp;4.2.</p><p>&nbsp;</p><p><em><u>Lipid monitoring</u></em></p><p>Treatment with tofacitinib was associated with increases in lipid parameters such as total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Maximum effects were generally observed within 6&nbsp;weeks. Assessment of lipid parameters should be performed after 8&nbsp;weeks following initiation of tofacitinib therapy. Patients should be managed according to clinical guidelines for the management of hyperlipidaemia. Increases in total and LDL cholesterol associated with tofacitinib may be decreased to pretreatment levels with statin therapy.</p><p><u>&nbsp;</u></p><p><u>Hypoglycaemia in patients treated for diabetes</u></p><p>&nbsp;</p><p>There have been reports of hypoglycaemia following initiation of tofacitinib in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycaemia occurs.</p><p><em>&nbsp;</em></p><p><u>Vaccinations</u></p><p>&nbsp;</p><p>Prior to initiating tofacitinib, it is recommended that all patients, particularly pJIA and jPsA patients, be brought up to date with all immunisations in agreement with current immunisation guidelines. It is recommended that live vaccines not be given concurrently with tofacitinib. The decision to use live vaccines prior to tofacitinib treatment should take into account the pre-existing immunosuppression in a given patient.</p><p>&nbsp;</p><p>Prophylactic zoster vaccination should be considered in accordance with vaccination guidelines. Particular consideration should be given to patients with longstanding RA who have previously received two or more biological DMARDs. If live zoster vaccine is administered; it should only be administered to patients with a known history of chickenpox or those that are seropositive for varicella zoster virus (VZV). If the history of chickenpox is considered doubtful or unreliable it is recommended to test for antibodies against VZV.</p><p>&nbsp;</p><p>Vaccination with live vaccines should occur at least 2&nbsp;weeks but preferably 4 weeks prior to initiation of tofacitinib or in accordance with current vaccination guidelines regarding immunomodulatory medicinal products. No data are available on the secondary transmission of infection by live vaccines to patients receiving tofacitinib.</p><p><em>&nbsp;</em></p><p><u>Excipients contents</u></p><p>&nbsp;</p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Potential for other medicinal products to influence the pharmacokinetics (PK) of tofacitinib</u></p><p><u>&nbsp;</u></p><p>Since tofacitinib is metabolised by CYP3A4, interaction with medicinal products that inhibit or induce CYP3A4 is likely. Tofacitinib exposure is increased when coadministered with potent inhibitors of CYP3A4 (e.g., ketoconazole)<strong><sup> </sup></strong>or when administration of one or more concomitant medicinal products results in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g.,&nbsp;fluconazole)<strong><sup> </sup></strong>(see section&nbsp;4.2)<em>.</em></p><p>&nbsp;</p><p>Tofacitinib exposure is decreased when coadministered with potent CYP inducers (e.g.,&nbsp;rifampicin). Inhibitors of CYP2C19 alone or P-glycoprotein are unlikely to significantly alter the PK of tofacitinib.</p><p>&nbsp;</p><p>Coadministration with ketoconazole (strong CYP3A4 inhibitor), fluconazole (moderate CYP3A4 and potent CYP2C19 inhibitor), tacrolimus (mild CYP3A4 inhibitor) and ciclosporin (moderate CYP3A4 inhibitor) increased tofacitinib AUC, while rifampicin (potent CYP inducer) decreased tofacitinib AUC. Coadministration of tofacitinib with potent CYP inducers (e.g., rifampicin) may result in a loss of or reduced clinical response (see&nbsp;Figure&nbsp;1). Coadministration of potent inducers of CYP3A4 with tofacitinib is not recommended. Coadministration with ketoconazole and fluconazole increased tofacitinib C<sub>max</sub>, while tacrolimus, ciclosporin and rifampicin decreased tofacitinib C<sub>max</sub>. Concomitant administration with MTX 15-25&nbsp;mg once weekly had no effect on the PK of tofacitinib in RA patients (see&nbsp;Figure&nbsp;1).</p><p>&nbsp;</p><p><strong>Figure&nbsp;1. Impact of other medicinal products on PK of tofacitinib</strong></p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Canvas_x0020_1519" o:spid="_x0000_s1026" editas="canvas" style='width:453.55pt;
 height:263.8pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="57600,33496" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;
  width:57600;height:33496;visibility:visible;mso-wrap-style:square'>
  <v:fill o:detectmouseclick="t"/>
  <v:path o:connecttype="none"/>
 </v:shape><v:group id="Group_x0020_4" o:spid="_x0000_s1028" style='position:absolute;
  top:4762;width:52184;height:29483' coordorigin="-125,750" coordsize="8218,4643"
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:rect id="Rectangle_x0020_5" o:spid="_x0000_s1029" style='position:absolute;
   left:5213;top:918;width:28;height:111;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQB1P9jDxAAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9PawIx
FMTvBb9DeIK3mlW06GoULQi9FPx30Ntz89xd3Lxsk6irn74RCj0OM/MbZjpvTCVu5HxpWUGvm4Ag
zqwuOVew363eRyB8QNZYWSYFD/Iwn7Xepphqe+cN3bYhFxHCPkUFRQh1KqXPCjLou7Ymjt7ZOoMh
SpdL7fAe4aaS/ST5kAZLjgsF1vRZUHbZXo2C5Xi0/FkP+Pu5OR3peDhdhn2XKNVpN4sJiEBN+A//
tb+0giG8rsQbIGe/AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAHU/2MPEAAAA2gAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_6" o:spid="_x0000_s1030" style='position:absolute;
   left:5213;top:918;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_7" o:spid="_x0000_s1031" style='position:absolute;
   left:5213;top:1016;width:28;height:13;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_8" o:spid="_x0000_s1032" style='position:absolute;
   left:5185;top:932;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_9" o:spid="_x0000_s1033" style='position:absolute;
   left:5185;top:988;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_10" o:spid="_x0000_s1034" style='position:absolute;
   left:5171;top:960;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_11" o:spid="_x0000_s1035" style='position:absolute;
   left:5171;top:974;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_12" o:spid="_x0000_s1036" style='position:absolute;
   left:5171;top:974;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_13" o:spid="_x0000_s1037" style='position:absolute;
   left:5171;top:960;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_14" o:spid="_x0000_s1038" style='position:absolute;
   left:5171;top:918;width:98;height:98;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_15" o:spid="_x0000_s1039" style='position:absolute;
   left:4209;top:1141;width:28;height:112;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCNVteZxgAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvgv9heUJvutHaYmNW0UKhl4LaHurtmX0mIdm3cXersb/eFQo9DjPzDZMtO9OIMzlfWVYwHiUg
iHOrKy4UfH2+DWcgfEDW2FgmBVfysFz0exmm2l54S+ddKESEsE9RQRlCm0rp85IM+pFtiaN3tM5g
iNIVUju8RLhp5CRJnqXBiuNCiS29lpTXux+jYP0yW582U/743R72tP8+1E8Tlyj1MOhWcxCBuvAf
/mu/awWPY7h/iT9ALm4AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAjVbXmcYAAADbAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_16" o:spid="_x0000_s1040" style='position:absolute;
   left:4209;top:1141;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_17" o:spid="_x0000_s1041" style='position:absolute;
   left:4209;top:1239;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_18" o:spid="_x0000_s1042" style='position:absolute;
   left:4181;top:1155;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_19" o:spid="_x0000_s1043" style='position:absolute;
   left:4181;top:1211;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_20" o:spid="_x0000_s1044" style='position:absolute;
   left:4168;top:1183;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_21" o:spid="_x0000_s1045" style='position:absolute;
   left:4168;top:1197;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_22" o:spid="_x0000_s1046" style='position:absolute;
   left:4168;top:1197;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_23" o:spid="_x0000_s1047" style='position:absolute;
   left:4168;top:1183;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_24" o:spid="_x0000_s1048" style='position:absolute;
   left:4168;top:1141;width:97;height:98;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_25" o:spid="_x0000_s1049" style='position:absolute;
   left:4934;top:1574;width:28;height:112;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_26" o:spid="_x0000_s1050" style='position:absolute;
   left:4934;top:1574;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAlgjqTxgAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvhf6H5RW81U2DFY1upBYEL4Vqe9DbM/tMQrJv091V0/56tyB4HGbmG2a+6E0rzuR8bVnByzAB
QVxYXXOp4Ptr9TwB4QOyxtYyKfglD4v88WGOmbYX3tB5G0oRIewzVFCF0GVS+qIig35oO+LoHa0z
GKJ0pdQOLxFuWpkmyVgarDkuVNjRe0VFsz0ZBcvpZPnzOeKPv81hT/vdoXlNXaLU4Kl/m4EI1Id7
+NZeawWjFP6/xB8g8ysAAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAJYI6k8YAAADbAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_27" o:spid="_x0000_s1051" style='position:absolute;
   left:4934;top:1672;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_28" o:spid="_x0000_s1052" style='position:absolute;
   left:4906;top:1588;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_29" o:spid="_x0000_s1053" style='position:absolute;
   left:4906;top:1644;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_30" o:spid="_x0000_s1054" style='position:absolute;
   left:4892;top:1616;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_31" o:spid="_x0000_s1055" style='position:absolute;
   left:4892;top:1630;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQA19ZkLxQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BawIx
FITvgv8hPMGbZhWtdjWKFgq9CNX2UG/PzXN3cfOyTaKu/vpGKHgcZuYbZr5sTCUu5HxpWcGgn4Ag
zqwuOVfw/fXem4LwAVljZZkU3MjDctFuzTHV9spbuuxCLiKEfYoKihDqVEqfFWTQ921NHL2jdQZD
lC6X2uE1wk0lh0nyIg2WHBcKrOmtoOy0OxsF69fp+vdzxJv79rCn/c/hNB66RKlup1nNQARqwjP8
3/7QCkYTeHyJP0Au/gAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQA19ZkLxQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_32" o:spid="_x0000_s1056" style='position:absolute;
   left:4892;top:1630;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_33" o:spid="_x0000_s1057" style='position:absolute;
   left:4892;top:1616;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_34" o:spid="_x0000_s1058" style='position:absolute;
   left:4892;top:1574;width:98;height:98;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_35" o:spid="_x0000_s1059" style='position:absolute;
   left:4335;top:1797;width:28;height:112;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_36" o:spid="_x0000_s1060" style='position:absolute;
   left:4335;top:1797;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_37" o:spid="_x0000_s1061" style='position:absolute;
   left:4335;top:1895;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDPFwnVxQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9PawIx
FMTvQr9DeAVvmq1W0a1RakHoRfDfQW/Pzevu4uZlm0Rd++kbQfA4zMxvmMmsMZW4kPOlZQVv3QQE
cWZ1ybmC3XbRGYHwAVljZZkU3MjDbPrSmmCq7ZXXdNmEXEQI+xQVFCHUqZQ+K8ig79qaOHo/1hkM
UbpcaofXCDeV7CXJUBosOS4UWNNXQdlpczYK5uPR/Hf1zsu/9fFAh/3xNOi5RKn2a/P5ASJQE57h
R/tbKxj04f4l/gA5/QcAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDPFwnVxQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_38" o:spid="_x0000_s1062" style='position:absolute;
   left:4307;top:1811;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_39" o:spid="_x0000_s1063" style='position:absolute;
   left:4307;top:1867;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_40" o:spid="_x0000_s1064" style='position:absolute;
   left:4293;top:1839;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_41" o:spid="_x0000_s1065" style='position:absolute;
   left:4293;top:1853;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_42" o:spid="_x0000_s1066" style='position:absolute;
   left:4293;top:1853;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_43" o:spid="_x0000_s1067" style='position:absolute;
   left:4293;top:1839;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_44" o:spid="_x0000_s1068" style='position:absolute;
   left:4293;top:1797;width:98;height:98;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_45" o:spid="_x0000_s1069" style='position:absolute;
   left:3052;top:2244;width:28;height:111;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_46" o:spid="_x0000_s1070" style='position:absolute;
   left:3052;top:2244;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_47" o:spid="_x0000_s1071" style='position:absolute;
   left:3052;top:2342;width:28;height:13;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_48" o:spid="_x0000_s1072" style='position:absolute;
   left:3025;top:2258;width:83;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_49" o:spid="_x0000_s1073" style='position:absolute;
   left:3025;top:2314;width:83;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_50" o:spid="_x0000_s1074" style='position:absolute;
   left:3011;top:2286;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_51" o:spid="_x0000_s1075" style='position:absolute;
   left:3011;top:2300;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_52" o:spid="_x0000_s1076" style='position:absolute;
   left:3011;top:2300;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_53" o:spid="_x0000_s1077" style='position:absolute;
   left:3011;top:2286;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_54" o:spid="_x0000_s1078" style='position:absolute;
   left:3011;top:2244;width:97;height:98;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_55" o:spid="_x0000_s1079" style='position:absolute;
   left:3164;top:2467;width:28;height:112;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_56" o:spid="_x0000_s1080" style='position:absolute;
   left:3164;top:2467;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_57" o:spid="_x0000_s1081" style='position:absolute;
   left:3164;top:2565;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_58" o:spid="_x0000_s1082" style='position:absolute;
   left:3136;top:2481;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_59" o:spid="_x0000_s1083" style='position:absolute;
   left:3136;top:2537;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_60" o:spid="_x0000_s1084" style='position:absolute;
   left:3122;top:2509;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_61" o:spid="_x0000_s1085" style='position:absolute;
   left:3122;top:2523;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_62" o:spid="_x0000_s1086" style='position:absolute;
   left:3122;top:2523;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_63" o:spid="_x0000_s1087" style='position:absolute;
   left:3122;top:2509;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_64" o:spid="_x0000_s1088" style='position:absolute;
   left:3122;top:2467;width:98;height:98;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_65" o:spid="_x0000_s1089" style='position:absolute;
   left:4056;top:2900;width:28;height:111;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_66" o:spid="_x0000_s1090" style='position:absolute;
   left:4056;top:2900;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_67" o:spid="_x0000_s1091" style='position:absolute;
   left:4056;top:2998;width:28;height:13;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_68" o:spid="_x0000_s1092" style='position:absolute;
   left:4028;top:2914;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_69" o:spid="_x0000_s1093" style='position:absolute;
   left:4028;top:2970;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_70" o:spid="_x0000_s1094" style='position:absolute;
   left:4014;top:2942;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_71" o:spid="_x0000_s1095" style='position:absolute;
   left:4014;top:2956;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_72" o:spid="_x0000_s1096" style='position:absolute;
   left:4014;top:2956;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_73" o:spid="_x0000_s1097" style='position:absolute;
   left:4014;top:2942;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_74" o:spid="_x0000_s1098" style='position:absolute;
   left:4014;top:2900;width:98;height:98;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_75" o:spid="_x0000_s1099" style='position:absolute;
   left:4056;top:3123;width:28;height:112;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_76" o:spid="_x0000_s1100" style='position:absolute;
   left:4056;top:3123;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_77" o:spid="_x0000_s1101" style='position:absolute;
   left:4056;top:3221;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_78" o:spid="_x0000_s1102" style='position:absolute;
   left:4028;top:3137;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_79" o:spid="_x0000_s1103" style='position:absolute;
   left:4028;top:3193;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_80" o:spid="_x0000_s1104" style='position:absolute;
   left:4014;top:3165;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_81" o:spid="_x0000_s1105" style='position:absolute;
   left:4014;top:3179;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_82" o:spid="_x0000_s1106" style='position:absolute;
   left:4014;top:3179;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_83" o:spid="_x0000_s1107" style='position:absolute;
   left:4014;top:3165;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_84" o:spid="_x0000_s1108" style='position:absolute;
   left:4014;top:3123;width:98;height:98;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_85" o:spid="_x0000_s1109" style='position:absolute;
   left:4265;top:3570;width:28;height:111;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_86" o:spid="_x0000_s1110" style='position:absolute;
   left:4265;top:3570;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_87" o:spid="_x0000_s1111" style='position:absolute;
   left:4265;top:3667;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_88" o:spid="_x0000_s1112" style='position:absolute;
   left:4237;top:3584;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_89" o:spid="_x0000_s1113" style='position:absolute;
   left:4237;top:3640;width:84;height:27;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_90" o:spid="_x0000_s1114" style='position:absolute;
   left:4223;top:3612;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_91" o:spid="_x0000_s1115" style='position:absolute;
   left:4223;top:3626;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_92" o:spid="_x0000_s1116" style='position:absolute;
   left:4223;top:3626;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDAPW4xxAAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/LasJA
FN0X+g/DLbirE4MtMWaUWih0U6iPhe5uMtckmLmTzkw1+vWdRcHl4byL5WA6cSbnW8sKJuMEBHFl
dcu1gt324zkD4QOyxs4yKbiSh+Xi8aHAXNsLr+m8CbWIIexzVNCE0OdS+qohg35se+LIHa0zGCJ0
tdQOLzHcdDJNkldpsOXY0GBP7w1Vp82vUbCaZauf7yl/3dblgQ778vSSukSp0dPwNgcRaAh38b/7
UytI0zg/nolHQC7+AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAMA9bjHEAAAA3AAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_93" o:spid="_x0000_s1117" style='position:absolute;
   left:4223;top:3612;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_94" o:spid="_x0000_s1118" style='position:absolute;
   left:4223;top:3570;width:98;height:97;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_95" o:spid="_x0000_s1119" style='position:absolute;
   left:3917;top:3793;width:28;height:112;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAw7/BGxgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvQv/D8gq9mU1jWzS6ShUKvQhqPejtmX1Ngtm36e5WU3+9KxQ8DjPzDTOZdaYRJ3K+tqzgOUlB
EBdW11wq2H599IcgfEDW2FgmBX/kYTZ96E0w1/bMazptQikihH2OCqoQ2lxKX1Rk0Ce2JY7et3UG
Q5SulNrhOcJNI7M0fZMGa44LFba0qKg4bn6NgvloOP9ZvfDysj7sab87HF8zlyr19Ni9j0EE6sI9
/N/+1AqybAC3M/EIyOkVAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAMO/wRsYAAADcAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_96" o:spid="_x0000_s1120" style='position:absolute;
   left:3917;top:3793;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_97" o:spid="_x0000_s1121" style='position:absolute;
   left:3917;top:3891;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_98" o:spid="_x0000_s1122" style='position:absolute;
   left:3889;top:3807;width:83;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_99" o:spid="_x0000_s1123" style='position:absolute;
   left:3889;top:3863;width:83;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_100" o:spid="_x0000_s1124" style='position:absolute;
   left:3875;top:3835;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_101" o:spid="_x0000_s1125" style='position:absolute;
   left:3875;top:3849;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_102" o:spid="_x0000_s1126" style='position:absolute;
   left:3875;top:3849;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_103" o:spid="_x0000_s1127" style='position:absolute;
   left:3875;top:3835;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_104" o:spid="_x0000_s1128" style='position:absolute;
   left:3875;top:3793;width:97;height:98;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_105" o:spid="_x0000_s1129" style='position:absolute;
   left:4864;top:4240;width:28;height:111;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_106" o:spid="_x0000_s1130" style='position:absolute;
   left:4864;top:4240;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_107" o:spid="_x0000_s1131" style='position:absolute;
   left:4864;top:4337;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_108" o:spid="_x0000_s1132" style='position:absolute;
   left:4837;top:4254;width:83;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_109" o:spid="_x0000_s1133" style='position:absolute;
   left:4837;top:4310;width:83;height:27;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_110" o:spid="_x0000_s1134" style='position:absolute;
   left:4823;top:4282;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_111" o:spid="_x0000_s1135" style='position:absolute;
   left:4823;top:4296;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_112" o:spid="_x0000_s1136" style='position:absolute;
   left:4823;top:4296;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_113" o:spid="_x0000_s1137" style='position:absolute;
   left:4823;top:4282;width:111;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_114" o:spid="_x0000_s1138" style='position:absolute;
   left:4823;top:4240;width:97;height:97;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAAl0fAwwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/fa8Iw
EH4X9j+EG/imqUPHqMYyBkNBKKgbez2bW9OuuZQmtfW/XwYD3+7j+3mbbLSNuFLnK8cKFvMEBHHh
dMWlgo/z++wFhA/IGhvHpOBGHrLtw2SDqXYDH+l6CqWIIexTVGBCaFMpfWHIop+7ljhy366zGCLs
Sqk7HGK4beRTkjxLixXHBoMtvRkqfk69VWDzo+k/L7au+nw8hK/aLXdnp9T0cXxdgwg0hrv4373X
cf5ysYK/b+IJcvsLAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAAJdHwMMAAADdAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:rect id="Rectangle_x0020_115" o:spid="_x0000_s1139" style='position:absolute;
   left:3833;top:4449;width:28;height:112;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_116" o:spid="_x0000_s1140" style='position:absolute;
   left:3833;top:4449;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_117" o:spid="_x0000_s1141" style='position:absolute;
   left:3833;top:4547;width:28;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCKuksrxwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bb8Iw
DIXvSPsPkZF2gxTEEBQCGpMm7TJpMA5wM41pKxqnSzLo9uvnA9Jutt7ze5+X68416koh1p4NjIYZ
KOLC25pLA/vP18EMVEzIFhvPZOCHIqxXD70l5tbfeEvXXSqVhHDM0UCVUptrHYuKHMahb4lFO/vg
MMkaSm0D3iTcNXqcZVPtsGZpqLCll4qKy+7bGdjMZ5uvjwm//25PRzoeTpencciMeex3zwtQibr0
b75fv1nBn4wEV76REfTqDwAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAIq6SyvHAAAA3QAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_118" o:spid="_x0000_s1142" style='position:absolute;
   left:3805;top:4463;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_119" o:spid="_x0000_s1143" style='position:absolute;
   left:3805;top:4519;width:84;height:28;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_120" o:spid="_x0000_s1144" style='position:absolute;
   left:3791;top:4491;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_121" o:spid="_x0000_s1145" style='position:absolute;
   left:3791;top:4505;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_122" o:spid="_x0000_s1146" style='position:absolute;
   left:3791;top:4505;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:rect id="Rectangle_x0020_123" o:spid="_x0000_s1147" style='position:absolute;
   left:3791;top:4491;width:112;height:14;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" fillcolor="black" stroked="f"/>
  <v:oval id="Oval_x0020_124" o:spid="_x0000_s1148" style='position:absolute;
   left:3791;top:4449;width:98;height:98;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDO+419wwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/fa8Iw
EH4X9j+EG+zNphMdozbKGAyFQUHd2OvZ3Jq65lKa1Nb/3ggD3+7j+3n5erSNOFPna8cKnpMUBHHp
dM2Vgq/Dx/QVhA/IGhvHpOBCHtarh0mOmXYD7+i8D5WIIewzVGBCaDMpfWnIok9cSxy5X9dZDBF2
ldQdDjHcNnKWpi/SYs2xwWBL74bKv31vFdhiZ/rvoz3VfTF+hp+Tm28OTqmnx/FtCSLQGO7if/dW
x/nz2QJu38QT5OoKAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAzvuNfcMAAADdAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" filled="f" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:oval><v:line id="Line_x0020_125" o:spid="_x0000_s1149" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="5087,974" to="5380,974"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_126" o:spid="_x0000_s1150" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4098,1197" to="4377,1197"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_127" o:spid="_x0000_s1151" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4781,1630" to="5143,1630"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_128" o:spid="_x0000_s1152" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4181,1853" to="4544,1853"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD9K/w+wwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9NawIx
EL0L/Q9hCr1Iza4U0dUoRbAUPNX20tuYTDfLbibLJrrpvzeFgrd5vM/Z7JLrxJWG0HhWUM4KEMTa
m4ZrBV+fh+cliBCRDXaeScEvBdhtHyYbrIwf+YOup1iLHMKhQgU2xr6SMmhLDsPM98SZ+/GDw5jh
UEsz4JjDXSfnRbGQDhvODRZ72lvS7eniFJzT8tu1ZVuMdurL/epNH5PRSj09ptc1iEgp3sX/7neT
57/MV/D3TT5Bbm8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA/Sv8PsMAAADdAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_129" o:spid="_x0000_s1153" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="3039,2300" to="3080,2300"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_130" o:spid="_x0000_s1154" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="3150,2523" to="3234,2523"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_131" o:spid="_x0000_s1155" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4028,2956" to="4112,2956"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_132" o:spid="_x0000_s1156" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="3972,3179" to="4181,3179"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_133" o:spid="_x0000_s1157" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4195,3626" to="4377,3626"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_134" o:spid="_x0000_s1158" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="3847,3849" to="4028,3849"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_135" o:spid="_x0000_s1159" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4753,4296" to="5032,4296"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAJbf6RwwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9NawIx
EL0X+h/CFLwUzW5bRFejFKFS6Km2F29jMm6W3UyWTerGf28Khd7m8T5nvU2uExcaQuNZQTkrQBBr
bxquFXx/vU0XIEJENth5JgVXCrDd3N+tsTJ+5E+6HGItcgiHChXYGPtKyqAtOQwz3xNn7uwHhzHD
oZZmwDGHu04+FcVcOmw4N1jsaWdJt4cfp+CUFkfXlm0x2kdf7pZ7/ZGMVmrykF5XICKl+C/+c7+b
PP/leQ6/3+QT5OYGAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEACW3+kcMAAADdAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_136" o:spid="_x0000_s1160" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="3708,4505" to="4000,4505"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBmIVsKxAAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9NSwMx
EL0L/ocwQi/SZreKrWvTIoUWoSerF29jMm6W3UyWTdpN/70RCt7m8T5ntUmuE2caQuNZQTkrQBBr
bxquFXx+7KZLECEiG+w8k4ILBdisb29WWBk/8judj7EWOYRDhQpsjH0lZdCWHIaZ74kz9+MHhzHD
oZZmwDGHu07Oi+JJOmw4N1jsaWtJt8eTU/Cdll+uLdtitPe+3D7v9SEZrdTkLr2+gIiU4r/46n4z
ef7jwwL+vsknyPUvAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAGYhWwrEAAAA3QAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_137" o:spid="_x0000_s1161" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="5087,932" to="5087,1002"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_138" o:spid="_x0000_s1162" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4098,1155" to="4098,1225"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_139" o:spid="_x0000_s1163" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4781,1602" to="4781,1672"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_140" o:spid="_x0000_s1164" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4181,1825" to="4181,1895"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCb3HpewwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/bisIw
EH0X/Icwwr5pqohI1yiyreAiyqr7AUMztnWbSWlirX9vBGHf5nCus1h1phItNa60rGA8ikAQZ1aX
nCv4PW+GcxDOI2usLJOCBzlYLfu9Bcba3vlI7cnnIoSwi1FB4X0dS+myggy6ka2JA3exjUEfYJNL
3eA9hJtKTqJoJg2WHBoKrOmroOzvdDMKtonfHPb7fH49fs/SdZomP8nurNTHoFt/gvDU+X/x273V
Yf50OobXN+EEuXwCAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAm9x6XsMAAADdAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_141" o:spid="_x0000_s1165" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="3039,2272" to="3039,2328"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_142" o:spid="_x0000_s1166" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="3150,2481" to="3150,2551"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_143" o:spid="_x0000_s1167" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4028,2928" to="4028,2998"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCLq9nGwwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/bisIw
EH0X9h/CLPimqUsRqUYRW0FZFG8fMDRjW20mpclq9+83C4JvczjXmS06U4sHta6yrGA0jEAQ51ZX
XCi4nNeDCQjnkTXWlknBLzlYzD96M0y0ffKRHidfiBDCLkEFpfdNIqXLSzLohrYhDtzVtgZ9gG0h
dYvPEG5q+RVFY2mw4tBQYkOrkvL76cco2KR+vd/tisntuB1nyyxLD+n3Wan+Z7ecgvDU+bf45d7o
MD+OY/j/Jpwg538AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAi6vZxsMAAADdAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_144" o:spid="_x0000_s1168" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="3972,3151" to="3972,3221"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_145" o:spid="_x0000_s1169" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4195,3598" to="4195,3654"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_146" o:spid="_x0000_s1170" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="3847,3807" to="3847,3877"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_147" o:spid="_x0000_s1171" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4753,4254" to="4753,4324"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_148" o:spid="_x0000_s1172" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="3708,4477" to="3708,4547"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_149" o:spid="_x0000_s1173" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="5380,932" to="5380,1002"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_150" o:spid="_x0000_s1174" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4377,1155" to="4377,1225"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_151" o:spid="_x0000_s1175" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="5143,1602" to="5143,1672"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDu13L0xQAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/basJA
EH0v9B+WKfhWNw0aJHWV0ESwlEjVfsCQnSZps7Mhu9X4911B8G0O5zrL9Wg6caLBtZYVvEwjEMSV
1S3XCr6Om+cFCOeRNXaWScGFHKxXjw9LTLU9855OB1+LEMIuRQWN930qpasaMuimticO3LcdDPoA
h1rqAc8h3HQyjqJEGmw5NDTY01tD1e/hzyjY5n6zK8t68bN/T4qsKPLP/OOo1ORpzF5BeBr9XXxz
b3WYP5vHcP0mnCBX/wAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDu13L0xQAAAN0AAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_152" o:spid="_x0000_s1176" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4544,1825" to="4544,1895"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCBm9dvxQAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/basJA
EH0X/IdlBN90Y21FUleRJoKlKJr0A4bsNEnNzobsVtO/d4VC3+ZwrrPa9KYRV+pcbVnBbBqBIC6s
rrlU8JnvJksQziNrbCyTgl9ysFkPByuMtb3xma6ZL0UIYRejgsr7NpbSFRUZdFPbEgfuy3YGfYBd
KXWHtxBuGvkURQtpsObQUGFLbxUVl+zHKNgnfnc8HMrl9/l9kW7TNDklH7lS41G/fQXhqff/4j/3
Xof5zy9zeHwTTpDrOwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQCBm9dvxQAAAN0AAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_153" o:spid="_x0000_s1177" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="3080,2272" to="3080,2328"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_154" o:spid="_x0000_s1178" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="3234,2481" to="3234,2551"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_155" o:spid="_x0000_s1179" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4112,2928" to="4112,2998"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_156" o:spid="_x0000_s1180" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4181,3151" to="4181,3221"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_157" o:spid="_x0000_s1181" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4377,3598" to="4377,3654"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_158" o:spid="_x0000_s1182" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4028,3807" to="4028,3877"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_159" o:spid="_x0000_s1183" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="5032,4254" to="5032,4324"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQC/JYOlxwAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/dasJA
EIXvC32HZQre1U1LCRJdRZoIilj8e4AhOyax2dmQ3Wp8+85FoXcznDPnfDNbDK5VN+pD49nA2zgB
RVx623Bl4HxavU5AhYhssfVMBh4UYDF/fpphZv2dD3Q7xkpJCIcMDdQxdpnWoazJYRj7jli0i+8d
Rln7Stse7xLuWv2eJKl22LA01NjRZ03l9/HHGVjncfW121WT62GTFsuiyPf59mTM6GVYTkFFGuK/
+e96bQX/IxV++UZG0PNfAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAL8lg6XHAAAA3QAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_160" o:spid="_x0000_s1184" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4000,4477" to="4000,4547"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight="1.4pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_161" o:spid="_x0000_s1185" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="2871,4896" to="5770,4896"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_162" o:spid="_x0000_s1186" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="2871,4896" to="2871,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_163" o:spid="_x0000_s1187" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="3164,4896" to="3164,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_164" o:spid="_x0000_s1188" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="3457,4896" to="3457,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAgMK0ZxAAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9LS8NA
EL4X/A/LCN7sxqKlxG6LLRTqSUyleByyY5I2O5tmJw/99a4g9DYf33OW69HVqqc2VJ4NPEwTUMS5
txUXBj4Ou/sFqCDIFmvPZOCbAqxXN5MlptYP/E59JoWKIRxSNFCKNKnWIS/JYZj6hjhyX751KBG2
hbYtDjHc1XqWJHPtsOLYUGJD25Lyc9Y5A6emK2RTSaYXP59d9zocL/3b0Zi72/HlGZTQKFfxv3tv
4/zH+RP8fRNP0KtfAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhACAwrRnEAAAA3QAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_165" o:spid="_x0000_s1189" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="3749,4896" to="3749,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_166" o:spid="_x0000_s1190" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4042,4896" to="4042,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_167" o:spid="_x0000_s1191" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4321,4896" to="4321,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_168" o:spid="_x0000_s1192" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4614,4896" to="4614,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQChfaccxAAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9LS8NA
EL4L/Q/LCN7sRpHSpt0WKwh6kqal9Dhkp0lqdjZmJw/99W5B8DYf33NWm9HVqqc2VJ4NPEwTUMS5
txUXBg771/s5qCDIFmvPZOCbAmzWk5sVptYPvKM+k0LFEA4pGihFmlTrkJfkMEx9Qxy5s28dSoRt
oW2LQwx3tX5Mkpl2WHFsKLGhl5Lyz6xzBi5NV8i2kkzPf05d9z4cv/qPozF3t+PzEpTQKP/iP/eb
jfOfZgu4fhNP0OtfAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAKF9pxzEAAAA3QAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_169" o:spid="_x0000_s1193" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="4906,4896" to="4906,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_170" o:spid="_x0000_s1194" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="5199,4896" to="5199,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_171" o:spid="_x0000_s1195" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="5492,4896" to="5492,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:line id="Line_x0020_172" o:spid="_x0000_s1196" style='position:absolute;
   visibility:visible;mso-wrap-style:square' from="5770,4896" to="5770,5021"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:rect id="Rectangle_x0020_173" o:spid="_x0000_s1197" style='position:absolute;
   left:2753;top:5133;width:101;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt;
      color:black'>0</span></b><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_174" o:spid="_x0000_s1198" style='position:absolute;
   left:3248;top:5133;width:251;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCRMMA9wQAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/bagIx
EH0v+A9hBN9qVrEqq1GkINjii6sfMGxmL5hMliR1t3/fFATf5nCus90P1ogH+dA6VjCbZiCIS6db
rhXcrsf3NYgQkTUax6TglwLsd6O3Leba9XyhRxFrkUI45KigibHLpQxlQxbD1HXEiauctxgT9LXU
HvsUbo2cZ9lSWmw5NTTY0WdD5b34sQrktTj268L4zH3Pq7P5Ol0qckpNxsNhAyLSEF/ip/uk0/zF
6gP+v0knyN0fAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAJEwwD3BAAAA3QAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt;
      color:black'>0.5</span></b><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_175" o:spid="_x0000_s1199" style='position:absolute;
   left:3924;top:5133;width:101;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt;
      color:black'>1</span></b><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_176" o:spid="_x0000_s1200" style='position:absolute;
   left:4405;top:5133;width:251;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt;
      color:black'>1.5</span></b><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_177" o:spid="_x0000_s1201" style='position:absolute;
   left:5081;top:5133;width:101;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt;
      color:black'>2</span></b><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_178" o:spid="_x0000_s1202" style='position:absolute;
   left:5561;top:5133;width:251;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt;
      color:black'>2.5</span></b><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:line id="Line_x0020_179" o:spid="_x0000_s1203" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="2676,750" to="2676,4728"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:rect id="Rectangle_x0020_180" o:spid="_x0000_s1204" style='position:absolute;
   left:2077;top:4449;width:416;height:256;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>Cmax</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_181" o:spid="_x0000_s1205" style='position:absolute;
   left:2161;top:4225;width:347;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>AUC</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_182" o:spid="_x0000_s1206" style='position:absolute;
   left:2077;top:3779;width:416;height:256;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>Cmax</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_183" o:spid="_x0000_s1207" style='position:absolute;
   left:2161;top:3569;width:347;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>AUC</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_184" o:spid="_x0000_s1208" style='position:absolute;
   left:2077;top:3123;width:416;height:256;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>Cmax</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_185" o:spid="_x0000_s1209" style='position:absolute;
   left:2161;top:2899;width:347;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>AUC</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_186" o:spid="_x0000_s1210" style='position:absolute;
   left:2077;top:2453;width:416;height:256;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>Cmax</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_187" o:spid="_x0000_s1211" style='position:absolute;
   left:2161;top:2229;width:347;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>AUC</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_188" o:spid="_x0000_s1212" style='position:absolute;
   left:2077;top:1797;width:416;height:256;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAlqLofwAAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/bagIx
EH0X/Icwgm+aVUpZV6MUQbDFF1c/YNjMXmgyWZLU3f69KQh9m8O5zu4wWiMe5EPnWMFqmYEgrpzu
uFFwv50WOYgQkTUax6TglwIc9tPJDgvtBr7So4yNSCEcClTQxtgXUoaqJYth6XrixNXOW4wJ+kZq
j0MKt0aus+xdWuw4NbTY07Gl6rv8sQrkrTwNeWl85r7W9cV8nq81OaXms/FjCyLSGP/FL/dZp/lv
+Qb+vkknyP0TAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAAAAAA
AAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAAAAAA
AAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAJai6H8AAAADdAAAADwAAAAAA
AAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPQCAAAAAA==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>Cmax</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_189" o:spid="_x0000_s1213" style='position:absolute;
   left:2161;top:1573;width:347;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>AUC</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_190" o:spid="_x0000_s1214" style='position:absolute;
   left:2077;top:1127;width:416;height:256;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>Cmax</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_191" o:spid="_x0000_s1215" style='position:absolute;
   left:2161;top:903;width:347;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span lang=EN-GB style='font-size:8.0pt;color:black'>AUC</span></b><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:line id="Line_x0020_192" o:spid="_x0000_s1216" style='position:absolute;
   flip:y;visibility:visible;mso-wrap-style:square' from="4042,750" to="4042,4728"
   o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokeweight=".7pt">
   <v:stroke endcap="round"/>
  </v:line><v:rect id="Rectangle_x0020_193" o:spid="_x0000_s1217" style='position:absolute;
   left:502;top:792;width:1082;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><i><span lang=EN-GB style='font-size:8.0pt;color:black'>CYP3A
      Inhibitor</span></i><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_194" o:spid="_x0000_s1218" style='position:absolute;
   left:543;top:959;width:880;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Ketoconazole</span><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_195" o:spid="_x0000_s1219" style='position:absolute;
   left:-125;top:1462;width:1926;height:260;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><i><span lang=EN-GB style='font-size:8.0pt;color:black'>CYP3A
      &amp; CYP2C19 Inhibitor</span></i><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_196" o:spid="_x0000_s1220" style='position:absolute;
   left:586;top:1601;width:782;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQC+oh0rwQAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/bagIx
EH0v+A9hBN9qVpGqq1GkINjii6sfMGxmL5hMliR1t3/fFATf5nCus90P1ogH+dA6VjCbZiCIS6db
rhXcrsf3FYgQkTUax6TglwLsd6O3Leba9XyhRxFrkUI45KigibHLpQxlQxbD1HXEiauctxgT9LXU
HvsUbo2cZ9mHtNhyamiwo8+GynvxYxXIa3HsV4XxmfueV2fzdbpU5JSajIfDBkSkIb7ET/dJp/mL
9RL+v0knyN0fAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAL6iHSvBAAAA3QAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Fluconazole</span><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_197" o:spid="_x0000_s1221" style='position:absolute;
   left:558;top:2132;width:833;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><i><span lang=EN-GB style='font-size:8.0pt;color:black'>CYP
      Inducer</span></i><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_198" o:spid="_x0000_s1222" style='position:absolute;
   left:725;top:2285;width:720;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Rifampicin</span><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_199" o:spid="_x0000_s1223" style='position:absolute;
   left:585;top:2885;width:853;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Methotrexate</span><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_200" o:spid="_x0000_s1224" style='position:absolute;
   left:752;top:3555;width:730;height:259;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDA7LrewQAAAN0AAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/bagIx
EH0X+g9hCn3TZAWLbI2LCIKVvrj6AcNm9kKTyZKk7vbvm0Khb3M419lVs7PiQSEOnjUUKwWCuPFm
4E7D/XZabkHEhGzQeiYN3xSh2j8tdlgaP/GVHnXqRA7hWKKGPqWxlDI2PTmMKz8SZ671wWHKMHTS
BJxyuLNyrdSrdDhwbuhxpGNPzWf95TTIW32atrUNyl/W7Yd9P19b8lq/PM+HNxCJ5vQv/nOfTZ6/
UQX8fpNPkPsfAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAMDsut7BAAAA3QAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Tacrolimus</span><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_201" o:spid="_x0000_s1225" style='position:absolute;
   left:599;top:4214;width:747;height:260;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Ciclosporin</span><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_202" o:spid="_x0000_s1226" style='position:absolute;
   left:5757;top:903;width:2336;height:256;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Tofacitinib
      dose should be reduced <sup>a</sup></span><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_203" o:spid="_x0000_s1227" style='position:absolute;
   left:5757;top:1057;width:98;height:259;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_204" o:spid="_x0000_s1228" style='position:absolute;
   left:5757;top:1559;width:2336;height:256;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Tofacitinib
      dose should be reduced <sup>a</sup></span><span lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect></v:group><v:rect id="Rectangle_x0020_205" o:spid="_x0000_s1229"
  style='position:absolute;left:37350;top:10877;width:623;height:1645;
  visibility:visible;mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_206" o:spid="_x0000_s1230" style='position:absolute;
  left:37350;top:14154;width:10916;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Efficacy
     may be decreased</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_207" o:spid="_x0000_s1231" style='position:absolute;
  left:37350;top:18319;width:8071;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>No
     dose adjustment</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_208" o:spid="_x0000_s1232" style='position:absolute;
  left:37350;top:22574;width:13411;height:1625;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Combined
     use of tofacitinib with </span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_209" o:spid="_x0000_s1233" style='position:absolute;
  left:37350;top:23552;width:11938;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>tacrolimus
     should be avoided</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_210" o:spid="_x0000_s1234" style='position:absolute;
  left:37350;top:26828;width:13437;height:3302;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>Combined
     use of tofacitinib with </span><span lang=EN-GB><o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_211" o:spid="_x0000_s1235" style='position:absolute;
  left:37350;top:27757;width:12167;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;color:black'>ciclosporin
     should be avoided</span><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_212" o:spid="_x0000_s1236" style='position:absolute;
  left:21069;top:34810;width:14141;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt;color:black'>Ratio
     relative to reference</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_213" o:spid="_x0000_s1237" style='position:absolute;
  left:4203;top:692;width:8681;height:1651;visibility:visible;mso-wrap-style:none;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Coadministered</span></b><span
     lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_214" o:spid="_x0000_s1238" style='position:absolute;
  left:2978;top:2024;width:10128;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Medicinal
     Product</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_215" o:spid="_x0000_s1239" style='position:absolute;
  left:15354;top:692;width:1765;height:1644;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>PK </span></b><span
     lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_216" o:spid="_x0000_s1240" style='position:absolute;
  left:20396;top:692;width:9918;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Ratio and
     90% CI</span></b><span lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><v:rect id="Rectangle_x0020_217" o:spid="_x0000_s1241" style='position:absolute;
  left:36734;top:692;width:9525;height:1651;visibility:visible;
  mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><b><span lang=EN-GB style='font-size:10.0pt'>Recommendation</span></b><span
     lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:rect><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="606" height="384" src="file:///C:/Users/Bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:453.55pt;height:263.8pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>Note: Reference group is administration of tofacitinib alone.</p><p><sup>a</sup>&nbsp;&nbsp; Tofacitinib dose should be reduced to 5&nbsp;mg twice daily in patients receiving 10&nbsp;mg twice daily. Tofacitinib dose should be reduced to 5&nbsp;mg once daily in patients receiving 5&nbsp;mg twice daily (see section&nbsp;4.2).</p><p><u>&nbsp;</u></p><p><u>Potential for tofacitinib to influence the PK of other medicinal products</u></p><p><em>&nbsp;</em></p><p>Coadministration of tofacitinib did not have an effect on the PK of oral contraceptives, levonorgestrel and ethinyl estradiol, in healthy female volunteers.</p><p>&nbsp;</p><p>In RA patients, coadministration of tofacitinib with MTX 15-25&nbsp;mg once weekly decreased the AUC and C<sub>max</sub> of MTX by 10% and 13%, respectively. The extent of decrease in MTX exposure does not warrant modifications to the individualised dosing of MTX.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate and well-controlled studies on the use of tofacitinib in pregnant women. Tofacitinib has been shown to be teratogenic in rats and rabbits, and to affect parturition and peri/postnatal development (see section&nbsp;5.3).</p><p>&nbsp;</p><p>As a precautionary measure, the use of tofacitinib during pregnancy is contraindicated (see section&nbsp;4.3).</p><p>&nbsp;</p><p><u>Women of childbearing potential/contraception in females</u></p><p>&nbsp;</p><p>Women of childbearing potential should be advised to use effective contraception during treatment with tofacitinib and for at least 4&nbsp;weeks after the last dose.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is not known whether tofacitinib is secreted in human milk. A risk to the breast-fed child cannot be excluded. Tofacitinib was secreted in the milk of lactating rats (see section&nbsp;5.3). As a precautionary measure, the use of tofacitinib during breast-feeding is contraindicated (see section&nbsp;4.3).</p><p><em>&nbsp;</em></p><p><u>Fertility</u></p><p>&nbsp;</p><p>Formal studies of the potential effect on human fertility have not been conducted. Tofacitinib impaired female fertility but not male fertility in rats (see section&nbsp;5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tofacitinib has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p><em><u>Rheumatoid arthritis</u></em></p><p>The most common serious adverse reactions were serious infections (see section&nbsp;4.4). In the long-term safety all exposure population, the most common serious infections reported with tofacitinib were pneumonia (1.7%), herpes zoster (0.6%), urinary tract infection (0.4%), cellulitis (0.4%), diverticulitis (0.3%), and appendicitis (0.2%). Among opportunistic infections, TB and other mycobacterial infections, cryptococcus, histoplasmosis, oesophageal candidiasis, multidermatomal herpes zoster, cytomegalovirus infection, BK virus infections and listeriosis were reported with tofacitinib. Some patients have presented with disseminated rather than localised disease. Other serious infections that were not reported in clinical studies may also occur (e.g.,&nbsp;coccidioidomycosis).</p><p>&nbsp;</p><p>The most commonly reported adverse reactions during the first 3&nbsp;months of the double-blind, placebo or MTX controlled clinical studies were headache (3.9%), upper respiratory tract infections (3.8%), viral upper respiratory tract infection (3.3%), diarrhoea (2.9%), nausea (2.7%), and hypertension (2.2%).</p><p>&nbsp;</p><p>The proportion of patients who discontinued treatment due to adverse reactions during first 3&nbsp;months of the double-blind, placebo or MTX controlled studies was 3.8% for patients taking tofacitinib. The most common infections resulting in discontinuation of therapy during the first 3 months in controlled clinical studies were herpes zoster (0.19%) and pneumonia (0.15%).</p><p><em>&nbsp;</em></p><p><em><u>Psoriatic arthritis</u></em></p><p>Overall, the safety profile observed in patients with active PsA treated with tofacitinib was consistent with the safety profile observed in patients with RA treated with tofacitinib.</p><p><em>&nbsp;</em></p><p><em><u>Ankylosing spondylitis</u></em></p><p>Overall, the safety profile observed in patients with active AS treated with tofacitinib was consistent with the safety profile observed in patients with RA treated with tofacitinib.</p><p>&nbsp;</p><p><em><u>Ulcerative colitis</u></em></p><p>The most commonly reported adverse reactions in patients receiving tofacitinib 10&nbsp;mg twice daily in the induction studies were headache, nasopharyngitis, nausea, and arthralgia.</p><p>&nbsp;</p><p>In the induction and maintenance studies, across tofacitinib and placebo treatment groups, the most common categories of serious adverse reactions were gastrointestinal disorders and infections, and the most common serious adverse reaction was worsening of UC.</p><p>&nbsp;</p><p>Overall, the safety profile observed in patients with UC treated with tofacitinib was consistent with the safety profile of tofacitinib in the RA indication.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The adverse reactions listed in the table below are from clinical studies in patients with RA, PsA, AS, and UC and are presented by System Organ Class (SOC) and frequency categories, defined using the following convention: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table&nbsp;8:&nbsp;&nbsp; </strong><strong>Adverse reactions</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge;1/100 to &lt;1/10</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge;1/1,000 to</strong></p><p><strong>&lt;1/100</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge;1/10,000 to</strong></p><p><strong>&lt;1/1,000</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p><strong>&lt;1/10,000</strong></p></td><td style="vertical-align:top"><p><strong>Not known (cannot be estimated from the available data)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Pneumonia</p><p>Influenza</p><p>Herpes zoster</p><p>Urinary tract infection</p><p>Sinusitis</p><p>Bronchitis</p><p>Nasopharyngitis</p><p>Pharyngitis</p></td><td style="vertical-align:top"><p>Tuberculosis</p><p>Diverticulitis</p><p>Pyelonephritis</p><p>Cellulitis</p><p>Herpes simplex</p><p>Gastroenteritis viral</p><p>Viral infection</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sepsis</p><p>Urosepsis</p><p>Disseminated TB</p><p>Bacteraemia</p><p><em>Pneumocystis jirovecii</em> pneumonia</p><p>Pneumonia pneumococcal</p><p>Pneumonia bacterial</p><p>Cytomegalovirus infection</p><p>Arthritis bacterial</p></td><td style="vertical-align:top"><p>Tuberculosis of central nervous system</p><p>Meningitis cryptococcal</p><p>Necrotizing fasciitis</p><p>Encephalitis</p><p>Staphylococcal bacteraemia</p><p><em>Mycobacterium avium</em> complex infection</p><p>Atypical mycobacterial infection</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Lung cancer</p><p>Non-melanoma skin cancers</p></td><td style="vertical-align:top"><p>Lymphoma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Lymphopenia</p><p>Anaemia</p></td><td style="vertical-align:top"><p>Leukopenia</p><p>Neutropenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity*</p><p>Angioedema*</p><p>Urticaria*</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyslipidaemia</p><p>Hyperlipidaemia</p><p>Dehydration</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial infarction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypertension</p></td><td style="vertical-align:top"><p>Venous thromboembolism**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Dyspnoea</p><p>Sinus congestion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain</p><p>Vomiting</p><p>Diarrhoea</p><p>Nausea</p><p>Gastritis</p><p>Dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic steatosis</p><p>Hepatic enzyme</p><p>increased</p><p>Transaminases increased</p><p>Gamma glutamyl-transferase increased</p></td><td style="vertical-align:top"><p>Liver function test abnormal</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Erythema</p><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Joint swelling</p><p>Tendonitis</p></td><td style="vertical-align:top"><p>Musculoskeletal pain</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Oedema peripheral</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia</p><p>Fatigue</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatine phosphokinase increased</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p><p>Blood cholesterol increased</p><p>Low density lipoprotein increased</p><p>Weight increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ligament sprain</p><p>Muscle strain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>*Spontaneous reporting data</p><p>**Venous thromboembolism includes PE, DVT, and Retinal Venous Thrombosis</p><p><strong>&nbsp;</strong></p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Venous thromboembolism</u></em></p><p>&nbsp;</p><p><em>Rheumatoid arthritis</em></p><p>In a large (N=4,362), randomised post-authorisation safety study of rheumatoid arthritis patients who were 50 years of age and older and had at least one additional cardiovascular (CV) risk factor, VTE was observed at an increased and dose-dependent incidence in patients treated with tofacitinib compared to TNF inhibitors (see section 5.1). The majority of these events were serious and some resulted in death. The incidence rates (95%&nbsp;CI) for PE for tofacitinib 5&nbsp;mg twice daily, tofacitinib 10&nbsp;mg twice daily, and TNF inhibitors were 0.17 (0.08‑0.33), 0.50 (0.32‑0.74), and 0.06 (0.01‑0.17) patients with events per 100 patient‑years, respectively. Compared with TNF inhibitors, the hazard ratio (HR) for PE was 2.93 (0.79-10.83) and 8.26 (2.49, 27.43) for tofacitinib 5&nbsp;mg twice daily and tofacitinib 10&nbsp;mg twice daily, respectively (see section 5.1). In tofacitinib-treated patients where PE was observed, the majority (97%) had VTE risk factors.</p><p>&nbsp;</p><p><em>Ankylosing spondylitis</em></p><p>In the combined Phase 2 and Phase 3 randomised controlled clinical studies, there were no VTE events in 420 patients (233 patient-years of observation) receiving tofacitinib up to 48&nbsp;weeks.</p><p>&nbsp;</p><p><em>Ulcerative colitis (UC)</em></p><p>In the UC ongoing extension trial, cases of PE and DVT have been observed in patients using tofacitinib 10&nbsp;mg twice daily and with underlying VTE risk factor(s).</p><p>&nbsp;</p><p><u>Overall infections</u></p><p>&nbsp;</p><p><em>Rheumatoid arthritis</em></p><p>In controlled phase&nbsp;3 clinical studies, the rates of infections over 0-3&nbsp;months in the 5&nbsp;mg twice daily (total 616&nbsp;patients) and 10&nbsp;mg twice daily (total 642&nbsp;patients) tofacitinib monotherapy groups were 16.2% (100&nbsp;patients) and 17.9% (115&nbsp;patients), respectively, compared to 18.9% (23&nbsp;patients) in the placebo group (total 122&nbsp;patients). In controlled phase 3&nbsp;clinical studies with background DMARDs, the rates of infections over 0‑3&nbsp;months in the 5&nbsp;mg twice daily (total 973&nbsp;patients)<em> </em>and 10&nbsp;mg twice daily (total 969&nbsp;patients) tofacitinib plus DMARD group were 21.3% (207&nbsp;patients) and 21.8%&nbsp;(211&nbsp;patients), respectively, compared to 18.4% (103&nbsp;patients) in the placebo plus DMARD group (total 559&nbsp;patients).</p><p>&nbsp;</p><p>The most commonly reported infections were upper respiratory tract infections and nasopharyngitis (3.7% and 3.2%, respectively).</p><p>&nbsp;</p><p>The overall incidence rate of infections with tofacitinib in the long-term safety all exposure population (total 4,867 patients) was 46.1&nbsp;patients with events per 100&nbsp;patient-years (43.8 and 47.2&nbsp;patients with events for 5&nbsp;mg and 10&nbsp;mg twice daily, respectively). For patients (total 1,750) on monotherapy, the rates were 48.9 and 41.9&nbsp;patients with events per 100&nbsp;patient-years for 5&nbsp;mg and 10&nbsp;mg twice daily, respectively. For patients (total 3,117) on background DMARDs, the rates were 41.0 and 50.3&nbsp;patients with events per 100&nbsp;patient-years for 5&nbsp;mg and 10&nbsp;mg twice daily, respectively.</p><p><u>&nbsp;</u></p><p><em>Ankylosing spondylitis</em></p><p>In the combined Phase 2 and Phase 3 clinical studies, during the placebo-controlled period of up to 16&nbsp;weeks, the frequency of infections in the tofacitinib 5 mg twice daily group (185&nbsp;patients) was 27.6% and the frequency in the placebo group (187 patients) was 23.0%. In the combined Phase 2 and Phase 3 clinical studies, among the 316 patients treated with tofacitinib 5 mg twice daily for up to 48&nbsp;weeks, the frequency of infections was 35.1%.</p><p><em>&nbsp;</em></p><p><em>Ulcerative colitis</em></p><p>In the randomised 8-week Phase&nbsp;2/3 induction studies, the proportions of patients with infections were 21.1% (198 patients) in the tofacitinib 10&nbsp;mg twice daily group compared to 15.2% (43&nbsp;patients) in the placebo group. In the randomised 52-week phase&nbsp;3 maintenance study, the proportion of patients with infections were 35.9% (71&nbsp;patients) in the 5 mg twice daily and 39.8% (78&nbsp;patients) in the 10&nbsp;mg twice daily tofacitinib groups, compared to 24.2% (48&nbsp;patients) in the placebo group.</p><p>&nbsp;</p><p>In the entire treatment experience with tofacitinib, the most commonly reported infection was nasopharyngitis, occurring in 18.2% of patients (211 patients).</p><p>&nbsp;</p><p>In the entire treatment experience with tofacitinib, the overall incidence rate of infections was 60.3&nbsp;events per 100&nbsp;patient-years (involving 49.4% of patients; total 572&nbsp;patients).</p><p><strong><u>&nbsp;</u></strong></p><p><em><u>Serious infections</u></em></p><p>&nbsp;</p><p><em>Rheumatoid arthritis</em></p><p>In the 6-month and 24-month, controlled clinical studies, the rate of serious infections in the 5&nbsp;mg twice daily tofacitinib monotherapy group was 1.7&nbsp;patients with events per 100&nbsp;patient-years. In the 10&nbsp;mg twice daily tofacitinib monotherapy group the rate was 1.6&nbsp;patients with events per 100&nbsp;patient‑years, the rate was 0&nbsp;events per 100&nbsp;patient-years for the placebo group, and the rate was 1.9&nbsp;patients with events per 100&nbsp;patient-years for the MTX group.</p><p>&nbsp;</p><p>In studies of 6-, 12-, or 24-month duration, the rates of serious infections in the 5&nbsp;mg twice daily and 10&nbsp;mg twice daily tofacitinib plus DMARD groups were 3.6 and 3.4&nbsp;patients with events per 100&nbsp;patient-years, respectively, compared to 1.7&nbsp;patients with events per 100&nbsp;patient-years in the placebo plus DMARD group.</p><p>In the long-term safety all exposure population, the overall rates of serious infections were 2.4 and 3.0&nbsp;patients with&nbsp;events per 100&nbsp;patient-years for 5&nbsp;mg and 10&nbsp;mg twice daily tofacitinib groups, respectively. The most common serious infections included pneumonia, herpes zoster, urinary tract infection, cellulitis, gastroenteritis and diverticulitis. Cases of opportunistic infections have been reported (see section&nbsp;4.4).</p><p><u>&nbsp;</u></p><p>In a large (N=4,362) randomised post-authorisation safety study in patients with RA who were 50&nbsp;years or older with at least one additional cardiovascular risk factor, a dose‑dependent increase in serious infections was observed with tofacitinib compared to TNF inhibitors (see section 4.4).</p><p>&nbsp;</p><p>The incidence rates (95%&nbsp;CI) for serious infections for tofacitinib 5&nbsp;mg twice daily, tofacitinib 10&nbsp;mg twice daily, and TNF inhibitors were 2.86 (2.41, 3.37), 3.64 (3.11, 4.23), and 2.44 (2.02, 2.92) patients with events per 100 patient-years, respectively. Compared with TNF inhibitors, the hazard ratio (HR) for serious infections was 1.17 (0.92, 1.50) and 1.48 (1.17, 1.87) for tofacitinib 10&nbsp;mg twice daily and tofacitinib 5&nbsp;mg twice daily, respectively.</p><p><u>&nbsp;</u></p><p><em>Ankylosing spondylitis</em></p><p>In the combined Phase 2 and Phase 3 clinical studies, among the 316 patients treated with tofacitinib 5&nbsp;mg twice daily for up to 48&nbsp;weeks, there was one serious infection (aseptic meningitis) yielding a rate of 0.43 patients with events per 100 patient-years.</p><p>&nbsp;</p><p><em>Ulcerative colitis</em></p><p>The incidence rates and types of serious infections in the UC clinical studies were generally similar to those reported in RA clinical studies with tofacitinib monotherapy treatment groups.</p><p>&nbsp;</p><p><em><u>Serious infections in the elderly</u></em></p><p>Of the 4,271&nbsp;patients who enrolled in RA studies I-VI (see section&nbsp;5.1), a total of 608&nbsp;RA patients were 65&nbsp;years of age and older, including 85&nbsp;patients 75&nbsp;years and older. The frequency of serious infection among tofacitinib-treated patients 65&nbsp;years of age and older was higher than those under the age of 65&nbsp;(4.8 per 100 patient-years versus 2.4 per 100 patient-years, respectively).</p><p>&nbsp;</p><p>In a large (N=4,362) randomised post-authorisation safety study in patients with RA who were 50&nbsp;years or older with at least one additional cardiovascular risk factor, an increase in serious infections was observed in patients 65 years of age and older for tofacitinib 10 mg twice daily compared to TNF inhibitors and to tofacitinib 5 mg twice daily (see section 4.4). The incidence rates (95% CI) for serious infections in patients &ge;65 years were 4.03 (3.02, 5.27), 5.85 (4.64, 7.30), and 3.73 (2.81, 4.85) patients with events per 100 patient-years for tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, and TNF inhibitors, respectively.</p><p>&nbsp;</p><p>Compared with TNF inhibitors, the hazard ratio (HR) for serious infections in patients &ge;65 years of age was 1.08 (0.74, 1.58) and 1.55 (1.10, 2.19) for tofacitinib 5 mg twice daily and tofacitinib 10 mg twice daily, respectively.</p><p>&nbsp;</p><p><em><u>Serious infections from non-interventional post approval safety study</u></em></p><p>Data from a non-interventional post approval safety study that evaluated tofacitinib in RA patients from a registry (US Corrona) showed that a numerically higher incidence rate of serious infection was observed for the 11&nbsp;mg prolonged-release tablet administered once daily than the 5 mg film-coated tablet administered twice daily. Crude incidence rates (95% CI) (i.e., not adjusted for age or sex) from availability of each formulation at 12 months following initiation of treatment were 3.45 (1.93, 5.69) and 2.78 (1.74, 4.21) and at 36 months were 4.71 (3.08, 6.91) and 2.79 (2.01, 3.77) patients with events per 100 patient-years in the 11&nbsp;mg prolonged-release tablet once daily and 5&nbsp;mg film-coated tablet twice daily groups, respectively. The unadjusted hazard ratio was 1.30 (95% CI: 0.67, 2.50) at 12 months and 1.93 (95% CI: 1.15, 3.24) at 36 months for the 11&nbsp;mg prolonged-release once daily dose compared to the 5&nbsp;mg film-coated twice daily dose. Data is based on a small number of patients with events observed with relatively large confidence intervals and limited follow up time.</p><p>&nbsp;</p><p><em><u>Viral reactivation</u></em></p><p>&nbsp;</p><p>Patients treated with tofacitinib who are Japanese or Korean, or patients with long standing RA who<sup> </sup>have previously received two or more biological DMARDs, or patients with an ALC less than&nbsp;1,000&nbsp;cells/mm<sup>3</sup>, or patients treated with 10&nbsp;mg twice daily may have an increased risk of herpes zoster (see section&nbsp;4.4).</p><p>&nbsp;</p><p>In a large (N=4,362) randomised post-authorisation safety study in patients with RA who were 50&nbsp;years or older with at least one additional cardiovascular risk factor, an increase in herpes zoster events was observed in patients treated with tofacitinib compared to TNF inhibitors. The incidence rates (95% CI) for herpes zoster for tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, and TNF inhibitors were 3.75 (3.22, 4.34), 3.94 (3.38, 4.57), and 1.18 (0.90, 1.52) patients with events per 100 patient-years, respectively.</p><p>&nbsp;</p><p><em><u>Laboratory tests</u></em></p><p><em>&nbsp;</em></p><p><em>Lymphocytes</em></p><p>In the controlled RA clinical studies, confirmed decreases in ALC below 500&nbsp;cells/mm<sup>3</sup> occurred in 0.3% of patients and for ALC between 500 and 750&nbsp;cells/mm<sup>3</sup> in 1.9% of patients for the 5&nbsp;mg twice daily and 10&nbsp;mg twice daily doses combined.</p><p>&nbsp;</p><p>In the RA long-term safety population, confirmed decreases in ALC below 500&nbsp;cells/mm<sup>3</sup> occurred in 1.3% of patients and for ALC between 500 and 750&nbsp;cells/mm<sup>3</sup> in 8.4% of patients for the 5&nbsp;mg twice daily and 10&nbsp;mg twice daily doses combined.</p><p>&nbsp;</p><p>Confirmed ALC less than 750&nbsp;cells/mm<sup>3</sup> were associated with an increased incidence of serious infections (see section&nbsp;4.4).</p><p>&nbsp;</p><p>In the clinical studies in UC, changes in ALC observed with tofacitinib treatment were similar to the changes observed in clinical studies in RA.</p><p><em>&nbsp;</em></p><p><em>Neutrophils</em></p><p>In the controlled RA clinical studies, confirmed decreases in ANC below 1,000&nbsp;cells/mm<sup>3</sup> occurred in 0.08% of patients for the 5&nbsp;mg twice daily and 10&nbsp;mg twice daily doses combined. There were no confirmed decreases in ANC below 500&nbsp;cells/mm<sup>3</sup> observed in any treatment group. There was no clear relationship between neutropenia and the occurrence of serious infections.</p><p>&nbsp;</p><p>In the RA long-term safety population, the pattern and incidence of confirmed decreases in ANC remained consistent with what was seen in the controlled clinical studies (see section&nbsp;4.4).</p><p>&nbsp;</p><p>In the clinical studies in UC, changes in ANC observed with tofacitinib treatment were similar to the changes observed in clinical studies in RA.</p><p><u>&nbsp;</u></p><p><em>Platelets</em></p><p>Patients in the Phase 3 controlled clinical studies (RA, PsA, AS, UC) were required to have a platelet count &ge;&nbsp;100,000 cells/mm<sup>3</sup> to be eligible for enrolment, therefore, there is no information available for patients with a platelet count &lt;&nbsp;100,000 cells/mm<sup>3</sup> before starting treatment with tofacitinib.</p><p>&nbsp;</p><p><em>Liver enzyme tests</em></p><p>Confirmed increases in liver enzymes greater than 3 times the upper limit of normal (3x&nbsp;ULN) were uncommonly observed in RA patients. In those patients experiencing liver enzyme elevation, modification of treatment regimen, such as reduction in the dose of concomitant DMARD, interruption of tofacitinib, or reduction in tofacitinib dose, resulted in decrease or normalisation of liver enzymes.</p><p>&nbsp;</p><p>In the controlled portion of the RA phase 3 monotherapy study (0-3 months) (study I, see section&nbsp;5.1), ALT elevations greater than 3x&nbsp;ULN were observed in 1.65%, 0.41%, and 0% of patients receiving placebo, tofacitinib 5&nbsp;mg and 10&nbsp;mg twice daily, respectively. In this study, AST elevations&nbsp;greater than 3x ULN were observed in 1.65%, 0.41% and 0% of patients receiving placebo, tofacitinib 5&nbsp;mg and 10&nbsp;mg twice daily, respectively.</p><p>&nbsp;</p><p>In the RA phase&nbsp;3 monotherapy study (0-24 months) (study&nbsp;VI, see section&nbsp;5.1), ALT elevations greater than&nbsp;3x&nbsp;ULN were observed in 7.1%, 3.0%, and 3.0% of patients receiving MTX, tofacitinib 5&nbsp;mg and 10&nbsp;mg twice daily, respectively. In this study, AST elevations greater than&nbsp;3x&nbsp;ULN were observed in 3.3%, 1.6% and 1.5% of patients receiving MTX, tofacitinib 5&nbsp;mg and 10&nbsp;mg twice daily, respectively.</p><p>&nbsp;</p><p>In the controlled portion of the RA phase&nbsp;3 studies on background DMARDs (0-3&nbsp;months) (studies&nbsp;II‑V, see section&nbsp;5.1), ALT elevations greater than 3x&nbsp;ULN were observed in 0.9%, 1.24% and 1.14% of patients receiving placebo, tofacitinib 5&nbsp;mg and 10&nbsp;mg twice daily, respectively. In these studies, AST elevations&nbsp;greater than 3x&nbsp;ULN were observed in 0.72%, 0.5% and 0.31% of patients receiving placebo, tofacitinib 5&nbsp;mg and 10&nbsp;mg twice daily, respectively.</p><p>&nbsp;</p><p>In the RA long-term extension studies, on monotherapy, ALT elevations greater than 3x ULN were observed in 1.1% and 1.4% of patients receiving tofacitinib 5 mg and 10 mg twice daily, respectively. AST elevations greater than 3x ULN were observed in &lt;&nbsp;1.0% in both the tofacitinib 5&nbsp;mg and 10 mg twice daily groups.</p><p>&nbsp;</p><p>In the RA long-term extension studies, on background DMARDs, ALT elevations greater than 3x&nbsp;ULN were observed in 1.8% and 1.6% of patients receiving tofacitinib 5 mg and 10 mg twice daily, respectively. AST elevations greater than 3x ULN were observed in &lt;&nbsp;1.0% in both the tofacitinib 5&nbsp;mg and 10 mg twice daily groups.</p><p>&nbsp;</p><p>In a large (N=4,362) randomised post-authorisation safety study in patients with RA who were 50&nbsp;years or older with at least one additional cardiovascular risk factor, ALT elevations greater than or equal to 3x&nbsp;ULN were observed in 6.01%, 6.54% and 3.77% of patients receiving tofacitinib 5&nbsp;mg twice daily, tofacitinib 10&nbsp;mg twice daily, and TNF inhibitors respectively. AST elevations greater than or equal to 3x&nbsp;ULN were observed in 3.21%, 4.57% and 2.38% of patients receiving tofacitinib 5&nbsp;mg twice daily, tofacitinib 10&nbsp;mg twice daily, and TNF inhibitors respectively.</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>In the clinical studies in UC, changes in liver enzyme tests observed with tofacitinib treatment were similar to the changes observed in clinical studies in RA.</p><p><em>&nbsp;</em></p><p><em>Lipids</em></p><p>Elevations in lipid parameters (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) were first assessed at 1 month following initiation of tofacitinib in the controlled double-blind clinical studies of RA. Increases were observed at this time point and remained stable thereafter.</p><p>&nbsp;</p><p>Changes in lipid parameters from baseline through the end of the study (6-24&nbsp;months) in the controlled clinical studies in RA are summarised below:</p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean LDL cholesterol increased by 15% in the tofacitinib 5&nbsp;mg twice daily arm and 20% in the tofacitinib 10&nbsp;mg twice daily arm at month&nbsp;12, and increased by 16% in the tofacitinib 5&nbsp;mg twice daily arm and 19% in the tofacitinib 10&nbsp;mg twice daily arm at month&nbsp;24.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean HDL cholesterol increased by 17% in the tofacitinib 5&nbsp;mg twice daily arm and 18% in the tofacitinib 10&nbsp;mg twice daily arm at month&nbsp;12, and increased by 19% in the tofacitinib 5&nbsp;mg twice daily arm and 20% in the tofacitinib 10&nbsp;mg twice daily arm at month&nbsp;24.</p><p>&nbsp;</p><p>Upon withdrawal of tofacitinib treatment, lipid levels returned to baseline.</p><p>&nbsp;</p><p>Mean LDL cholesterol/HDL cholesterol ratios and Apolipoprotein B (ApoB)/ApoA1 ratios were essentially unchanged in tofacitinib-treated patients.</p><p>&nbsp;</p><p>In an RA controlled clinical study, elevations in LDL cholesterol and ApoB decreased to pretreatment levels in response to statin therapy.</p><p>&nbsp;</p><p>In the RA long-term safety populations, elevations in the lipid parameters remained consistent with what was seen in the controlled clinical studies.</p><p>&nbsp;</p><p>In a large (N=4,362) randomised post-authorisation safety study in patients with RA who were 50&nbsp;years or older with at least one additional cardiovascular risk factor, changes in lipid parameters from baseline through 24&nbsp;months are summarised below:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean LDL cholesterol increased by 13.80%, 17.04%, and 5.50% in patients receiving tofacitinib 5&nbsp;mg twice daily, tofacitinib 10&nbsp;mg twice daily, and TNF inhibitor, respectively, at month&nbsp;12. At month 24, the increase was 12.71%, 18.14%, and 3.64%, respectively,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean HDL cholesterol increased by 11.71%, 13.63%, and 2.82% in patients receiving tofacitinib 5&nbsp;mg twice daily, tofacitinib 10&nbsp;mg twice daily, and TNF inhibitor, respectively, at month&nbsp;12. At month 24, the increase was 11.58%, 13.54%, and 1.42%, respectively.</p><p>&nbsp;</p><p>In the clinical studies in UC, changes in lipids observed with tofacitinib treatment were similar to the changes observed in clinical studies in RA.</p><p><u>&nbsp;</u></p><p><em><u>Myocardial infarction</u></em></p><p><u>&nbsp;</u></p><p><em>Rheumatoid arthritis</em></p><p>In a large (N=4,362) randomised post-authorisation safety study in patients with RA who were 50&nbsp;years of age or older with at least one additional cardiovascular risk factor, the incidence rates (95% CI) for non-fatal myocardial infarction for tofacitinib 5&nbsp;mg twice daily, tofacitinib 10&nbsp;mg twice daily, and TNF inhibitors were 0.37 (0.22, 0.57), 0.33 (0.19, 0.53), and 0.16 (0.07, 0.31) patients with events per 100&nbsp;patient-years, respectively. Few fatal myocardial infarctions were reported with rates similar in patients treated with tofacitinib compared to TNF inhibitors (see sections 4.4 and 5.1). The study required at least 1500&nbsp;patients to be followed for 3&nbsp;years.</p><p><u>&nbsp;</u></p><p><em><u>Malignancies excluding NMSC</u></em></p><p><em><u>&nbsp;</u></em></p><p><em>Rheumatoid arthritis</em></p><p>In a large (N=4,362) randomised post-authorisation safety study in patients with RA who were 50&nbsp;years of age or older with at least one additional cardiovascular risk factor, the incidence rates (95% CI) for lung cancer for tofacitinib 5&nbsp;mg twice daily, tofacitinib 10&nbsp;mg twice daily, and TNF inhibitors were 0.23 (0.12, 0.40), 0.32 (0.18, 0.51), and 0.13 (0.05, 0.26) patients with events per 100&nbsp;patient-years, respectively (see sections 4.4 and 5.1). The study required at least 1500&nbsp;patients to be followed for 3&nbsp;years.</p><p>&nbsp;</p><p>The incidence rates (95% CI) for lymphoma for tofacitinib 5&nbsp;mg twice daily, tofacitinib 10&nbsp;mg twice daily, and TNF inhibitors were 0.07 (0.02, 0.18), 0.11 (0.04, 0.24), and 0.02 (0.00, 0.10) patients with events per 100&nbsp;patient-years, respectively (see sections 4.4 and 5.1).</p><p><u>&nbsp;</u></p><p><u>Paediatric population </u></p><p>&nbsp;</p><p><em><u>Polyarticular juvenile idiopathic arthritis and juvenile PsA </u></em></p><p>The adverse reactions in JIA patients in the clinical development program were consistent in type and frequency with those seen in adult RA patients, with the exception of some infections (influenza, pharyngitis, sinusitis, viral infection) and gastrointestinal or general disorders (abdominal pain, nausea, vomiting, pyrexia, headache, cough), which were more common in JIA paediatric population. MTX was the most frequent concomitant csDMARD used (on Day 1, 156 of 157 patients on csDMARDs took MTX). There are insufficient data regarding the safety profile of tofacitinib used concomitantly with any other csDMARDs.</p><p>&nbsp;</p><p><em>Infections</em></p><p>In the double-blind portion of the pivotal Phase 3 trial (Study JIA-I), infection was the most commonly reported adverse reaction (44.3%). The infections were generally mild to moderate in severity.</p><p>&nbsp;</p><p>In the integrated safety population, 7 patients had serious infections during treatment with tofacitinib within the reporting period (up to 28 days after the last dose of study medication), representing an incidence rate of 1.92 patients with events per 100 patient-years: pneumonia, epidural empyema (with sinusitis and subperiosteal abscess), pilonidal cyst, appendicitis, escherichia pyelonephritis, abscess limb, and UTI.</p><p>&nbsp;</p><p>In the integrated safety population, 3 patients had non-serious events of herpes zoster within the reporting window representing an incidence rate of 0.82 patients with events per 100 patient-years. One (1) additional patient had an event of serious HZ outside the reporting window.</p><p>&nbsp;</p><p><em>Hepatic events</em></p><p>&nbsp;</p><p>Patients in the JIA pivotal study were required to have AST and ALT levels less than 1.5 times the upper limit of normal to be eligible for enrolment. In the integrated safety population, there were 2&nbsp;patients with ALT elevations &ge;&nbsp;3 times the ULN at 2 consecutive visits. Neither event met Hy&rsquo;s Law criteria. Both patients were on background MTX therapy and each event resolved after discontinuation of MTX and permanent discontinuation of tofacitinib.</p><p>&nbsp;</p><p><em>Laboratory tests</em></p><p>&nbsp;</p><p>Changes in laboratory tests in JIA patients in the clinical development program were consistent with those seen in adult RA patients. Patients in the JIA pivotal study were required to have a platelet count &ge;&nbsp;100,000 cells/mm<sup>3</sup> to be eligible for enrolment, therefore, there is no information available for JIA patients with a platelet count &lt;100,000 cells/mm<sup>3</sup> before starting treatment with tofacitinib.&nbsp;</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Center (NPC).</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other <strong>GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. There is no specific antidote for overdose with tofacitinib. Treatment should be symptomatic and supportive.</p><p>&nbsp;</p><p>Pharmacokinetic data up to and including a single dose of 100&nbsp;mg in healthy volunteers indicate that more than 95% of the administered dose is expected to be eliminated within 24&nbsp;hours.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic groups: Immunosuppressants, Selective Immunosuppressants; ATC code:&nbsp;L04AA29</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Tofacitinib is a potent, selective inhibitor of the JAK family. In enzymatic assays, tofacitinib inhibits JAK1, JAK2, JAK3, and to a lesser extent TyK2. In contrast, tofacitinib has a high degree of selectivity against other kinases in the human genome. In human cells, tofacitinib preferentially inhibits signalling by heterodimeric cytokine receptors that associate with JAK3 and/or JAK1 with functional selectivity over cytokine receptors that signal via pairs of JAK2. Inhibition of JAK1 and JAK3 by tofacitinib attenuates signalling of interleukins (IL-2, -4, -6, -7, -9, -15, -21) and type I and type II interferons, which will result in modulation of the immune and inflammatory response.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>In patients with RA, treatment up to 6&nbsp;months with tofacitinib was associated with dose‑dependent reductions of circulating CD16/56+ natural killer (NK) cells, with estimated maximum reductions occurring at approximately 8-10&nbsp;weeks after initiation of therapy. These changes generally resolved within 2-6&nbsp;weeks after discontinuation of treatment. Treatment with tofacitinib was associated with dose-dependent increases in B cell counts. Changes in circulating T-lymphocyte counts and T‑lymphocyte subsets (CD3+, CD4+ and CD8+) were small and inconsistent.</p><p>&nbsp;</p><p>Following long-term treatment (median duration of tofacitinib treatment of approximately 5&nbsp;years), CD4+ and CD8+ counts showed median reductions of 28% and 27%, respectively, from baseline. In contrast to the observed decrease after short-term dosing, CD16/56+ natural killer cell counts showed a median increase of 73% from baseline. CD19+ B cell counts showed no further increases after long‑term tofacitinib treatment. All these lymphocyte subset changes returned toward baseline after temporary discontinuation of treatment. There was no evidence of a relationship between serious or opportunistic infections or herpes zoster and lymphocyte subset counts (see section 4.2 for absolute lymphocyte count monitoring).</p><p>&nbsp;</p><p>Changes in total serum IgG, IgM, and IgA levels over 6-month tofacitinib dosing in patients with RA were small, not dose-dependent and similar to those seen on placebo, indicating a lack of systemic humoral suppression.</p><p>&nbsp;</p><p>After treatment with tofacitinib in RA patients, rapid decreases in serum C‑reactive protein (CRP) were observed and maintained throughout dosing. Changes in CRP observed with tofacitinib treatment do not reverse fully within 2&nbsp;weeks after discontinuation, indicating a longer duration of pharmacodynamic activity compared to the half-life.</p><p>&nbsp;</p><p><u>Vaccine studies</u></p><p>&nbsp;</p><p>In a controlled clinical study of patients with RA initiating tofacitinib 10&nbsp;mg twice daily or placebo, the number of responders to influenza vaccine was similar in both groups: tofacitinib (57%) and placebo (62%). For pneumococcal polysaccharide vaccine the number of responders was as follows: 32% in patients receiving both tofacitinib and MTX; 62% for tofacitinib monotherapy; 62% for MTX monotherapy; and 77% for placebo. The clinical significance of this is unknown, however, similar results were obtained in a separate vaccine study with influenza and pneumococcal polysaccharide vaccines in patients receiving long-term tofacitinib 10&nbsp;mg twice daily.</p><p>&nbsp;</p><p>A controlled study was conducted in patients with RA on background MTX immunised with a live attenuated herpes virus vaccine 2 to 3&nbsp;weeks before initiating a 12-week treatment with tofacitinib 5&nbsp;mg twice daily or placebo. Evidence of humoral and cell-mediated responses to VZV was observed in both tofacitinib and placebo-treated patients at 6&nbsp;weeks. These responses were similar to those observed in healthy volunteers aged 50&nbsp;years and older. A patient with no previous history of varicella infection and no anti-varicella antibodies at baseline experienced dissemination of the vaccine strain of varicella 16&nbsp;days after vaccination. Tofacitinib was discontinued and the patient recovered after treatment with standard doses of antiviral medicinal product. This patient subsequently made a robust, though delayed, humoral and cellular response to the vaccine (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><em>Rheumatoid arthritis</em></p><p>The efficacy and safety of tofacitinib film-coated tablets were assessed in 6&nbsp;randomised, double-blind, controlled multicentre studies in patients greater than 18&nbsp;years of age with active RA diagnosed according to American College of Rheumatology (ACR) criteria.<em> </em>Table&nbsp;9 provides information regarding the pertinent study design and population characteristics.</p><p>&nbsp;</p><p><strong>Table&nbsp;9:&nbsp; Phase&nbsp;3 clinical studies of tofacitinib 5&nbsp;mg and 10 mg twice daily doses in patients with RA</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>Studies</p></td><td style="vertical-align:top"><p>Study I</p><p>(ORAL</p><p>Solo)</p></td><td style="vertical-align:top"><p>Study II</p><p>(ORAL</p><p>Sync)</p></td><td style="vertical-align:top"><p>Study III</p><p>(ORAL</p><p>Standard)</p></td><td style="vertical-align:top"><p>Study IV</p><p>(ORAL</p><p>Scan)</p></td><td style="vertical-align:top"><p>Study V</p><p>(ORAL</p><p>Step)</p></td><td style="vertical-align:top"><p>Study VI</p><p>(ORAL</p><p>Start)</p></td><td style="vertical-align:top"><p>Study VII</p><p>(ORAL</p><p>Strategy)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Population</p></td><td style="vertical-align:top"><p>DMARD-IR</p></td><td style="vertical-align:top"><p>DMARD-IR</p></td><td style="vertical-align:top"><p>MTX-IR</p></td><td style="vertical-align:top"><p>MTX-IR</p></td><td style="vertical-align:top"><p>TNFi-IR</p></td><td style="vertical-align:top"><p>MTX-na&iuml;ve<sup>a</sup></p></td><td style="vertical-align:top"><p>MTX-IR</p></td></tr><tr><td style="vertical-align:top"><p>Control</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>MTX</p></td><td style="vertical-align:top"><p>MTX,</p><p>ADA</p></td></tr><tr><td style="vertical-align:top"><p>Background treatment</p></td><td style="vertical-align:top"><p>None<sup>b</sup></p></td><td style="vertical-align:top"><p>csDMARDs</p></td><td style="vertical-align:top"><p>MTX</p></td><td style="vertical-align:top"><p>MTX</p></td><td style="vertical-align:top"><p>MTX</p></td><td style="vertical-align:top"><p>None<sup>b</sup></p></td><td style="vertical-align:top"><p>3 Parallel arms:</p><p>&middot;&nbsp;&nbsp; Tofacitinib monotherapy</p><p>&middot;&nbsp;&nbsp; Tofacitinib+MTX</p><p>&middot;&nbsp;&nbsp; ADA+MTX</p></td></tr><tr><td style="vertical-align:top"><p>Key features</p></td><td style="vertical-align:top"><p>Monotherapy</p></td><td style="vertical-align:top"><p>Various csDMARDs</p></td><td style="vertical-align:top"><p>Active control (ADA)</p></td><td style="vertical-align:top"><p>X-Ray</p></td><td style="vertical-align:top"><p>TNFi-IR</p></td><td style="vertical-align:top"><p>Monotherapy, Active comparator (MTX),</p><p>X-Ray</p></td><td style="vertical-align:top"><p>Tofacitinib with and without MTX in comparison to ADA with MTX</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients treated</p></td><td style="vertical-align:top"><p>610</p></td><td style="vertical-align:top"><p>792</p></td><td style="vertical-align:top"><p>717</p></td><td style="vertical-align:top"><p>797</p></td><td style="vertical-align:top"><p>399</p></td><td style="vertical-align:top"><p>956</p></td><td style="vertical-align:top"><p>1,146</p></td></tr><tr><td style="vertical-align:top"><p>Total study duration</p></td><td style="vertical-align:top"><p>6 months</p></td><td style="vertical-align:top"><p>1 year</p></td><td style="vertical-align:top"><p>1 year</p></td><td style="vertical-align:top"><p>2 years</p></td><td style="vertical-align:top"><p>6 months</p></td><td style="vertical-align:top"><p>2 years</p></td><td style="vertical-align:top"><p>1 year</p></td></tr><tr><td style="vertical-align:top"><p>Co-primary efficacy endpoints<sup>c</sup></p></td><td style="vertical-align:top"><p>Month 3:</p><p>ACR20</p><p>HAQ-DI</p><p>DAS28-4(ESR)&lt;2.6</p></td><td style="vertical-align:top"><p>Month 6:</p><p>ACR20</p><p>DAS28-4(ESR)&lt;2.6</p><p>Month 3:</p><p>HAQ-DI</p></td><td style="vertical-align:top"><p>Month 6:</p><p>ACR20</p><p>DAS28-4(ESR)&lt;2.6</p><p>Month 3:</p><p>HAQ-DI</p></td><td style="vertical-align:top"><p>Month 6:</p><p>ACR20</p><p>mTSS</p><p>DAS28-4(ESR)&lt;2.6</p><p>Month 3:</p><p>HAQ-DI</p></td><td style="vertical-align:top"><p>Month 3:</p><p>ACR20</p><p>HAQ-DI</p><p>DAS28-4(ESR)&lt;2.6</p></td><td style="vertical-align:top"><p>Month 6:</p><p>mTSS</p><p>ACR70</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Month 6:</p><p>ACR50</p></td></tr><tr><td style="vertical-align:top"><p>Time of mandatory placebo rescue to tofacitinib 5 or 10&nbsp;mg twice daily</p></td><td style="vertical-align:top"><p>Month 3</p></td><td colspan="3" style="vertical-align:top"><p>Month 6 (placebo subjects with &lt;&nbsp;20% improvement in swollen and tender joint counts advanced to tofacitinib at month&nbsp;3)</p></td><td style="vertical-align:top"><p>Month 3</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p><sup>a. </sup>&le;3 weekly doses (MTX-na&iuml;ve).</p><p><sup>b.</sup>Antimalarials were allowed.</p><p><sup>c.</sup> Co-primary endpoints as follows: mean change from baseline in mTSS; percent of subjects achieving ACR20 or ACR70 responses; mean change from baseline in HAQ-DI; percent of subjects achieving a DAS28-4(ESR) &lt;2.6 (remission).</p><p>mTSS=modified Total Sharp Score, ACR20(70)=American College of Rheumatology &ge;20% (&ge;70%) improvement, DAS28=Disease Activity Score 28 joints, ESR=Erythrocyte Sedimentation Rate, HAQ-DI=Health Assessment Questionnaire Disability Index, DMARD=disease-modifying antirheumatic drug, IR=inadequate responder, csDMARD=conventional synthetic DMARD, TNFi=tumour necrosis factor inhibitor, NA=not applicable, ADA=adalimumab, MTX=methotrexate.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><em><u>Clinical response</u></em></p><p><u>&nbsp;</u></p><p><em>ACR response</em></p><p>The percentages of tofacitinib-treated patients achieving ACR20, ACR50 and ACR70 responses in studies ORAL Solo, ORAL Sync, ORAL Standard, ORAL Scan, ORAL Step, ORAL Start, and ORAL Strategy are shown in Table 10. In all studies, patients treated with either 5&nbsp;mg or 10&nbsp;mg twice daily tofacitinib had statistically significant ACR20, ACR50 and ACR70 response rates at month 3 and month 6 versus placebo (or versus MTX in ORAL Start) treated patients.</p><p>&nbsp;</p><p>Over the course of ORAL Strategy, responses with tofacitinib 5 mg twice daily + MTX were numerically similar compared to adalimumab 40 mg + MTX and both were numerically higher than tofacitinib 5 mg twice daily.</p><p><strong>&nbsp;</strong></p><p>The treatment effect was similar in patients independent of rheumatoid factor status, age, gender, race, or disease status. Time to onset was rapid (as early as week&nbsp;2 in studies&nbsp;ORAL Solo, ORAL Sync, and ORAL Step) and the magnitude of response continued to improve with duration of treatment. As with the overall ACR response in patients treated with 5&nbsp;mg or 10&nbsp;mg twice daily tofacitinib, each of the components of the ACR response was consistently improved from baseline including: tender and swollen joint counts; patient and physician global assessment; disability index scores; pain assessment and CRP compared to patients receiving placebo plus MTX or other DMARDs in all studies.</p><p>&nbsp;</p><p><strong>Table&nbsp;10: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion (%) of patients with an ACR response </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="7"><p><strong>ORAL Solo:</strong> <strong>DMARD inadequate responders</strong></p></td></tr><tr><td><p><strong>Endpoint</strong></p></td><td><p><strong>Time</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>N=122</strong></p></td><td colspan="2"><p><strong>Tofacitinib 5&nbsp;mg twice daily monotherapy </strong></p><p><strong>N=241</strong></p></td><td colspan="2"><p><strong>Tofacitinib 10&nbsp;mg twice daily</strong><strong> </strong><strong>monotherapy</strong></p><p><strong>N=243</strong></p></td></tr><tr><td rowspan="2"><p>ACR20</p></td><td><p>Month 3</p></td><td><p>26</p></td><td colspan="2"><p>60***</p></td><td colspan="2"><p>65***</p></td></tr><tr><td><p>Month 6</p></td><td><p>NA</p></td><td colspan="2"><p>69</p></td><td colspan="2"><p>71</p></td></tr><tr><td rowspan="2"><p>ACR50</p></td><td><p>Month 3</p></td><td><p>12</p></td><td colspan="2"><p>31***</p></td><td colspan="2"><p>37***</p></td></tr><tr><td><p>Month 6</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>42</p></td><td colspan="2"><p>47</p></td></tr><tr><td rowspan="2"><p>ACR70</p></td><td><p>Month 3</p></td><td><p>6</p></td><td colspan="2"><p>15*</p></td><td colspan="2"><p>20***</p></td></tr><tr><td><p>Month 6</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>22</p></td><td colspan="2"><p>29</p></td></tr><tr><td colspan="7"><p><strong>ORAL Sync:</strong> <strong>DMARD inadequate responders</strong></p></td></tr><tr><td><p><strong>Endpoint</strong></p></td><td><p><strong>Time</strong></p></td><td><p><strong>Placebo + DMARD(s)</strong></p><p><strong>&nbsp;</strong></p><p><strong>N=158</strong></p></td><td colspan="2"><p><strong>Tofacitinib 5&nbsp;mg twice daily + DMARD(s)</strong></p><p><strong>N=312</strong></p></td><td colspan="2"><p><strong>Tofacitinib 10&nbsp;mg twice daily</strong><strong> + </strong><strong>DMARD(s)</strong></p><p><strong>N=315</strong></p></td></tr><tr><td rowspan="3"><p>ACR20</p></td><td><p>Month 3</p></td><td style="vertical-align:top"><p>27</p></td><td colspan="2" style="vertical-align:top"><p>56***</p></td><td colspan="2" style="vertical-align:top"><p>63***</p></td></tr><tr><td><p>Month 6</p></td><td style="vertical-align:top"><p>31</p></td><td colspan="2" style="vertical-align:top"><p>53***</p></td><td colspan="2" style="vertical-align:top"><p>57***</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2" style="vertical-align:top"><p>51</p></td><td colspan="2" style="vertical-align:top"><p>56</p></td></tr><tr><td rowspan="3"><p>ACR50</p></td><td><p>Month 3</p></td><td style="vertical-align:top"><p>9</p></td><td colspan="2" style="vertical-align:top"><p>27***</p></td><td colspan="2" style="vertical-align:top"><p>33***</p></td></tr><tr><td><p>Month 6</p></td><td style="vertical-align:top"><p>13</p></td><td colspan="2" style="vertical-align:top"><p>34***</p></td><td colspan="2" style="vertical-align:top"><p>36***</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2" style="vertical-align:top"><p>33</p></td><td colspan="2" style="vertical-align:top"><p>42</p></td></tr><tr><td rowspan="3"><p>ACR70</p></td><td><p>Month 3</p></td><td style="vertical-align:top"><p>2</p></td><td colspan="2" style="vertical-align:top"><p>8**</p></td><td colspan="2" style="vertical-align:top"><p>14***</p></td></tr><tr><td><p>Month 6</p></td><td style="vertical-align:top"><p>3</p></td><td colspan="2" style="vertical-align:top"><p>13***</p></td><td colspan="2" style="vertical-align:top"><p>16***</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2" style="vertical-align:top"><p>19</p></td><td colspan="2" style="vertical-align:top"><p>25</p></td></tr><tr><td colspan="7"><p><strong>ORAL Standard: MTX inadequate responders</strong></p></td></tr><tr><td><p><strong>Endpoint</strong></p></td><td><p><strong>Time</strong></p></td><td><p><strong>Placebo</strong></p></td><td colspan="3"><p><strong>Tofacitinib twice daily + MTX</strong></p></td><td><p><strong>Adalimumab 40&nbsp;mg QOW<br />+ MTX</strong></p></td></tr><tr><td rowspan="4"><p>ACR20</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>&nbsp;</strong></p><p><strong>N=105</strong></p></td><td><p><strong>5&nbsp;mg</strong></p><p><strong>N=198</strong></p></td><td colspan="2"><p><strong>10&nbsp;mg</strong></p><p><strong>N=197</strong></p></td><td><p>&nbsp;</p><p><strong>N=199</strong></p></td></tr><tr><td style="vertical-align:top"><p>Month 3</p></td><td><p>26</p></td><td><p>59***</p></td><td colspan="2"><p>57***</p></td><td><p>56***</p></td></tr><tr><td style="vertical-align:top"><p>Month 6</p></td><td style="vertical-align:top"><p>28</p></td><td><p>51***</p></td><td colspan="2"><p>51***</p></td><td><p>46**</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>NA</p></td><td><p>48</p></td><td colspan="2"><p>49</p></td><td><p>48</p></td></tr><tr><td rowspan="3"><p>ACR50</p></td><td><p>Month 3</p></td><td><p>7</p></td><td><p>33***</p></td><td colspan="2"><p>27***</p></td><td><p>24***</p></td></tr><tr><td><p>Month 6</p></td><td><p>12</p></td><td><p>36***</p></td><td colspan="2"><p>34***</p></td><td><p>27**</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>NA</p></td><td><p>36</p></td><td colspan="2"><p>36</p></td><td><p>33</p></td></tr><tr><td rowspan="3"><p>ACR70</p></td><td><p>Month 3</p></td><td><p>2</p></td><td><p>12**</p></td><td colspan="2"><p>15***</p></td><td><p>9*</p></td></tr><tr><td><p>Month 6</p></td><td><p>2</p></td><td><p>19***</p></td><td colspan="2"><p>21***</p></td><td><p>9*</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>NA</p></td><td><p>22</p></td><td colspan="2"><p>23</p></td><td><p>17</p></td></tr><tr><td colspan="7"><p><strong>ORAL Scan: MTX inadequate responders</strong></p></td></tr><tr><td><p><strong>Endpoint</strong></p></td><td><p><strong>Time</strong></p></td><td><p><strong>Placebo + MTX</strong></p><p><strong>N=156</strong></p></td><td colspan="2"><p><strong>Tofacitinib 5&nbsp;mg twice daily</strong></p><p><strong>&nbsp;+ MTX</strong></p><p><strong>N=316</strong></p></td><td colspan="2"><p><strong>Tofacitinib 10&nbsp;mg twice daily</strong></p><p><strong>&nbsp;+ MTX</strong></p><p><strong>N=309</strong></p></td></tr><tr><td rowspan="4"><p>ACR20</p></td><td><p>Month 3</p></td><td><p>27</p></td><td colspan="2"><p>55***</p></td><td colspan="2"><p>66***</p></td></tr><tr><td><p>Month 6</p></td><td><p>25</p></td><td colspan="2"><p>50***</p></td><td colspan="2"><p>62***</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>47</p></td><td colspan="2"><p>55</p></td></tr><tr><td><p>Month 24</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>40</p></td><td colspan="2"><p>50</p></td></tr><tr><td rowspan="4"><p>ACR50</p></td><td><p>Month 3</p></td><td><p>8</p></td><td colspan="2"><p>28***</p></td><td colspan="2"><p>36***</p></td></tr><tr><td><p>Month 6</p></td><td><p>8</p></td><td colspan="2"><p>32***</p></td><td colspan="2"><p>44***</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>32</p></td><td colspan="2"><p>39</p></td></tr><tr><td><p>Month 24</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>28</p></td><td colspan="2"><p>40</p></td></tr><tr><td rowspan="4"><p>ACR70</p></td><td><p>Month 3</p></td><td><p>3</p></td><td colspan="2"><p>10**</p></td><td colspan="2"><p>17***</p></td></tr><tr><td><p>Month 6</p></td><td><p>1</p></td><td colspan="2"><p>14***</p></td><td colspan="2"><p>22***</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>18</p></td><td colspan="2"><p>27</p></td></tr><tr><td><p>Month 24</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>17</p></td><td colspan="2"><p>26</p></td></tr><tr><td colspan="7"><p><strong>ORAL Step: TNF Inhibitor inadequate responders</strong></p></td></tr><tr><td><p><strong>Endpoint</strong></p></td><td><p><strong>Time</strong></p></td><td><p><strong>Placebo + MTX</strong></p><p><strong>N=132</strong></p></td><td colspan="2"><p><strong>Tofacitinib 5&nbsp;mg twice daily</strong></p><p><strong>&nbsp;+ MTX</strong></p><p><strong>N=133</strong></p></td><td colspan="2"><p><strong>Tofacitinib 10&nbsp;mg twice daily</strong></p><p><strong>&nbsp;+ MTX</strong></p><p><strong>N=134</strong></p></td></tr><tr><td rowspan="2"><p>ACR20</p></td><td><p>Month 3</p></td><td><p>24</p></td><td colspan="2"><p>41*</p></td><td colspan="2"><p>48***</p></td></tr><tr><td><p>Month 6</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>51</p></td><td colspan="2"><p>54</p></td></tr><tr><td rowspan="2"><p>ACR50</p></td><td><p>Month 3</p></td><td><p>8</p></td><td colspan="2"><p>26***</p></td><td colspan="2"><p>28***</p></td></tr><tr><td><p>Month 6</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>37</p></td><td colspan="2"><p>30</p></td></tr><tr><td rowspan="2"><p>ACR70</p></td><td><p>Month 3</p></td><td><p>2</p></td><td colspan="2"><p>14***</p></td><td colspan="2"><p>10*</p></td></tr><tr><td><p>Month 6</p></td><td style="vertical-align:top"><p>NA</p></td><td colspan="2"><p>16</p></td><td colspan="2"><p>16</p></td></tr><tr><td colspan="7"><p><strong>ORAL Start: MTX-na&iuml;ve</strong></p></td></tr><tr><td><p><strong>Endpoint</strong></p></td><td><p><strong>Time</strong></p></td><td><p><strong>MTX</strong></p><p><strong>N=184</strong></p></td><td colspan="2"><p><strong>Tofacitinib 5&nbsp;mg twice daily</strong> <strong>monotherapy</strong></p><p><strong>N=370</strong></p></td><td colspan="2"><p><strong>Tofacitinib 10&nbsp;mg twice daily</strong></p><p><strong>monotherapy</strong></p><p><strong>N=394</strong></p></td></tr><tr><td rowspan="4"><p>ACR20</p></td><td><p>Month 3</p></td><td><p>52</p></td><td colspan="2"><p>69***</p></td><td colspan="2"><p>77***</p></td></tr><tr><td><p>Month 6</p></td><td><p>51</p></td><td colspan="2"><p>71***</p></td><td colspan="2"><p>75***</p></td></tr><tr><td><p>Month 12</p></td><td><p>51</p></td><td colspan="2"><p>67**</p></td><td colspan="2"><p>71***</p></td></tr><tr><td><p>Month 24</p></td><td><p>42</p></td><td colspan="2"><p>63***</p></td><td colspan="2"><p>64***</p></td></tr><tr><td rowspan="4"><p>ACR50</p></td><td><p>Month 3</p></td><td><p>20</p></td><td colspan="2"><p>40***</p></td><td colspan="2"><p>49***</p></td></tr><tr><td><p>Month 6</p></td><td><p>27</p></td><td colspan="2"><p>46***</p></td><td colspan="2"><p>56***</p></td></tr><tr><td><p>Month 12</p></td><td><p>33</p></td><td colspan="2"><p>49**</p></td><td colspan="2"><p>55***</p></td></tr><tr><td><p>Month 24</p></td><td><p>28</p></td><td colspan="2"><p>48***</p></td><td colspan="2"><p>49***</p></td></tr><tr><td rowspan="4"><p>ACR70</p></td><td><p>Month 3</p></td><td><p>5</p></td><td colspan="2"><p>20***</p></td><td colspan="2"><p>26***</p></td></tr><tr><td><p>Month 6</p></td><td><p>12</p></td><td colspan="2"><p>25***</p></td><td colspan="2"><p>37***</p></td></tr><tr><td><p>Month 12</p></td><td><p>15</p></td><td colspan="2"><p>28**</p></td><td colspan="2"><p>38***</p></td></tr><tr><td><p>Month 24</p></td><td><p>15</p></td><td colspan="2"><p>34***</p></td><td colspan="2"><p>37***</p></td></tr><tr><td colspan="7"><p><strong>ORAL Strategy:</strong> <strong>MTX inadequate responders</strong></p></td></tr><tr><td><p><strong>Endpoint</strong></p></td><td><p><strong>Time</strong></p></td><td><p><strong>Tofacitinib 5 mg twice daily</strong></p><p><strong>N=384</strong></p></td><td colspan="2"><p><strong>Tofacitinib 5&nbsp;mg twice daily</strong></p><p><strong>&nbsp;+ MTX</strong></p><p><strong>N=376</strong></p></td><td colspan="2"><p><strong>Adalimumab</strong></p><p><strong>&nbsp;+ MTX</strong></p><p><strong>N=386</strong></p></td></tr><tr><td rowspan="3"><p>ACR20</p></td><td><p>Month 3</p></td><td><p>62.50</p></td><td colspan="2" style="vertical-align:top"><p>70.48ǂ</p></td><td colspan="2" style="vertical-align:top"><p>69.17</p></td></tr><tr><td><p>Month 6</p></td><td><p>62.84</p></td><td colspan="2" style="vertical-align:top"><p>73.14ǂ</p></td><td colspan="2" style="vertical-align:top"><p>70.98</p></td></tr><tr><td style="vertical-align:top"><p>Month 12</p></td><td style="vertical-align:top"><p>61.72</p></td><td colspan="2" style="vertical-align:top"><p>70.21ǂ</p></td><td colspan="2" style="vertical-align:top"><p>67.62</p></td></tr><tr><td rowspan="3"><p>ACR50</p></td><td><p>Month 3</p></td><td><p>31.51</p></td><td colspan="2" style="vertical-align:top"><p>40.96ǂ</p></td><td colspan="2" style="vertical-align:top"><p>37.31</p></td></tr><tr><td><p>Month 6</p></td><td><p>38.28</p></td><td colspan="2" style="vertical-align:top"><p>46.01ǂ</p></td><td colspan="2" style="vertical-align:top"><p>43.78</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>39.31</p></td><td colspan="2" style="vertical-align:top"><p>47.61ǂ</p></td><td colspan="2" style="vertical-align:top"><p>45.85</p></td></tr><tr><td rowspan="3"><p>ACR70</p></td><td><p>Month 3</p></td><td><p>13.54</p></td><td colspan="2" style="vertical-align:top"><p>19.41ǂ</p></td><td colspan="2" style="vertical-align:top"><p>14.51</p></td></tr><tr><td><p>Month 6</p></td><td><p>18.23</p></td><td colspan="2" style="vertical-align:top"><p>25.00ǂ</p></td><td colspan="2" style="vertical-align:top"><p>20.73</p></td></tr><tr><td><p>Month 12</p></td><td style="vertical-align:top"><p>21.09</p></td><td colspan="2" style="vertical-align:top"><p>28.99ǂ</p></td><td colspan="2" style="vertical-align:top"><p>25.91</p></td></tr><tr><td colspan="7"><p>*p&lt;0.05</p><p>**p&lt;0.001</p><p>***p&lt;0.0001 verses placebo (versus MTX for ORAL Start)</p><p>ǂp&lt;0.05 &ndash; tofacitinib 5&nbsp;mg + MTX versus tofacitinib 5&nbsp;mg for ORAL Strategy (normal p-values without multiple comparison adjustment)</p><p>QOW=every other week, N=number of subjects analysed, ACR20/50/70=American College of Rheumatology &ge;20, 50, 70% improvement, NA=not applicable, MTX=methotrexate.</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><em>DAS28-4(ESR) response</em></p><p>Patients in the phase&nbsp;3 studies had a mean Disease Activity Score (DAS28-4[ESR]) of 6.1‑6.7 at baseline. Significant reductions in DAS28-4(ESR) from baseline (mean improvement) of 1.8-2.0 and 1.9-2.2 were observed in patients treated with 5&nbsp;mg and 10&nbsp;mg twice daily doses, respectively, compared to placebo-treated patients (0.7-1.1) at month 3. The proportion of patients achieving a DAS28 clinical remission (DAS28-4(ESR) &lt;&nbsp;2.6) in ORAL Step, ORAL Sync, and ORAL Standard is shown in Table&nbsp;11.</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;11: Number (%) of subjects achieving DAS28-4(ESR)&nbsp;&lt;&nbsp;2.6 remission at months&nbsp;3&nbsp;and&nbsp;6 </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Time Point</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>%</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ORAL Step: </strong><strong>TNF Inhibitor inadequate responders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Tofacitinib 5&nbsp;mg twice daily + MTX</p></td><td style="vertical-align:top"><p>Month 3</p></td><td style="vertical-align:top"><p>133</p></td><td style="vertical-align:top"><p>6</p></td></tr><tr><td style="vertical-align:top"><p>Tofacitinib 10&nbsp;mg twice daily + MTX</p></td><td style="vertical-align:top"><p>Month 3</p></td><td style="vertical-align:top"><p>134</p></td><td style="vertical-align:top"><p>8*</p></td></tr><tr><td style="vertical-align:top"><p>Placebo + MTX</p></td><td style="vertical-align:top"><p>Month 3</p></td><td style="vertical-align:top"><p>132</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ORAL Sync: </strong><strong>DMARD inadequate responders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Tofacitinib 5&nbsp;mg twice daily</p></td><td style="vertical-align:top"><p>Month 6</p></td><td style="vertical-align:top"><p>312</p></td><td style="vertical-align:top"><p>8*</p></td></tr><tr><td style="vertical-align:top"><p>Tofacitinib 10&nbsp;mg twice daily</p></td><td style="vertical-align:top"><p>Month 6</p></td><td style="vertical-align:top"><p>315</p></td><td style="vertical-align:top"><p>11***</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Month 6</p></td><td style="vertical-align:top"><p>158</p></td><td style="vertical-align:top"><p>3</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>ORAL Standard: </strong><strong>MTX inadequate responders</strong><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>Tofacitinib 5&nbsp;mg twice daily + MTX</p></td><td style="vertical-align:top"><p>Month 6</p></td><td style="vertical-align:top"><p>198</p></td><td style="vertical-align:top"><p>6*</p></td></tr><tr><td style="vertical-align:top"><p>Tofacitinib 10&nbsp;mg twice daily + MTX</p></td><td style="vertical-align:top"><p>Month 6</p></td><td style="vertical-align:top"><p>197</p></td><td style="vertical-align:top"><p>11***</p></td></tr><tr><td style="vertical-align:top"><p>Adalimumab 40&nbsp;mg SC QOW + MTX</p></td><td style="vertical-align:top"><p>Month 6</p></td><td style="vertical-align:top"><p>199</p></td><td style="vertical-align:top"><p>6*</p></td></tr><tr><td style="vertical-align:top"><p>Placebo + MTX</p></td><td style="vertical-align:top"><p>Month 6</p></td><td style="vertical-align:top"><p>105</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*p &lt;0.05, ***p&lt;0.0001 versus placebo, SC=subcutaneous, QOW=every other week, N=number of subjects analysed, DAS28=Disease Activity Scale 28 joints, ESR=Erythrocyte Sedimentation Rate.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Radiographic response</em></p><p>In ORAL Scan and ORAL Start, inhibition of progression of structural joint damage was assessed radiographically and expressed as mean change from baseline in mTSS and its components, the erosion score and joint space narrowing (JSN) score, at months&nbsp;6 and 12.</p><p>&nbsp;</p><p>In ORAL Scan, tofacitinib 10&nbsp;mg twice daily plus background MTX resulted in significantly greater inhibition of the progression of structural damage compared to placebo plus MTX at months&nbsp;6 and 12. When given at a dose of 5&nbsp;mg twice daily, tofacitinib plus MTX exhibited similar effects on mean progression of structural damage (not statistically significant). Analysis of erosion and JSN scores were consistent with overall results.</p><p>&nbsp;</p><p>In the placebo plus MTX group, 78% of patients experienced no radiographic progression (mTSS change less than or equal to 0.5) at month&nbsp;6 compared to 89% and 87% of patients treated with tofacitinib 5 or 10&nbsp;mg (plus MTX) twice daily respectively, (both significant versus placebo plus MTX).</p><p><strong>&nbsp;</strong></p><p>In ORAL Start, tofacitinib monotherapy resulted in significantly greater inhibition of the progression of structural damage compared to MTX at months&nbsp;6 and 12 as shown in Table&nbsp;12, which was also maintained at month 24. Analyses of erosion and JSN scores were consistent with overall results.</p><p>&nbsp;</p><p>In the MTX group, 70% of patients experienced no radiographic progression at month&nbsp;6 compared to 83% and 90% of patients treated with tofacitinib 5 or 10&nbsp;mg twice daily respectively, both significant versus MTX.</p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;12:</strong><strong>&nbsp;&nbsp; </strong><strong>Radiographic changes at months&nbsp;6 and 12</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p><strong>ORAL Scan: MTX </strong><strong>inadequate responders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Placebo + MTX</strong></p><p><strong>N=139</strong></p><p><strong>Mean (SD)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 5&nbsp;mg</strong></p><p><strong>twice daily + MTX</strong></p><p><strong>N=277</strong></p><p><strong>Mean (SD)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>5&nbsp;mg</strong></p><p><strong>twice daily + MTX</strong></p><p><strong>Mean difference from placebo<sup>b</sup> (CI)<sup> </sup></strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>10&nbsp;mg</strong></p><p><strong>twice daily + MTX</strong></p><p><strong>N=290</strong></p><p><strong>Mean (SD)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>10&nbsp;mg</strong></p><p><strong>twice daily + MTX</strong></p><p><strong>Mean difference from placebo<sup>b</sup></strong></p><p><strong>(CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>mTSS<strong><sup>c</sup></strong></p><p>Baseline</p><p>Month&nbsp;6</p><p>Month&nbsp;12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>33 (42)</p><p>0.5 (2.0)</p><p>1.0 (3.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>31 (48)</p><p>0.1 (1.7)</p><p>0.3 (3.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-</p><p>-0.3 (-0.7, 0.0)</p><p>-0.6 (-1.3, 0.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>37 (54)</p><p>0.1 (2.0)</p><p>0.1 (2.9)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-</p><p>-0.4 (-0.8, 0.0)</p><p>-0.9 (-1.5, -0.2)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p><strong>ORAL Start: MTX-na&iuml;ve</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>MTX</strong></p><p><strong>N=168</strong></p><p><strong>Mean (SD)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>5&nbsp;mg</strong></p><p><strong>twice daily</strong></p><p><strong>N=344</strong></p><p><strong>Mean (SD)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>5&nbsp;mg</strong></p><p><strong>twice daily </strong></p><p><strong>Mean difference from MTX<sup>d </sup>(CI)</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>10&nbsp;mg</strong></p><p><strong>twice daily N=368</strong></p><p><strong>Mean (SD)<sup>a</sup></strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>10&nbsp;mg</strong></p><p><strong>twice daily </strong></p><p><strong>Mean difference from MTX<sup>d </sup>(CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p>mTSS<strong><sup>c</sup></strong></p><p>Baseline</p><p>Month&nbsp;6</p><p>Month&nbsp;12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16 (29)</p><p>0.9 (2.7)</p><p>1.3 (3.7)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>20 (41)</p><p>0.2 (2.3)</p><p>0.4 (3.0)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-</p><p>-0.7 (-1.0, -0.3)</p><p>-0.9 (-1.4, -0.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>19 (39)</p><p>0.0 (1.2)</p><p>0.0 (1.5)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-</p><p>-0.8 (-1.2, -0.4)</p><p>-1.3 (-1.8, -0.8)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>a </sup>SD = Standard Deviation</p><p><sup>b </sup>Difference between least squares means tofacitinib minus placebo (95% CI = 95% confidence interval)</p><p><strong><sup>c </sup></strong>Month 6 and month&nbsp;12 data are mean change from baseline</p><p><sup>d </sup>Difference between least squares means tofacitinib minus MTX (95% CI = 95% confidence interval)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><em>Physical function response and health-related outcomes</em></p><p>&nbsp;</p><p>Tofacitinib, alone or in combination with MTX, has shown improvements in physical function, as measured by the HAQ-DI. Patients receiving tofacitinib 5 or 10&nbsp;mg twice daily demonstrated significantly greater improvement from baseline in physical functioning compared to placebo at month&nbsp;3 (studies ORAL Solo, ORAL Sync, ORAL Standard, and ORAL Step) and month&nbsp;6 (studies ORAL Sync and ORAL Standard). Tofacitinib 5 or 10&nbsp;mg twice daily-treated patients demonstrated significantly greater improvement in physical functioning compared to placebo as early as week&nbsp;2 in ORAL Solo and ORAL Sync. Changes from baseline in HAQ-DI in studies ORAL Standard, ORAL Step and ORAL Sync are shown in Table 13.</p><p>&nbsp;</p><p><strong>Table&nbsp;13:&nbsp;&nbsp; LS mean change from baseline in HAQ-DI at month 3</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:98%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong><strong> + </strong><strong>MTX</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>5&nbsp;mg twice daily</strong></p><p><strong>+ MTX</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>10&nbsp;mg twice daily</strong></p><p><strong>+ MTX</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Adalimumab</strong></p><p><strong>40&nbsp;mg QOW</strong></p><p><strong>+ MTX</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>ORAL Standard:</strong><strong> MTX inadequate responders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>N=96</strong></p></td><td style="vertical-align:top"><p><strong>N=</strong><strong>185</strong></p></td><td style="vertical-align:top"><p><strong>N=</strong><strong>183</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>N=</strong><strong>188</strong></p></td></tr><tr><td colspan="2"><p>-0.24</p></td><td><p>-0.54***</p></td><td><p>-0.61***</p></td><td colspan="2"><p>-0.50***</p></td></tr><tr><td colspan="5"><p><strong>ORAL Step:</strong><strong> TNF inhibitor inadequate responders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>N=118</strong></p></td><td style="vertical-align:top"><p><strong>N=11</strong><strong>7</strong></p></td><td style="vertical-align:top"><p><strong>N=</strong><strong>125</strong></p></td><td colspan="2" style="vertical-align:top"><p>NA</p></td></tr><tr><td colspan="2"><p>-0.18</p></td><td><p>-0.43***</p></td><td><p>-0.46***</p></td><td colspan="2"><p>NA</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Placebo + DMARD(s)</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>5 mg twice daily + DMARD(s)</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>10</strong><strong>&nbsp;mg twice daily</strong></p><p><strong>+ DMARD(s)</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6"><p><strong>ORAL Sync: DMARD inadequate responders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>N=147</strong></p></td><td style="vertical-align:top"><p><strong>N=292</strong></p></td><td style="vertical-align:top"><p><strong>N=292</strong></p></td><td colspan="2" style="vertical-align:top"><p>NA</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>-0.21</p></td><td style="vertical-align:top"><p>-0.46***</p></td><td style="vertical-align:top"><p>-0.56***</p></td><td colspan="2" style="vertical-align:top"><p>NA</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>***</sup>&nbsp;&nbsp; p&lt;0.0001, tofacitinib versus placebo + MTX, LS = least squares, N = number of patients, QOW = every other week, NA&nbsp;=&nbsp;not applicable, HAQ-DI = Health Assessment Questionnaire Disability Index</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Health-related quality of life was assessed by the Short Form Health Survey (SF-36). Patients receiving either 5 or 10&nbsp;mg tofacitinib twice daily experienced significantly greater improvement from baseline compared to placebo in all 8&nbsp;domains as well as the Physical Component Summary and Mental Component Summary scores at month&nbsp;3 in ORAL Solo, ORAL Scan and ORAL Step. In ORAL Scan, mean SF-36 improvements were maintained to 12&nbsp;months in tofacitinib-treated patients.</p><p><strong><u>&nbsp;</u></strong></p><p>Improvement in fatigue was evaluated by the Functional Assessment of Chronic Illness Therapy‑Fatigue (FACIT-F) scale at month&nbsp;3 in all studies. Patients receiving tofacitinib 5&nbsp;or 10&nbsp;mg twice daily demonstrated significantly greater improvement from baseline in fatigue compared to placebo in all 5&nbsp;studies. In ORAL Standard and ORAL Scan, mean FACIT-F improvements were maintained to 12&nbsp;months in tofacitinib-treated patients.</p><p>&nbsp;</p><p>Improvement in sleep was assessed using the Sleep Problems Index&nbsp;I and II summary scales of the Medical Outcomes Study Sleep (MOS-Sleep) measure at month&nbsp;3 in all studies. Patients receiving tofacitinib 5 or 10&nbsp;mg twice daily demonstrated significantly greater improvement from baseline in both scales compared to placebo in ORAL Sync, ORAL Standard and ORAL Scan. In ORAL Standard and ORAL Scan, mean improvements in both scales were maintained to 12&nbsp;months in tofacitinib-treated patients.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Durability of clinical responses</u></p><p>&nbsp;</p><p>Durability of effect was assessed by ACR20, ACR50, ACR70 response rates in studies of duration of up to two years. Changes in mean HAQ-DI and DAS28-4(ESR) were maintained in both tofacitinib treatment groups through to the end of the studies.</p><p>&nbsp;</p><p>Evidence of persistence of efficacy with tofacitinib treatment for up to 5&nbsp;years is also provided from data in a randomised post‑authorisation safety study in patients with RA who were 50 years of age or older with at least one additional cardiovascular risk factor, as well as in completed open-label, long‑term follow-up studies up to 8 years.</p><p>&nbsp;</p><p><u>Long-term controlled safety data</u></p><p><em><u>&nbsp;</u></em></p><p>Study ORAL Surveillance (A3921133) was a large (N=4362), randomised active-controlled post‑authorisation safety surveillance study of rheumatoid arthritis patients who were 50&nbsp;years of age and older and had at least one additional cardiovascular risk factor (CV risk factors defined as: current cigarette smoker, diagnosis of hypertension, diabetes mellitus, family history of premature coronary heart disease, history of coronary artery disease including a history of revascularization procedure, coronary artery bypass grafting, myocardial infarction, cardiac arrest, unstable angina, acute coronary syndrome, and presence of extra-articular disease associated with RA, e.g. nodules, Sj&ouml;gren&rsquo;s syndrome, anaemia of chronic disease, pulmonary manifestations). The majority (more than 90%) of tofacitinib patients who were current or past smokers had a smoking duration of more than 10 years and a median of 35.0 and 39.0 smoking years, respectively. Patients were required to be on a stable dose of methotrexate at study entry; dose adjustment was permitted during the study.</p><p>&nbsp;</p><p>Patients were randomised to open-label tofacitinib 10&nbsp;mg twice daily, tofacitinib 5&nbsp;mg twice daily, or a TNF inhibitor (TNF inhibitor was either etanercept 50&nbsp;mg once weekly or adalimumab 40&nbsp;mg every other week) in a 1:1:1 ratio. The co-primary endpoints were adjudicated malignancies excluding NMSC and adjudicated major adverse cardiovascular events (MACE); cumulative incidence and statistical assessment of endpoints were blinded. The study was an event-powered study that also required at least 1500&nbsp;patients to be followed for 3&nbsp;years. The study treatment of tofacitinib 10&nbsp;mg twice daily was stopped and patients were switched to 5&nbsp;mg twice daily because of a dose‑dependent signal of venous thromboembolic events (VTE). For patients in the tofacitinib 10&nbsp;mg twice daily treatment arm, the data collected before and after the dose switch were analysed in their originally randomised treatment group.</p><p>&nbsp;</p><p>The study did not meet the non-inferiority criterion for the primary comparison of the combined tofacitinib doses to TNF inhibitor since the upper limit of the 95% CI for HR exceeded the pre‑specified non-inferiority criterion of 1.8 for adjudicated MACE and adjudicated malignancies excluding NMSC.</p><p>&nbsp;</p><p>The results for adjudicated MACE, adjudicated malignancies excluding NMSC, and selected other events are provided below.</p><p>&nbsp;</p><p><em><u>MACE (including myocardial infarction) and venous thromboembolism (VTE)</u></em></p><p>An increase in non-fatal myocardial infarction was observed in patients treated with tofacitinib compared to TNF inhibitor. A dose-dependent increase in VTE events was observed in patients treated with tofacitinib compared to TNF inhibitor (see sections 4.4 and 4.8).</p><p><strong>&nbsp;</strong></p><p><strong>Table 14: Incidence rate and hazard ratio for MACE, myocardial infarction and venous thromboembolism</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Tofacitinib 5&nbsp;mg twice daily</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 10&nbsp;mg twice daily<sup>a</sup> </strong></p></td><td style="vertical-align:top"><p><strong>All Tofacitinib<sup>b</sup> </strong></p></td><td style="vertical-align:top"><p><strong>TNF inhibitor (TNFi) </strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>MACE<sup>c </sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.91 (0.67, 1.21)</p></td><td style="vertical-align:top"><p>1.05 (0.78, 1.38)</p></td><td style="vertical-align:top"><p>0.98 (0.79, 1.19)</p></td><td style="vertical-align:top"><p>0.73 (0.52, 1.01)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>1.24 (0.81, 1.91)</p></td><td style="vertical-align:top"><p>1.43 (0.94, 2.18)</p></td><td style="vertical-align:top"><p>1.33 (0.91, 1.94)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Fatal MI<sup>c</sup> </strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.00 (0.00, 0.07)</p></td><td style="vertical-align:top"><p>0.06 (0.01, 0.18)</p></td><td style="vertical-align:top"><p>0.03 (0.01, 0.09)</p></td><td style="vertical-align:top"><p>0.06 (0.01, 0.17)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>0.00 (0.00, Inf)</p></td><td style="vertical-align:top"><p>1.03 (0.21, 5.11)</p></td><td style="vertical-align:top"><p>0.50 (0.10, 2.49)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Non-fatal MI<sup>c</sup> </strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.37 (0.22, 0.57)</p></td><td style="vertical-align:top"><p>0.33 (0.19, 0.53)</p></td><td style="vertical-align:top"><p>0.35 (0.24, 0.48)</p></td><td style="vertical-align:top"><p>0.16 (0.07, 0.31)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>2.32 (1.02, 5.30)</p></td><td style="vertical-align:top"><p>2.08 (0.89, 4.86)</p></td><td style="vertical-align:top"><p>2.20 (1.02, 4.75)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>VTE<sup>d</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.33 (0.19, 0.53)</p></td><td style="vertical-align:top"><p>0.70 (0.49, 0.99)</p></td><td style="vertical-align:top"><p>0.51 (0.38, 0.67)</p></td><td style="vertical-align:top"><p>0.20 (0.10, 0.37)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>1.66 (0.76, 3.63)</p></td><td style="vertical-align:top"><p>3.52 (1.74, 7.12)</p></td><td style="vertical-align:top"><p>2.56 (1.30, 5.05)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>PE<sup>d</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.17 (0.08, 0.33)</p></td><td style="vertical-align:top"><p>0.50 (0.32, 0.74)</p></td><td style="vertical-align:top"><p>0.33 (0.23, 0.46)</p></td><td style="vertical-align:top"><p>0.06 (0.01, 0.17)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>2.93 (0.79, 10.83)</p></td><td style="vertical-align:top"><p>8.26 (2.49, 27.43)</p></td><td style="vertical-align:top"><p>5.53 (1.70, 18.02)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>DVT<sup>d</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.21 (0.11, 0.38)</p></td><td style="vertical-align:top"><p>0.31 (0.17, 0.51)</p></td><td style="vertical-align:top"><p>0.26 (0.17, 0.38)</p></td><td style="vertical-align:top"><p>0.14 (0.06, 0.29)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>1.54 (0.60, 3.97)</p></td><td style="vertical-align:top"><p>2.21 (0.90, 5.43)</p></td><td style="vertical-align:top"><p>1.87 (0.81, 4.30)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a </sup>The tofacitinib 10&nbsp;mg twice daily treatment group includes data from patients that were switched from tofacitinib 10&nbsp;mg twice daily to tofacitinib 5&nbsp;mg twice daily as a result of a study modification.</p><p><sup>b</sup> Combined tofacitinib 5&nbsp;mg twice daily and tofacitinib 10&nbsp;mg twice daily.</p><p><sup>c</sup> Based on events occurring on treatment or within 60&nbsp;days of treatment discontinuation.</p><p><sup>d</sup> Based on events occurring on treatment or within 28 days of treatment discontinuation.</p><p>Abbreviations: MACE = major adverse cardiovascular events, MI = myocardial infarction, VTE = venous thromboembolism, PE = pulmonary embolism, DVT = deep vein thrombosis, TNF = tumour necrosis factor, IR = incidence rate, HR = hazard ratio, CI = confidence interval, PY = patient years, Inf = infinity</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>The following predictive factors for development of MI (fatal and non-fatal) were identified using a multivariate Cox model with backward selection: age &ge;65&nbsp;years, male, current or past smoking, history of diabetes, and history of coronary artery disease (which includes myocardial infarction, coronary heart disease, stable angina pectoris, or coronary artery procedures) (see sections 4.4 and 4.8).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Malignancies</u></em></p><p>&nbsp;</p><p>An increase in malignancies excluding NMSC, particularly lung cancer, lymphoma and an increase in NMSC was observed in patients treated with tofacitinib compared to TNF inhibitor.</p><p><strong>&nbsp;</strong></p><p><strong>Table 15: Incidence rate and hazard ratio for malignancies<sup>a</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Tofacitinib 5&nbsp;mg twice daily</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 10&nbsp;mg twice daily<sup>b</sup> </strong></p></td><td style="vertical-align:top"><p><strong>All Tofacitinib<sup>c</sup></strong></p></td><td style="vertical-align:top"><p><strong>TNF inhibitor (TNFi) </strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Malignancies excluding NMSC<sup> </sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>1.13 (0.87, 1.45)</p></td><td style="vertical-align:top"><p>1.13 (0.86, 1.45)</p></td><td style="vertical-align:top"><p>1.13 (0.94, 1.35)</p></td><td style="vertical-align:top"><p>0.77 (0.55, 1.04)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>1.47 (1.00, 2.18)</p></td><td style="vertical-align:top"><p>1.48 (1.00, 2.19)</p></td><td style="vertical-align:top"><p>1.48 (1.04, 2.09)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Lung cancer</strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.23 (0.12, 0.40)</p></td><td style="vertical-align:top"><p>0.32 (0.18, 0.51)</p></td><td style="vertical-align:top"><p>0.28 (0.19, 0.39)</p></td><td style="vertical-align:top"><p>0.13 (0.05, 0.26)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>1.84 (0.74, 4.62)</p></td><td style="vertical-align:top"><p>2.50 (1.04, 6.02)</p></td><td style="vertical-align:top"><p>2.17 (0.95, 4.93)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Lymphoma</strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.07 (0.02, 0.18)</p></td><td style="vertical-align:top"><p>0.11 (0.04, 0.24)</p></td><td style="vertical-align:top"><p>0.09 (0.04, 0.17)</p></td><td style="vertical-align:top"><p>0.02 (0.00, 0.10)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>3.99 (0.45, 35.70)</p></td><td style="vertical-align:top"><p>6.24 (0.75, 51.86)</p></td><td style="vertical-align:top"><p>5.09 (0.65, 39.78)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>NMSC</p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.61 (0.41, 0.86)</p></td><td style="vertical-align:top"><p>0.69 (0.47, 0.96)</p></td><td style="vertical-align:top"><p>0.64 (0.50, 0.82)</p></td><td style="vertical-align:top"><p>0.32 (0.18, 0.52)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>1.90 (1.04, 3.47)</p></td><td style="vertical-align:top"><p>2.16 (1.19, 3.92)</p></td><td style="vertical-align:top"><p>2.02 (1.17, 3.50)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><sup>a</sup> For malignancies excluding NMSC, lung cancer, and lymphoma, based on events occurring on treatment or after treatment discontinuation up to the end of the study. For NMSC based on events occurring on treatment or within 28 days of treatment discontinuation.</p><p><sup>b</sup> The tofacitinib 10&nbsp;mg twice daily treatment group includes data from patients that were switched from tofacitinib 10&nbsp;mg twice daily to tofacitinib 5&nbsp;mg twice daily as a result of a study modification.</p><p><sup>c</sup> Combined tofacitinib 5&nbsp;mg twice daily and tofacitinib 10&nbsp;mg twice daily.</p><p>Abbreviations: NMSC = non melanoma skin cancer, TNF = tumour necrosis factor, IR = incidence rate, HR = hazard ratio, CI = confidence interval, PY = patient years</p></td></tr></tbody></table><p>&nbsp;</p><p>The following predictive factors for development of malignancies excluding NMSC were identified using a Multivariate Cox model with backward selection: age &ge;65 years and current or past smoking (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><em><u>Mortality</u></em></p><p>Increased mortality was observed in patients treated with tofacitinib compared to TNF inhibitors. Mortality was mainly due to cardiovascular events, infections and malignancies.</p><p>&nbsp;</p><p><strong>Table&nbsp;16:&nbsp;&nbsp; Incidence rate and hazard ratio for mortality<sup>a</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 5&nbsp;mg twice daily</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 10&nbsp;mg twice daily</strong><strong><sup>b</sup></strong></p></td><td style="vertical-align:top"><p><strong>All Tofacitinib<sup>c</sup></strong></p></td><td style="vertical-align:top"><p><strong>TNF inhibitor</strong></p><p><strong>(TNFi)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Mortality (all cause)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.50 (0.33, 0.74)</p></td><td style="vertical-align:top"><p>0.80 (0.57, 1.09)</p></td><td style="vertical-align:top"><p>0.65 (0.50, 0.82)</p></td><td style="vertical-align:top"><p>0.34 (0.20, 0.54)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>1.49 (0.81, 2.74)</p></td><td style="vertical-align:top"><p>2.37 (1.34, 4.18)</p></td><td style="vertical-align:top"><p>1.91 (1.12, 3.27)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fatal infections</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.08 (0.02, 0.20)</p></td><td style="vertical-align:top"><p>0.18 (0.08, 0.35)</p></td><td style="vertical-align:top"><p>0.13 (0.07, 0.22)</p></td><td style="vertical-align:top"><p>0.06 (0.01, 0.17)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>1.30 (0.29, 5.79)</p></td><td style="vertical-align:top"><p>3.10 (0.84, 11.45)</p></td><td style="vertical-align:top"><p>2.17 (0.62, 7.62)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fatal CV events</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.25 (0.13, 0.43)</p></td><td style="vertical-align:top"><p>0.41 (0.25, 0.63)</p></td><td style="vertical-align:top"><p>0.33 (0.23, 0.46)</p></td><td style="vertical-align:top"><p>0.20 (0.10, 0.36)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>1.26 (0.55, 2.88)</p></td><td style="vertical-align:top"><p>2.05 (0.96, 4.39)</p></td><td style="vertical-align:top"><p>1.65 (0.81, 3.34)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fatal Malignancies</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>IR (95% CI) per 100 PY</p></td><td style="vertical-align:top"><p>0.10 (0.03, 0.23)</p></td><td style="vertical-align:top"><p>0.00 (0.00, 0.08)</p></td><td style="vertical-align:top"><p>0.05 (0.02, 0.12)</p></td><td style="vertical-align:top"><p>0.02 (0.00, 0.11)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI) vs TNFi</p></td><td style="vertical-align:top"><p>4.88 (0.57, 41.74)</p></td><td style="vertical-align:top"><p>0 (0.00, Inf)</p></td><td style="vertical-align:top"><p>2.53 (0.30, 21.64)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup> Based on events occurring on treatment or within 28 days of treatment discontinuation.</p><p><sup>b</sup> The tofacitinib 10 mg twice daily treatment group includes data from patients that were switched from tofacitinib 10 mg twice daily to tofacitinib 5 mg twice daily as a result of a study modification.</p><p><sup>c</sup> Combined tofacitinib 5 mg twice daily and tofacitinib 10 mg twice daily.</p><p>Abbreviations: TNF = tumor necrosis factor, IR = incidence rate, HR = hazard ratio, CI = confidence interval, PY = patient years, CV = cardiovascular, Inf = infinity</p><p><em>&nbsp;</em></p><p><em>Psoriatic arthritis</em></p><p>The efficacy and safety of tofacitinib film-coated tablets were assessed in 2 randomised, double-blind, placebo‑controlled Phase 3 studies in adult patients with active PsA (&ge;&nbsp;3 swollen and &ge;&nbsp;3 tender joints). Patients were required to have active plaque psoriasis at the screening visit. For both studies, the primary endpoints were ACR20 response rate and change from baseline in HAQ‑DI at month 3.</p><p>&nbsp;</p><p>Study PsA‑I (OPAL BROADEN) evaluated 422 patients who had a previous inadequate response (due to lack of efficacy or intolerance) to a csDMARD (MTX for 92.7% of patients); 32.7% of the patients in this study had a previous inadequate response to &gt;&nbsp;1&nbsp;csDMARD or 1 csDMARD and a targeted synthetic DMARD (tsDMARD). In OPAL BROADEN, previous treatment with TNF&nbsp;inhibitor was not allowed. All patients were required to have 1 concomitant csDMARD; 83.9% of patients received concomitant MTX, 9.5% of patients received concomitant sulfasalazine, and 5.7% of patients received concomitant leflunomide. The median PsA disease duration was 3.8 years. At baseline, 79.9% and 56.2% of patients had enthesitis and dactylitis, respectively. Patients randomised to tofacitinib received 5 mg twice daily or tofacitinib 10 mg twice daily for 12&nbsp;months. Patients randomised to placebo were advanced in a blinded manner at month&nbsp;3 to either tofacitinib 5&nbsp;mg twice daily or tofacitinib 10&nbsp;mg twice daily and received treatment until month&nbsp;12. Patients randomised to adalimumab (active‑control arm) received 40 mg subcutaneously every 2 weeks for 12&nbsp;months.</p><p>&nbsp;</p><p>Study PsA‑II (OPAL BEYOND) evaluated 394 patients who had discontinued a TNF inhibitor due to lack of efficacy or intolerance; 36.0% had a previous inadequate response to &gt;&nbsp;1 biological DMARD. All patients were required to have 1 concomitant csDMARD; 71.6% of patients received concomitant MTX, 15.7% of patients received concomitant sulfasalazine, and 8.6% of patients received concomitant leflunomide. The median PsA disease duration was 7.5&nbsp;years. At baseline, 80.7% and 49.2% of patients had enthesitis and dactylitis, respectively<strong>.</strong> Patients randomised to tofacitinib received 5&nbsp;mg twice daily or tofacitinib 10 mg twice daily for 6 months. Patients randomised to placebo were advanced in a blinded manner at month 3 to either tofacitinib 5&nbsp;mg twice daily or tofacitinib 10&nbsp;mg twice daily and received treatment until month 6.</p><p>&nbsp;</p><p><em>Signs and symptoms</em></p><p>Treatment with tofacitinib resulted in significant improvements in some signs and symptoms of PsA, as assessed by the ACR20 response criteria compared to placebo at month 3. The efficacy results for important endpoints assessed are shown in Table 17.</p><p>&nbsp;</p><p><strong>Table&nbsp;17:&nbsp;&nbsp; Proportion (%) of PsA patients who achieved clinical response and mean change from baseline in OPAL BROADEN and OPAL BEYOND studies</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Conventional synthetic DMARD </strong></p><p><strong>inadequate responders<sup>a</sup> (TNFi-Na&iuml;ve)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>TNFi </strong></p><p><strong>inadequate responders<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>OPAL BROADEN</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>OPAL BEYOND<sup>c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment group</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 5 mg </strong><strong>twice daily</strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab 40 mg SC q2W</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 5 mg </strong><strong>twice daily</strong></p></td></tr><tr><td><p>N</p></td><td><p>105</p></td><td><p>107</p></td><td style="vertical-align:top"><p>106</p></td><td><p>131</p></td><td><p>131</p></td></tr><tr><td style="vertical-align:top"><p>ACR20</p><p>Month 3</p><p>Month 6</p><p>Month 12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; 33%</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50%<sup>d,*</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 59%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 68%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 52%<sup>*</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 64%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 60%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; 24%</p><p>&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp; -</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50%<sup>d,***</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 60%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td></tr><tr><td style="vertical-align:top"><p>ACR50</p><p>Month 3</p><p>Month 6</p><p>Month 12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; 10%</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28%<sup>e,**</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33%<sup>***</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; 15%</p><p>&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp; -</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30%<sup>e,*</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td></tr><tr><td style="vertical-align:top"><p>ACR70</p><p>Month 3</p><p>Month 6</p><p>Month 12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; 5%</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17%<sup>e,*</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19%<sup>*</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; 10%</p><p>&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp; -</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td></tr><tr><td style="vertical-align:top"><p>∆LEI<sup>f</sup></p><p>Month 3</p><p>Month 6</p><p>Month 12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; -0.4</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -0.8</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -1.3</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -1.7</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -1.1<sup>*</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -1.3</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -1.6</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; -0.5</p><p>&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp; -</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -1.3<sup>*</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -1.5</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td></tr><tr><td style="vertical-align:top"><p>∆DSS<sup>f</sup></p><p>Month 3</p><p>Month 6</p><p>Month 12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; -2.0</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -3.5</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -5.2</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -7.4</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -4.0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -5.4</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -6.1</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; -1.9</p><p>&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp; -</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -5.2<sup>*</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -6.0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td></tr><tr><td style="vertical-align:top"><p>PASI75<sup>g</sup></p><p>Month 3</p><p>Month 6</p><p>Month 12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp; 15%</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp;&nbsp; NA</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 43%<sup>d,***</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 46%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 56%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39%<sup>**</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 55%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 56%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp; 14%</p><p>&nbsp;&nbsp;&nbsp; NA</p><p>&nbsp;&nbsp;&nbsp; -</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 34%</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>* </sup>Nominal p&le;0.05; <sup>** </sup>Nominal p&lt;0.001; <sup>*** </sup>Nominal p&lt;0.0001 for active treatment versus placebo at month&nbsp;3.</p><p>Abbreviations: BSA=body surface area; ∆LEI=change from baseline in Leeds Enthesitis Index; ∆DSS=change from baseline in Dactylitis Severity Score; ACR20/50/70=American College of Rheumatology &ge;&nbsp;20%, 50%, 70% improvement; csDMARD=conventional synthetic disease‑modifying antirheumatic drug; N=number of randomised and treated patients; NA=Not applicable, as data for placebo treatment is not available beyond month 3 due to placebo advanced to tofacitinib 5&nbsp;mg twice daily or tofacitinib 10&nbsp;mg twice daily; SC q2w=subcutaneously once every 2 weeks; TNFi=tumour necrosis factor inhibitor; PASI=Psoriasis Area and Severity index; PASI75=&ge;&nbsp;75% improvement in PASI.</p><p><sup>a&nbsp;&nbsp;&nbsp; </sup>Inadequate response to at least 1 csDMARD due to lack of efficacy and/or intolerability.</p><p><sup>b&nbsp;&nbsp;&nbsp; </sup>Inadequate response to a least 1 TNFi due to lack of efficacy and/or intolerability.</p><p><sup>c</sup> &nbsp; OPAL BEYOND had a duration of 6 months.</p><p><sup>d &nbsp;&nbsp; </sup>Achieved statistical significance globally at p&le;&nbsp;0.05 per the pre-specified step-down testing procedure.</p><p><sup>e &nbsp;&nbsp; </sup>Achieved statistical significance within the ACR family (ACR50 and ACR70) at p&le;&nbsp;0.05 per the pre‑specified step‑down testing procedure.</p><p><sup>f</sup> &nbsp; For patients with Baseline score &gt; 0.</p><p><sup>g</sup> For patients with Baseline BSA &ge; 3% and PASI &gt; 0.</p></td></tr></tbody></table><p>&nbsp;</p><p>Both TNF inhibitor na&iuml;ve and TNF inhibitor inadequate responder tofacitinib 5 mg twice daily ‑treated patients had significantly higher ACR20 response rates compared to placebo at month 3. Examination of age, sex, race, baseline disease activity and PsA subtype did not identify differences in response to tofacitinib. The number of patients with arthritis mutilans or axial involvement was too small to allow meaningful assessment. Statistically significant ACR20 response rates were observed with tofacitinib 5 mg twice daily in both studies as early as week 2 (first post-baseline assessment) in comparison to placebo.</p><p>&nbsp;</p><p>In OPAL BROADEN, Minimal Disease Activity (MDA) response was achieved by 26.2%, 25.5% and 6.7% of tofacitinib 5 mg twice daily, adalimumab and placebo treated patients, respectively (tofacitinib&nbsp;5&nbsp;mg twice daily treatment difference from placebo 19.5% [95% CI: 9.9, 29.1]) at month 3. In OPAL BEYOND, MDA was achieved by 22.9% and 14.5% of tofacitinib 5 mg twice daily and placebo treated patients, respectively, however tofacitinib 5 mg twice daily did not achieve nominal statistical significance (treatment difference from placebo 8.4% [95% CI: -1.0, 17.8] at month 3).</p><p><em>&nbsp;</em></p><p><em>Radiographic response </em></p><p>In study OPAL BROADEN, the progression of structural joint damage was assessed radiographically utilising the van der Heijde modified Total Sharp Score (mTSS) and the proportion of patients with radiographic progression (mTSS increase from baseline greater than 0.5) was assessed at month 12. At month 12, 96% and 98% of patients receiving tofacitinib 5&nbsp;mg twice daily, and adalimumab 40 mg subcutaneously every 2 weeks, respectively, did not have radiographic progression (mTSS increase from baseline less than or equal to 0.5).</p><p>&nbsp;</p><p><em>Physical function and health-related quality of life</em></p><p>Improvement in physical functioning was measured by the HAQ-DI. Patients receiving tofacitinib 5&nbsp;mg twice daily demonstrated greater improvement (p&le;&nbsp;0.05) from baseline in physical functioning compared to placebo at month 3 (see Table 18).</p><p>&nbsp;</p><p><strong>Table 18:&nbsp;&nbsp; Change from baseline in HAQ-DI in PsA studies OPAL BROADEN and OPAL BEYOND</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:bottom"><p><strong>Least squares mean change from baseline in HAQ-DI</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Conventional synthetic DMARD</strong></p><p><strong>inadequate responders<sup>a</sup> (TNFi-na&iuml;ve)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>TNFi</strong></p><p><strong>inadequate responders<sup>b</sup></strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OPAL BROADEN</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>OPAL BEYOND</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Treatment group</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 5&nbsp;mg </strong><strong>twice daily</strong><strong> </strong></p></td><td style="vertical-align:top"><p><strong>Adalimumab 40&nbsp;mg SC q2W</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 5&nbsp;mg </strong><strong>twice daily</strong></p></td></tr><tr><td><p>N</p></td><td><p>&nbsp;&nbsp; 104</p></td><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 107</p></td><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 106</p></td><td><p>&nbsp;&nbsp;&nbsp; 131</p></td><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 129</p></td></tr><tr><td style="vertical-align:top"><p>Month 3</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp; -0.18</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -0.35<sup>c,*</sup></p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -0.38<sup>*</sup></p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; -0.14</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -0.39<sup>c,***</sup></p></td></tr><tr><td style="vertical-align:top"><p>Month 6</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp; NA</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -0.45</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -0.43</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; NA</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -0.44</p></td></tr><tr><td style="vertical-align:top"><p>Month 12</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp; NA</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -0.54</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -0.45</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; NA</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NA</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>* </sup>Nominal p&le;0.05; <sup>*** </sup>Nominal p&lt;0.0001 for active treatment versus placebo at month 3.</p><p>Abbreviations: DMARD=disease‑modifying antirheumatic drug; HAQ-DI=Health Assessment Questionnaire Disability Index; N=total number of patients in the statistical analysis; SC q2w=subcutaneously once every 2&nbsp;weeks; TNFi=tumour necrosis factor inhibitor.</p><p><sup>a &nbsp;&nbsp; </sup>Inadequate response to at least one conventional synthetic DMARD (csDMARD) due to lack of efficacy and/or intolerability.</p><p><sup>b &nbsp;&nbsp; </sup>Inadequate response to a least one TNF inhibitor (TNFi) due to lack of efficacy and/or intolerability.</p><p><sup>c&nbsp;&nbsp;&nbsp; </sup>Achieved statistical significance globally at p&le;&nbsp;0.05 per the pre-specified step-down testing procedure.</p></td></tr></tbody></table><p>&nbsp;</p><p>The HAQ-DI responder rate (response defined as having decrease from baseline of &ge;&nbsp;0.35) at month&nbsp;3 in studies OPAL BROADEN and OPAL BEYOND was 53% and 50%, respectively in patients receiving tofacitinib 5 mg twice daily, 31% and 28%, respectively in patients receiving placebo, and 53% in patients receiving adalimumab 40 mg subcutaneously once every 2 weeks (OPAL BROADEN only).</p><p>&nbsp;</p><p>Health-related quality of life was assessed by SF-36v2, fatigue was assessed by the FACIT-F. Patients receiving tofacitinib 5&nbsp;mg twice daily demonstrated greater improvement from baseline compared to placebo in the SF-36v2 physical functioning domain, the SF-36v2 physical component summary score, and FACIT-F scores at month 3 in studies&nbsp;OPAL BROADEN and OPAL BEYOND (nominal p&le;&nbsp;0.05). Improvements from baseline in SF-36v2 and FACIT-F were maintained through month 6 (OPAL BROADEN and OPAL BEYOND) and month 12 (OPAL BROADEN).</p><p>&nbsp;</p><p>Patients receiving tofacitinib 5&nbsp;mg twice daily demonstrated a greater improvement in arthritis pain (as measured on a 0-100 visual analogue scale) from baseline at week 2 (first post-baseline assessment) through month 3 compared to placebo in studies OPAL BROADEN and OPAL BEYOND (nominal p&le;&nbsp;0.05).</p><p><u>&nbsp;</u></p><p><u>Ankylosing spondylitis</u></p><p>The tofacitinib clinical development program to assess the efficacy and safety included one placebo‑controlled confirmatory trial (Study AS-I). Study&nbsp;AS‑I was a randomised, double-blind, placebo-controlled, 48-week treatment clinical study in 269&nbsp;adult patients who had an inadequate response (inadequate clinical response or intolerance) to at least 2 NSAIDs. Patients were randomised and treated with tofacitinib 5&nbsp;mg twice daily or placebo for 16&nbsp;weeks of blinded treatment and then all were advanced to tofacitinib 5 mg twice daily for an additional 32&nbsp;weeks. Patients had active disease as defined by both Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and back pain score (BASDAI question 2) of greater or equal to 4 despite non‑steroidal anti-inflammatory drug (NSAID), corticosteroid or DMARD therapy.</p><p>&nbsp;</p><p>Approximately 7% and 21% of patients used concomitant methotrexate or sulfasalazine, respectively, from baseline to Week 16. Patients were allowed to receive a stable low dose of oral corticosteroids (8.6% received) and/or NSAIDs (81.8% received) from baseline to Week 48. Twenty-two percent of patients had an inadequate response to 1 or 2 TNF blockers. The primary endpoint was to evaluate the proportion of patients who achieved an ASAS20 response at Week 16.</p><p>&nbsp;</p><p><u>Clinical response</u></p><p><u>&nbsp;</u></p><p>Patients treated with tofacitinib 5&nbsp;mg twice daily achieved greater improvements in ASAS20 and ASAS40 responses compared to placebo at Week 16 (Table 19). The responses were maintained from Week 16 through to Week 48 in patients receiving tofacitinib 5 mg twice daily.</p><p>&nbsp;</p><p><strong>Table 19: ASAS20 and ASAS40 Responses at Week 16, Study AS-I </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=136)</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 5 mg Twice Daily</strong></p><p><strong>(N=133)</strong></p></td><td style="vertical-align:top"><p><strong>Difference from Placebo </strong></p><p><strong>(95% CI) </strong></p></td></tr><tr><td style="vertical-align:top"><p>ASAS20 response*, %</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>27 (16, 38)**</p></td></tr><tr><td style="vertical-align:top"><p>ASAS40 response*, %</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>28 (18, 38)**</p></td></tr></tbody></table><p>* type I error-controlled.</p><p>** p &lt; 0.0001.</p><p><strong>&nbsp;</strong></p><p>The efficacy of tofacitinib was demonstrated in bDMARD na&iuml;ve and TNF-inadequate responders (IR)/bDMARD experienced (non-IR) patients (Table 20).</p><p>&nbsp;</p><p>Table&nbsp;20.&nbsp;&nbsp;&nbsp; ASAS20 and ASAS40 Responses (%) by Treatment History at Week 16, Study AS-I</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td rowspan="3" style="vertical-align:top"><p>Prior Treatment History</p></td><td colspan="6" style="vertical-align:top"><p>Efficacy Endpoint</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ASAS20</p></td><td colspan="3" style="vertical-align:top"><p>ASAS40</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>N</p></td><td style="vertical-align:top"><p>Tofacitinib 5 mg Twice Daily</p><p>N</p></td><td style="vertical-align:top"><p>Difference from Placebo</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>Placebo</p><p>N</p></td><td style="vertical-align:top"><p>Tofacitinib 5 mg Twice Daily</p><p>N</p></td><td style="vertical-align:top"><p>Difference from Placebo</p><p>(95% CI)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>bDMARD-Na&iuml;ve</p></td><td style="vertical-align:top"><p>105</p></td><td style="vertical-align:top"><p>102</p></td><td style="vertical-align:top"><p>28</p><p>(15, 41)</p></td><td style="vertical-align:top"><p>105</p></td><td style="vertical-align:top"><p>102</p></td><td style="vertical-align:top"><p>31</p><p>(19, 43)</p></td></tr><tr><td style="vertical-align:top"><p>TNFi-IR or bDMARD Use (Non-IR)</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>23</p><p>(1, 44)</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>19</p><p>(2, 37)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>ASAS20 = An improvement from Baseline &ge;&nbsp;20% and &ge;&nbsp;1 unit increase in at least 3 domains on a scale of 0 to 10, and no worsening of &ge;&nbsp;20% and &ge;&nbsp;1 unit in the remaining domain; ASAS40 = An improvement from Baseline &ge;&nbsp;40% and &ge;&nbsp;2&nbsp;units in at least 3 domains on a scale of 0 to 10 and no worsening at all in the remaining domain; bDMARD = biologic disease-modifying anti-rheumatic drug; CI = confidence interval; Non-IR = non-inadequate response; TNFi-IR = tumour necrosis factor inhibitor inadequate response.</p></td></tr></tbody></table><p>&nbsp;</p><p>The improvements in the components of the ASAS response and other measures of disease activity were higher in tofacitinib 5 mg twice daily compared to placebo at Week 16 as shown in Table 21. The improvements were maintained from Week 16 through to Week 48 in patients receiving tofacitinib 5 mg twice daily.</p><p>&nbsp;</p><p><strong>Table 21: ASAS Components and Other Measures of Disease Activity at Week 16, Study AS-I</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><thead><tr><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>(N=136)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Tofacitinib 5 mg Twice Daily</strong></p><p><strong>(N=133)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><strong>Baseline </strong></p><p><strong>(mean)</strong></p></td><td style="vertical-align:top"><p><strong>Week 16</strong></p><p><strong>(LSM change from Baseline)</strong></p></td><td style="vertical-align:top"><p><strong>Baseline </strong></p><p><strong>(mean)</strong></p></td><td style="vertical-align:top"><p><strong>Week 16</strong></p><p><strong>(LSM change from Baseline)</strong></p></td><td style="vertical-align:top"><p><strong>Difference from Placebo</strong></p><p><strong>(95% CI)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>ASAS Components</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Global Assessment of Disease Activity (0‑10)<sup>a,</sup>*</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>-0.9</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>-2.5</p></td><td style="vertical-align:top"><p>-1.6 (‑2.07, ‑1.05)**</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total spinal pain (0-10)<sup>a,</sup>*</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>-1.0</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>-2.6</p></td><td style="vertical-align:top"><p>-1.6 (‑2.10, ‑1.14)**</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BASFI</p><p>(0‑10)<sup>b,</sup>*</p></td><td style="vertical-align:top"><p>5.9</p></td><td style="vertical-align:top"><p>-0.8</p></td><td style="vertical-align:top"><p>5.8</p></td><td style="vertical-align:top"><p>-2.0</p></td><td style="vertical-align:top"><p>-1.2 (‑1.66, ‑0.80)**</p></td></tr><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation (0‑10)<sup>c,</sup>*</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>-1.0</p></td><td style="vertical-align:top"><p>6.6</p></td><td style="vertical-align:top"><p>-2.7</p></td><td style="vertical-align:top"><p>-1.7 (‑2.18, ‑1.25)**</p></td></tr><tr><td style="vertical-align:top"><p>BASDAI Score<sup>d</sup></p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>-1.1</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>-2.6</p></td><td style="vertical-align:top"><p>-1.4 (‑1.88, ‑1.00)**</p></td></tr><tr><td style="vertical-align:top"><p>BASMI<sup>e,</sup>*</p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>4.4</p></td><td style="vertical-align:top"><p>-0.1</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>-0.6</p></td><td style="vertical-align:top"><p>-0.5 (‑0.67, ‑0.37)**</p></td></tr><tr><td style="vertical-align:top"><p>hsCRP<sup>f,</sup>* (mg/dL)</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>-0.1</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>-1.1</p></td><td style="vertical-align:top"><p>-1.0 (‑1.20, ‑0.72)**</p></td></tr><tr><td style="vertical-align:top"><p>ASDAScrp<sup>g,</sup>*</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>-0.4</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>-1.4</p></td><td style="vertical-align:top"><p>-1.0 (‑1.16, ‑0.79)**</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p>* type I error-controlled.</p><p>** p &lt; 0.0001.</p><p><sup>a </sup>Measured on a numerical rating scale with 0 = not active or no pain, 10 = very active or most severe pain.</p><p><sup>b </sup>Bath Ankylosing Spondylitis Functional Index measured on a numerical rating scale with 0 = easy and 10 = impossible.</p><p><sup>c </sup>Inflammation is the mean of two patient-reported stiffness self-assessments in BASDAI.</p><p><sup>d </sup>Bath Ankylosing Spondylitis Disease Activity Index total score.</p><p><sup>e </sup>Bath Ankylosing Spondylitis Metrology Index.</p><p><sup>f </sup>High sensitivity C-reactive protein.</p><p><sup>g </sup>Ankylosing Spondylitis Disease Activity Score with C-reactive protein.</p><p>LSM = least squares mean</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Other health-related outcomes</u></p><p>Patients treated with tofacitinib 5 mg twice daily achieved greater improvements from baseline in Ankylosing Spondylitis Quality of Life (ASQoL) (-4.0 vs -2.0) and Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total score (6.5 vs 3.1) compared to placebo-treated patients at Week 16 (p&lt;0.001). Patients treated with tofacitinib 5 mg twice daily achieved consistently greater improvements from baseline in the Short Form health survey version 2 (SF-36v2), Physical Component Summary (PCS) domain compared to placebo-treated patients at Week 16.</p><p>&nbsp;</p><p><em>Ulcerative colitis</em></p><p>The efficacy and safety of tofacitinib film-coated tablets for the treatment of adult patients with moderately to severely active UC (Mayo score 6 to 12 with endoscopy subscore &ge;&nbsp;2 and rectal bleeding subscore&nbsp;&ge;&nbsp;1) were assessed in 3&nbsp;multicentre, double‑blind, randomised, placebo‑controlled studies: 2&nbsp;identical induction studies (OCTAVE Induction 1 and OCTAVE Induction 2) followed by 1&nbsp;maintenance study (OCTAVE Sustain). Enrolled patients had failed at least 1 conventional therapy, including corticosteroids, immunomodulators, and/or a TNF inhibitor. Concomitant stable doses of oral aminosalicylates and corticosteroids (prednisone or equivalent daily dose up to 25&nbsp;mg) were permitted with taper of corticosteroids to discontinuation mandated within 15&nbsp;weeks of entering the maintenance study. Tofacitinib was administered as monotherapy (i.e., without concomitant use of biologics and immunosuppressants) for UC.</p><p>&nbsp;</p><p>Table 22 provides additional information regarding pertinent study design and population characteristics.</p><p>&nbsp;</p><p><strong>Table&nbsp;22: Phase&nbsp;3 clinical studies of tofacitinib 5&nbsp;mg and 10&nbsp;mg twice daily doses in patients with UC</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>OCTAVE Induction 1</p></td><td style="vertical-align:top"><p>OCTAVE Induction 2</p></td><td style="vertical-align:top"><p>OCTAVE Sustain</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Treatment groups</strong></p><p><strong>(randomisation ratio) </strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 10&nbsp;mg</strong></p><p><strong>twice daily</strong></p><p><strong>placebo</strong></p><p><strong>(4:1)</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 10&nbsp;mg</strong></p><p><strong>twice daily</strong></p><p><strong>placebo</strong></p><p><strong>(4:1)</strong></p></td><td><p><strong>Tofacitinib 5&nbsp;mg</strong></p><p><strong>twice daily</strong></p><p><strong>Tofacitinib 10&nbsp;mg</strong></p><p><strong>twice daily</strong></p><p><strong>placebo</strong></p><p><strong>(1:1:1)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of patients enrolled</p></td><td style="vertical-align:top"><p>598</p></td><td style="vertical-align:top"><p>541</p></td><td style="vertical-align:top"><p>593</p></td></tr><tr><td style="vertical-align:top"><p>Study duration</p></td><td style="vertical-align:top"><p>8&nbsp;weeks</p></td><td style="vertical-align:top"><p>8&nbsp;weeks</p></td><td style="vertical-align:top"><p>52&nbsp;weeks</p></td></tr><tr><td style="vertical-align:top"><p>Primary efficacy endpoint</p></td><td style="vertical-align:top"><p>Remission</p></td><td style="vertical-align:top"><p>Remission</p></td><td style="vertical-align:top"><p>Remission</p></td></tr><tr><td style="vertical-align:top"><p>Key secondary efficacy endpoints</p></td><td style="vertical-align:top"><p>Improvement of endoscopic appearance of the mucosa</p></td><td style="vertical-align:top"><p>Improvement of endoscopic appearance of the mucosa</p></td><td style="vertical-align:top"><p>Improvement of endoscopic appearance of the mucosa</p><p>&nbsp;</p><p>Sustained corticosteroid-free remission among patients in remission at baseline</p></td></tr><tr><td style="vertical-align:top"><p>Prior TNFi failure</p></td><td style="vertical-align:top"><p>51.3%</p></td><td style="vertical-align:top"><p>52.1%</p></td><td style="vertical-align:top"><p>44.7%</p></td></tr><tr><td style="vertical-align:top"><p>Prior corticosteroid failure</p></td><td style="vertical-align:top"><p>74.9%</p></td><td style="vertical-align:top"><p>71.3%</p></td><td style="vertical-align:top"><p>75.0%</p></td></tr><tr><td style="vertical-align:top"><p>Prior immunosuppressant failure</p></td><td style="vertical-align:top"><p>74.1%</p></td><td style="vertical-align:top"><p>69.5%</p></td><td style="vertical-align:top"><p>69.6%</p></td></tr><tr><td style="vertical-align:top"><p>Baseline corticosteroid use</p></td><td style="vertical-align:top"><p>45.5%</p></td><td style="vertical-align:top"><p>46.8%</p></td><td style="vertical-align:top"><p>50.3%</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Abbreviations: TNFi=tumour necrosis factor inhibitor; UC=ulcerative colitis.</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p>In addition, safety and efficacy of tofacitinib were assessed in an open‑label long‑term extension study (OCTAVE Open). Patients who completed 1 of the induction studies (OCTAVE Induction 1 or OCTAVE Induction 2) but did not achieve clinical response or patients who completed or withdrew early due to treatment failure in the maintenance study (OCTAVE Sustain) were eligible for OCTAVE Open. Patients from OCTAVE Induction 1 or OCTAVE Induction 2 who did not achieve clinical response after 8&nbsp;weeks in OCTAVE Open were to be discontinued from OCTAVE Open. Corticosteroid tapering was also required upon entrance into OCTAVE Open.</p><p>&nbsp;</p><p><em><u>Induction efficacy data (OCTAVE Induction 1 and OCTAVE Induction 2) </u></em></p><p>The primary endpoint of OCTAVE Induction 1 and OCTAVE Induction 2 was the proportion of patients in remission at week&nbsp;8, and the key secondary endpoint was the proportion of patients with improvement of endoscopic appearance of the mucosa at week&nbsp;8. Remission was defined as clinical remission (a total Mayo score &le;&nbsp;2 with no individual subscore &gt;&nbsp;1) and rectal bleeding subscore of 0. Improvement of endoscopic appearance of the mucosa was defined as endoscopy subscore of 0 or 1.</p><p>&nbsp;</p><p>A significantly greater proportion of patients treated with tofacitinib 10&nbsp;mg twice daily achieved remission, improvement of endoscopic appearance of the mucosa, and clinical response at week&nbsp;8 compared to placebo in both studies, as shown in Table 23.</p><p>&nbsp;</p><p>The efficacy results based on the endoscopic readings at the study sites were consistent with the results based on the central endoscopy readings.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table 23: Proportion of patients meeting efficacy endpoints at week 8 (OCTAVE induction study&nbsp;1 and OCTAVE induction study 2)</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>OCTAVE induction study&nbsp;1</strong></p></td></tr><tr><td colspan="2"><p><strong>Central endoscopy read</strong></p></td><td colspan="2"><p><strong>Local endoscopy read</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td><p><strong>Tofacitinib</strong></p><p><strong>10&nbsp;mg</strong></p><p><strong>twice daily</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td><p><strong>Tofacitinib</strong></p><p><strong>10&nbsp;mg</strong></p><p><strong>twice daily</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p><strong>N=122</strong></p></td><td><p><strong>N=476</strong></p></td><td><p><strong>N=122</strong></p></td><td><p><strong>N=476</strong></p></td></tr><tr><td style="vertical-align:top"><p>Remission<sup>a</sup></p></td><td style="vertical-align:top"><p>8.2%</p></td><td style="vertical-align:top"><p>18.5%<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>11.5%</p></td><td style="vertical-align:top"><p>24.8%<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Improvement of endoscopic appearance of the mucosa<sup>b</sup></p></td><td style="vertical-align:top"><p>15.6%</p></td><td style="vertical-align:top"><p>31.3%<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>23.0%</p></td><td style="vertical-align:top"><p>42.4%*</p></td></tr><tr><td style="vertical-align:top"><p>Normalisation of endoscopic appearance of the mucosa<sup>c</sup></p></td><td style="vertical-align:top"><p>1.6%</p></td><td style="vertical-align:top"><p>6.7%<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>2.5%</p></td><td style="vertical-align:top"><p>10.9%<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Clinical response<sup>d</sup></p></td><td style="vertical-align:top"><p>32.8%</p></td><td style="vertical-align:top"><p>59.9%*</p></td><td style="vertical-align:top"><p>34.4%</p></td><td style="vertical-align:top"><p>60.7%*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p><strong>OCTAVE induction study&nbsp;2</strong></p></td></tr><tr><td colspan="2"><p><strong>Central endoscopy read</strong></p></td><td colspan="2"><p><strong>Local endoscopy read</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td><p><strong>Tofacitinib</strong></p><p><strong>10&nbsp;mg</strong></p><p><strong>twice daily</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td><p><strong>Tofacitinib</strong></p><p><strong>10&nbsp;mg</strong></p><p><strong>twice daily</strong></p></td></tr><tr><td style="vertical-align:top"><p><s>&nbsp;</s></p></td><td style="vertical-align:top"><p><strong>N=112</strong></p></td><td style="vertical-align:top"><p><strong>N=429</strong></p></td><td style="vertical-align:top"><p><strong>N=112</strong></p></td><td style="vertical-align:top"><p><strong>N=429</strong></p></td></tr><tr><td style="vertical-align:top"><p>Remission<sup>a</sup></p></td><td style="vertical-align:top"><p>3.6%</p></td><td style="vertical-align:top"><p>16.6%<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>5.4%</p></td><td style="vertical-align:top"><p>20.7%<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Improvement of endoscopic appearance of the mucosa<sup>b</sup></p></td><td style="vertical-align:top"><p>11.6%</p></td><td style="vertical-align:top"><p>28.4%<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>15.2%</p></td><td style="vertical-align:top"><p>36.4%*</p></td></tr><tr><td style="vertical-align:top"><p>Normalisation of endoscopic appearance of the mucosa<sup>c</sup></p></td><td style="vertical-align:top"><p>1.8%</p></td><td style="vertical-align:top"><p>7.0%<sup>&Dagger;</sup></p></td><td style="vertical-align:top"><p>0.0%</p></td><td style="vertical-align:top"><p>9.1%<sup>&Dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Clinical response<sup>d</sup></p></td><td style="vertical-align:top"><p>28.6%</p></td><td style="vertical-align:top"><p>55.0%*</p></td><td style="vertical-align:top"><p>29.5%</p></td><td style="vertical-align:top"><p>58.0%*</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>* p&lt;0.0001; &dagger; p&lt;0.001; &Dagger; p&lt;0.05.</p><p>N=number of patients in the analysis set.</p><p><sup>a.</sup>&nbsp;&nbsp;&nbsp; Primary endpoint: Remission was defined as clinical remission (a Mayo score &le;&nbsp;2 with no individual subscore &gt;&nbsp;1) and rectal bleeding subscore of 0.</p><p><sup>b.</sup>&nbsp;&nbsp;&nbsp; Key secondary endpoint: Improvement of endoscopic appearance of the mucosa was defined as Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern).</p><p><sup>c.</sup>&nbsp;&nbsp;&nbsp; Normalisation of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0.</p><p><sup>d.</sup>&nbsp;&nbsp;&nbsp; Clinical response was defined as a decrease from baseline in Mayo score of &ge;&nbsp;3 points and &ge;&nbsp;30%, with an accompanying decrease in the subscore for rectal bleeding of &ge;&nbsp;1 point or absolute subscore for rectal bleeding of 0 or 1.</p></td></tr></tbody></table><p>&nbsp;</p><p>In both subgroups of patients with or without prior TNF inhibitor failure, a greater proportion of patients treated with tofacitinib 10&nbsp;mg twice daily achieved remission and improvement of endoscopic appearance of the mucosa at week 8&nbsp;as compared to placebo. This treatment difference was consistent between the 2 subgroups (Table&nbsp;24).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 24. Proportion of patients meeting primary and key secondary efficacy endpoints at week&nbsp;8 by TNF inhibitor therapy subgroups (OCTAVE induction study 1 and OCTAVE induction study 2, central endoscopy read)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OCTAVE induction study 1</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=122</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 10 mg</strong></p><p><strong>twice daily</strong></p><p><strong>N=476</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Remission<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; With prior TNF inhibitor failure</p></td><td style="vertical-align:top"><p>1.6%</p><p>(1/64)</p></td><td style="vertical-align:top"><p>11.1%</p><p>(27/243)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Without prior TNF inhibitor failure<sup>b</sup></p></td><td style="vertical-align:top"><p>15.5%</p><p>(9/58)</p></td><td style="vertical-align:top"><p>26.2%</p><p>(61/233)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Improvement of endoscopic appearance of the mucosa<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; With prior TNF inhibitor failure</p></td><td style="vertical-align:top"><p>6.3%</p><p>(4/64)</p></td><td style="vertical-align:top"><p>22.6%</p><p>(55/243)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Without prior TNF inhibitor failure<sup>b</sup></p></td><td style="vertical-align:top"><p>25.9%</p><p>(15/58)</p></td><td style="vertical-align:top"><p>40.3%</p><p>(94/233)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OCTAVE induction study 2</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=112</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib 10 mg</strong></p><p><strong>twice daily</strong></p><p><strong>N=429</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Remission<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; With prior TNF inhibitor failure</p></td><td style="vertical-align:top"><p>0.0%</p><p>(0/60)</p></td><td style="vertical-align:top"><p>11.7%</p><p>(26/222)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp; Without prior TNF inhibitor failure<sup>b</sup></p></td><td style="vertical-align:top"><p>7.7%</p><p>(4/52)</p></td><td style="vertical-align:top"><p>21.7%</p><p>(45/207)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Improvement of endoscopic appearance of the mucosa<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; With prior TNF inhibitor failure</p></td><td style="vertical-align:top"><p>6.7%</p><p>(4/60)</p></td><td style="vertical-align:top"><p>21.6%</p><p>(48/222)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; Without prior TNF inhibitor failure<sup>b</sup></p></td><td style="vertical-align:top"><p>17.3%</p><p>(9/52)</p></td><td style="vertical-align:top"><p>35.7%</p><p>(74/207)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>TNF=tumour necrosis factor; N=number of patients in the analysis set.</p><p><sup>a.</sup>&nbsp;&nbsp;&nbsp; Remission was defined as clinical remission (a Mayo score &le;&nbsp;2 with no individual subscore &gt;&nbsp;1) and rectal bleeding subscore of 0.</p><p><sup>b.</sup>&nbsp;&nbsp;&nbsp; Included TNF Inhibitor na&iuml;ve patients</p><p><sup>c.</sup>&nbsp;&nbsp;&nbsp; Improvement of endoscopic appearance of the mucosa was defined as Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern).</p></td></tr></tbody></table><p>&nbsp;</p><p>As early as week 2, the earliest scheduled study visit, and at each visit thereafter, significant differences were observed between tofacitinib 10 mg twice daily and placebo in the change from baseline in rectal bleeding and stool frequency, and partial Mayo score.</p><p>&nbsp;</p><p><em><u>Maintenance (OCTAVE Sustain)</u></em></p><p>Patients who completed 8 weeks in 1 of the induction studies and achieved clinical response were re‑randomised into OCTAVE Sustain; 179 out of 593 (30.2%) patients were in remission at baseline of OCTAVE Sustain.</p><p>&nbsp;</p><p>The primary endpoint in OCTAVE Sustain was the proportion of patients in remission at week&nbsp;52. The 2 key secondary endpoints were the proportion of patients with improvement of endoscopic appearance at week 52, and the proportion of patients with sustained corticosteroid‑free remission at both week 24 and week 52 among patients in remission at baseline of OCTAVE Sustain.</p><p>&nbsp;</p><p>A significantly greater proportion of patients in both the tofacitinib 5&nbsp;mg twice daily and tofacitinib 10&nbsp;mg twice daily treatment groups achieved the following endpoints at week&nbsp;52 as compared to placebo: remission, improvement of endoscopic appearance of the mucosa, normalisation of endoscopic appearance of the mucosa, maintenance of clinical response, remission among patients in remission at baseline, and sustained corticosteroid-free remission at both week&nbsp;24 and week&nbsp;52 among patients in remission at baseline, as shown in Table 25.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="7" style="vertical-align:top"><p><strong>Table 25: </strong><strong>Proportion of patients meeting efficacy endpoints at week 52 (</strong><strong>OCTAVE sustain)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Central endoscopy read</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Local endoscopy read</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=198</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>5 mg</strong></p><p><strong>twice daily</strong></p><p><strong>N=198</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>10 mg</strong></p><p><strong>twice daily</strong></p><p><strong>N=197</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=198</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>5 mg</strong></p><p><strong>twice daily</strong></p><p><strong>N=198</strong></p></td><td style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>10 mg</strong></p><p><strong>twice daily</strong></p><p><strong>N=197</strong></p></td></tr><tr><td style="vertical-align:top"><p>Remission<sup>a</sup></p></td><td style="vertical-align:top"><p>11.1%</p></td><td style="vertical-align:top"><p>34.3%*</p></td><td style="vertical-align:top"><p>40.6%*</p></td><td style="vertical-align:top"><p>13.1%</p></td><td style="vertical-align:top"><p>39.4%*</p></td><td style="vertical-align:top"><p>47.7%*</p></td></tr><tr><td style="vertical-align:top"><p>Improvement of endoscopic appearance of the mucosa<sup>b</sup></p></td><td style="vertical-align:top"><p>13.1%</p></td><td style="vertical-align:top"><p>37.4%*</p></td><td style="vertical-align:top"><p>45.7%*</p></td><td style="vertical-align:top"><p>15.7%</p></td><td style="vertical-align:top"><p>44.9%*</p></td><td style="vertical-align:top"><p>53.8%*</p></td></tr><tr><td style="vertical-align:top"><p>Normalisation of endoscopic appearance of the mucosa<sup>c</sup></p></td><td style="vertical-align:top"><p>4.0%</p></td><td style="vertical-align:top"><p>14.6%**</p></td><td style="vertical-align:top"><p>16.8%*</p></td><td style="vertical-align:top"><p>5.6%</p></td><td style="vertical-align:top"><p>22.2%*</p></td><td style="vertical-align:top"><p>29.4%*</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance of clinical response<sup>d</sup></p></td><td style="vertical-align:top"><p>20.2%</p></td><td style="vertical-align:top"><p>51.5%*</p></td><td style="vertical-align:top"><p>61.9%*</p></td><td style="vertical-align:top"><p>20.7%</p></td><td style="vertical-align:top"><p>51.0%*</p></td><td style="vertical-align:top"><p>61.4%*</p></td></tr><tr><td style="vertical-align:top"><p>Remission among patients in remission at baseline<sup>a,f</sup></p></td><td style="vertical-align:top"><p>10.2%</p></td><td style="vertical-align:top"><p>46.2%*</p></td><td style="vertical-align:top"><p>56.4%*</p></td><td style="vertical-align:top"><p>11.9%</p></td><td style="vertical-align:top"><p>50.8%*</p></td><td style="vertical-align:top"><p>65.5%*</p></td></tr><tr><td style="vertical-align:top"><p>Sustained corticosteroid-free remission at both week 24 and week&nbsp;52 among patients in remission at baseline<sup>e,f</sup></p></td><td style="vertical-align:top"><p>5.1%</p></td><td style="vertical-align:top"><p>35.4%*</p></td><td style="vertical-align:top"><p>47.3%*</p></td><td style="vertical-align:top"><p>11.9%</p></td><td style="vertical-align:top"><p>47.7%*</p></td><td style="vertical-align:top"><p>58.2%*</p></td></tr><tr><td style="vertical-align:top"><p>Corticosteroid-free remission among patients taking corticosteroids at baseline<sup>a,g</sup></p></td><td style="vertical-align:top"><p>10.9%</p></td><td style="vertical-align:top"><p>27.7%<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>27.6%<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>13.9%</p></td><td style="vertical-align:top"><p>32.7%<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>31.0%<sup>&dagger;</sup></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>* p&lt;0.0001; **p&lt;0.001; &dagger;p&lt;0.05 for tofacitinib versus placebo.</p><p>N=number of patients in the analysis set.</p><p><sup>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Remission was defined as clinical remission (a Mayo score &le;&nbsp;2 with no individual subscore &gt;&nbsp;1) <u>and</u> rectal bleeding subscore of 0.</p><p><sup>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Improvement of endoscopic appearance of the mucosa was defined as Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern).</p><p><sup>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Normalisation of endoscopic appearance of the mucosa was defined as a Mayo endoscopic subscore of 0.</p><p><sup>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Maintenance of clinical response was defined by a decrease from the induction study (OCTAVE Induction&nbsp;1, OCTAVE Induction&nbsp;2) baseline Mayo score of &ge;&nbsp;3 points and &ge;&nbsp;30%, with an accompanying decrease in the rectal bleeding subscore of &ge;&nbsp;1 point or rectal bleeding subscore of 0 or 1. Patients were to be in clinical response at baseline of the maintenance study OCTAVE Sustain.</p><p><sup>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Sustained corticosteroid-free remission was defined as being in remission and not taking corticosteroids for at least 4&nbsp;weeks prior to the visit at both week 24 and week 52.</p><p><sup>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>N=59 for placebo, N=65 for tofacitinib 5&nbsp;mg twice daily, N=55 for tofacitinib 10&nbsp;mg twice daily.</p><p><sup>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>N=101 for placebo, N=101 for tofacitinib 5&nbsp;mg twice daily, N=87 for tofacitinib 10&nbsp;mg twice daily.</p></td></tr></tbody></table><p>&nbsp;</p><p>In both subgroups of patients with or without prior TNF inhibitor failure, a greater proportion of patients treated with either tofacitinib 5 mg twice daily or tofacitinib 10&nbsp;mg twice daily achieved the following endpoints at week&nbsp;52 of OCTAVE Sustain as compared to placebo: remission, improvement of endoscopic appearance of the mucosa, or sustained corticosteroid-free remission at both week 24 and week&nbsp;52 among patients in remission at baseline (Table 26). This treatment difference from placebo was similar between tofacitinib 5&nbsp;mg twice daily and tofacitinib 10&nbsp;mg twice daily in the subgroup of patients without prior TNF inhibitor failure. In the subgroup of patients with prior TNF inhibitor failure, the observed treatment difference from placebo was numerically greater for tofacitinib 10&nbsp;mg twice daily than tofacitinib 5&nbsp;mg twice daily by 9.7 to 16.7 percentage points across the primary and key secondary endpoints.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4"><p><strong>Table 26: Proportion of patients meeting primary and key secondary efficacy endpoints at week&nbsp;52 by TNF inhibitor therapy subgroup (OCTAVE sustain, central endoscopy read)</strong></p></td><td>&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N=198</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>5 mg</strong></p><p><strong>twice daily</strong></p><p><strong>N=198</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Tofacitinib</strong></p><p><strong>10 mg</strong></p><p><strong>twice daily</strong></p><p><strong>N=197</strong></p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p>Remission<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>With prior TNF inhibitor failure</p></td><td style="vertical-align:top"><p>10/89</p><p>(11.2%)</p></td><td style="vertical-align:top"><p>20/83</p><p>(24.1%)</p></td><td style="vertical-align:top"><p>34/93</p><p>(36.6%)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Without prior TNF inhibitor failure<sup>b</sup></p></td><td style="vertical-align:top"><p>12/109</p><p>(11.0%)</p></td><td style="vertical-align:top"><p>48/115</p><p>(41.7%)</p></td><td style="vertical-align:top"><p>46/104</p><p>(44.2%)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Improvement of endoscopic appearance of the mucosa<sup>c</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>With prior TNF inhibitor failure</p></td><td style="vertical-align:top"><p>11/89</p><p>(12.4%)</p></td><td style="vertical-align:top"><p>25/83</p><p>(30.1%)</p></td><td style="vertical-align:top"><p>37/93</p><p>(39.8%)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Without prior TNF inhibitor failure<sup>b</sup></p></td><td style="vertical-align:top"><p>15/109</p><p>(13.8%)</p></td><td style="vertical-align:top"><p>49/115</p><p>(42.6%)</p></td><td style="vertical-align:top"><p>53/104</p><p>(51.0%)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Sustained corticosteroid-free remission at both week 24 and week 52 among patients in remission at baseline<sup>d</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>With prior TNF inhibitor failure</p></td><td style="vertical-align:top"><p>1/21</p><p>(4.8%)</p></td><td style="vertical-align:top"><p>4/18</p><p>(22.2%)</p></td><td style="vertical-align:top"><p>7/18</p><p>(38.9%)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Without prior TNF inhibitor failure<sup>b</sup></p></td><td style="vertical-align:top"><p>2/38</p><p>(5.3%)</p></td><td style="vertical-align:top"><p>19/47</p><p>(40.4%)</p></td><td style="vertical-align:top"><p>19/37</p><p>(51.4%)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>TNF=tumour necrosis factor; N=number of patients in the analysis set.</p><p><sup>a.</sup>&nbsp;&nbsp;&nbsp; Remission was defined as clinical remission (a Mayo score &le;&nbsp;2 with no individual subscore &gt;&nbsp;1) <u>and</u> rectal bleeding subscore of 0.</p><p><sup>b.</sup>&nbsp;&nbsp;&nbsp; Included TNF Inhibitor na&iuml;ve patients.</p><p><sup>c.</sup>&nbsp;&nbsp;&nbsp; Improvement of endoscopic appearance of the mucosa was defined as Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (erythema, decreased vascular pattern).</p><p><sup>d.</sup>&nbsp;&nbsp;&nbsp; Sustained corticosteroid-free remission was defined as being in remission and not taking corticosteroids for at least 4&nbsp;weeks prior to the visit at both week 24 and week 52.</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>The proportion of patients in both tofacitinib groups who had treatment failure was lower compared to placebo at each time point as early as week&nbsp;8, the first time point where treatment failure was assessed, as shown in Figure&nbsp;2.</p><p>&nbsp;</p><p><strong>Figure 2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Time to treatment failure in maintenance study OCTAVE sustain (Kaplan-Meier Curves) </strong><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_3" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:453.75pt;height:263.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="605" height="351" src="file:///C:/Users/bakhsm/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /></p><p>p&lt;0.0001 for tofacitinib 5 mg twice daily versus placebo.</p><p>p&lt;0.0001 for tofacitinib 10 mg twice daily versus placebo.</p><p>BID=twice daily.</p><p>Treatment failure was defined as an increase in Mayo score of &ge;&nbsp;3 points from maintenance study baseline, accompanied by an increase in rectal bleeding subscore by &ge;&nbsp;1 point, and an increase of endoscopic subscore of &ge;&nbsp;1 point yielding an absolute endoscopic subscore of &ge;&nbsp;2 after a minimum treatment of 8&nbsp;weeks in the study.</p><p>&nbsp;</p><p><em><u>Health-related and quality of life outcomes</u></em></p><p>Tofacitinib 10&nbsp;mg twice daily demonstrated greater improvement from baseline compared to placebo in physical component summary (PCS) and mental component summary (MCS) scores, and in all 8&nbsp;domains of the SF-36 in the induction studies (OCTAVE Induction 1, OCTAVE Induction 2). In the maintenance study&nbsp;(OCTAVE Sustain), tofacitinib 5&nbsp;mg twice daily or tofacitinib 10&nbsp;mg twice daily demonstrated greater maintenance of improvement compared to placebo in PCS and MCS scores, and in all 8&nbsp;domains of the SF-36 at week&nbsp;24 and week&nbsp;52.</p><p>&nbsp;</p><p>Tofacitinib 10&nbsp;mg twice daily demonstrated greater improvement from baseline compared to placebo at week 8 in the total and all 4&nbsp;domain scores of the Inflammatory Bowel Disease Questionnaire (IBDQ) (bowel symptoms, systemic function, emotional function, and social function) in the induction studies (OCTAVE Induction 1, OCTAVE Induction 2). In the maintenance study (OCTAVE Sustain), tofacitinib 5&nbsp;mg twice daily or tofacitinib 10&nbsp;mg twice daily demonstrated greater maintenance of improvement compared to placebo in the total and all 4 domain scores of the IBDQ at week&nbsp;24 and week&nbsp;52.</p><p>&nbsp;</p><p>Improvements were also observed in the EuroQoL 5-Dimension (EQ-5D) and various domains of the Work Productivity and Activity Impairment (WPAI-UC) questionnaire in both induction and maintenance studies compared to placebo.</p><p>&nbsp;</p><p><em><u>Open-label extension study (OCTAVE Open)</u></em></p><p>Patients who did not achieve clinical response in one of the induction studies (OCTAVE Induction 1 or OCTAVE Induction 2) after 8&nbsp;weeks of tofacitinib 10&nbsp;mg twice daily were allowed to enter an open‑label extension study (OCTAVE Open). After an additional 8&nbsp;weeks of tofacitinib 10&nbsp;mg twice daily in OCTAVE Open, 53% (154/293) patients achieved clinical response and 14% (42/293) patients achieved remission.</p><p>&nbsp;</p><p>Patients who achieved clinical response in 1 of the induction studies (OCTAVE Induction 1 or OCTAVE Induction 2) with tofacitinib 10&nbsp;mg twice daily but experienced treatment failure after their dose was reduced to tofacitinib 5&nbsp;mg twice daily or following treatment interruption in OCTAVE Sustain (i.e., were randomised to placebo), had their dose increased to tofacitinib 10&nbsp;mg twice daily in OCTAVE Open. After 8&nbsp;weeks on tofacitinib 10&nbsp;mg twice daily in OCTAVE Open, remission was achieved in 35% (20/58) patients who received tofacitinib 5&nbsp;mg twice daily in OCTAVE Sustain and 40% (40/99) patients with dose interruption in OCTAVE Sustain. At month&nbsp;12 in OCTAVE Open, 52% (25/48) and 45% (37/83) of these patients achieved remission, respectively.</p><p>&nbsp;</p><p>Furthermore, at month&nbsp;12 of study OCTAVE Open, 74% (48/65) of patients who achieved remission at the end of study OCTAVE Sustain on either tofacitinib 5&nbsp;mg twice daily or tofacitinib 10&nbsp;mg twice daily remained in remission while receiving tofacitinib 5&nbsp;mg twice daily.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit results of studies with tofacitinib in one or more subsets of the paediatric population in other rarer types of juvenile idiopathic arthritis and in ulcerative colitis (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p><p><em>Polyarticular juvenile idiopathic arthritis and juvenile PsA</em></p><p><em>&nbsp;</em></p><p>The tofacitinib Phase 3 program for JIA consisted of one completed Phase 3 trial (Study JIA-I [A3921104]) and one ongoing long-term extension (LTE) (A3921145) trial. In these studies the following JIA subgroups were included: patients with either RF+ or RF- polyarthritis, extended oligoarthritis, systemic JIA with active arthritis and no current systemic symptoms (referred as pJIA dataset) and two separate subgroups of patients with juvenile PsA and enthesitis-related arthritis (ERA). However, the pJIA efficacy population only includes the subgroups with either RF+ or RF- polyarthritis or extended oligoarthritis; inconclusive results have been seen in the subgroup of patients with systemic JIA with active arthritis and no current systemic symptoms. Patients with juvenile PsA are included as separate efficacy subgroup. ERA patients are not included in the efficacy analysis.</p><p>&nbsp;</p><p>All eligible patients in Study JIA-I received open-label tofacitinib 5 mg film-coated tablets twice daily or tofacitinib oral solution weight-based equivalent twice daily for 18&nbsp;weeks (run-in phase); patients who achieved at least a JIA ACR30 response at the end of the open-label phase were randomised (1:1) to either active tofacitinib 5&nbsp;mg film-coated tablets or tofacitinib oral solution, or placebo in the 26‑week double-blind, placebo-controlled phase. Patients who did not achieve a JIA ACR30 response at the end of the open-label run-in phase or experienced a single episode of disease flare at any time were discontinued from the study. A total of 225 patients were enrolled in the open‑label run-in phase. Of these, 173 (76.9%) patients were eligible to be randomised into the double-blind phase to either active tofacitinib 5 mg film-coated tablets or tofacitinib oral solution weight-based equivalent twice daily (n=88) or placebo (n=85). There were 58&nbsp;(65.9%) patients in the tofacitinib group and 58&nbsp;(68.2%) patients in the placebo group taking MTX during the double-blind phase, which was permitted but not required per the protocol.</p><p>&nbsp;</p><p>There were 133 patients with pJIA [RF+ or RF- polyarthritis and extended oligoarthritis] and 15 with juvenile PsA randomised into the double-blind phase of the study and included in the efficacy analyses presented below.</p><p>&nbsp;</p><p><em>Signs and symptoms</em></p><p>A significantly smaller proportion of patients with pJIA in Study JIA-I treated with tofacitinib 5 mg film-coated tablets twice daily or tofacitinib oral solution weight-based equivalent twice daily flared at Week&nbsp;44 compared with patients treated with placebo. A significantly greater proportion of patients with pJIA treated with tofacitinib 5 mg film-coated tablets or tofacitinib oral solution achieved JIA ACR30, 50, and 70 responses compared to patients treated with placebo at Week&nbsp;44 (Table 27).</p><p><u>&nbsp;</u></p><p>The occurrence of disease flare and JIA ACR30/50/70 results were favourable to tofacitinib 5 mg twice daily in comparison to placebo across the RF+ polyarthritis, RF- polyarthritis, extended oligoarthritis, and jPsA JIA subtypes and were consistent with those for the overall study population.</p><p>The occurrence of disease flare and JIA ACR30/50/70 results were favourable to tofacitinib 5 mg twice daily in comparison to placebo for pJIA patients who received tofacitinib 5 mg twice daily with concomitant MTX use on Day 1 [n=101 (76%)] and those who were on tofacitinib monotherapy [n=32 (24%)]. In addition, the occurrence of disease flare and JIA ACR30/50/70 results were also favourable to tofacitinib 5 mg twice daily compared to placebo for pJIA patients who had prior bDMARD experience [n=39 (29%)] and those who were bDMARD na&iuml;ve [n=94 (71%)].&nbsp;</p><p>&nbsp;</p><p>In Study JIA-I at Week&nbsp;2 of the open-label run-in phase, the JIA ACR30 response in patients with pJIA was 45.03%.</p><p>&nbsp;</p><p><strong>Table 27: Primary and secondary efficacy endpoints in patients with pJIA at Week 44* in Study JIA-I (all p-values&lt;0.05)</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p>Primary endpoint</p><p><strong>(Type I error controlled)</strong></p></td><td style="vertical-align:bottom"><p>Treatment group</p></td><td style="vertical-align:bottom"><p>Occurrence rate</p></td><td style="vertical-align:bottom"><p>Difference (%) from placebo (95% CI)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Occurrence of disease flare</p></td><td style="vertical-align:top"><p>Tofacitinib 5 mg Twice Daily</p><p>(N=67)</p></td><td style="vertical-align:top"><p>28%</p></td><td rowspan="2" style="vertical-align:top"><p>-24.7 (-40.8, -8.5)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>(N=66)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>53%</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Secondary endpoints</strong></p><p><strong>(Type I error controlled)</strong></p></td><td style="vertical-align:bottom"><p><strong>Treatment group</strong></p></td><td style="vertical-align:bottom"><p><strong>Response</strong></p><p><strong>rate</strong></p></td><td style="vertical-align:bottom"><p>Difference (%) from placebo (95% CI)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>JIA ACR30</p></td><td style="vertical-align:top"><p>Tofacitinib 5&nbsp;mg Twice Daily</p><p>(N=67)</p></td><td style="vertical-align:top"><p>72%</p></td><td rowspan="2" style="vertical-align:top"><p>24.7 (8.50, 40.8)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>(N=66)</p></td><td style="vertical-align:top"><p>47%</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>JIA ACR50</p></td><td style="vertical-align:top"><p>Tofacitinib 5&nbsp;mg Twice Daily</p><p>(N=67)</p></td><td style="vertical-align:top"><p>67%</p></td><td rowspan="2" style="vertical-align:top"><p>20.2 (3.72, 36.7)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>(N=66)</p></td><td style="vertical-align:top"><p>47%</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>JIA ACR70</p></td><td style="vertical-align:top"><p>Tofacitinib 5&nbsp;mg Twice Daily</p><p>(N=67)</p></td><td style="vertical-align:top"><p>55%</p></td><td rowspan="2" style="vertical-align:top"><p>17.4 (0.65, 34.0)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>(N=66)</p></td><td style="vertical-align:top"><p>38%</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Secondary endpoint (Type I error controlled)</strong></p></td><td style="vertical-align:bottom"><p><strong>Treatment group</strong></p></td><td style="vertical-align:bottom"><p><strong>LS mean (SEM)</strong></p></td><td style="vertical-align:bottom"><p>Difference from placebo (95% CI)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Change from Double-Blind Baseline in CHAQ Disability Index</p></td><td style="vertical-align:top"><p>Tofacitinib 5&nbsp;mg Twice Daily</p><p>(N=67; n=46)</p></td><td style="vertical-align:top"><p>-0.11 (0.04)</p></td><td rowspan="2" style="vertical-align:top"><p>-0.11 (-0.22, -0.01)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p><p>(N=66; n=31)</p></td><td style="vertical-align:top"><p>0.00 (0.04)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>ACR = American College of Rheumatology; CHAQ = childhood health assessment questionnaire; CI = confidence interval; LS = least squares; n = number of patients with observations at the visit; N = total number of patients; JIA = juvenile idiopathic arthritis; SEM = standard error of the mean</p><p>* The 26-week double-blind phase is from Week&nbsp;18 through Week&nbsp;44 on and after randomisation day.</p><p>The Type-I error-controlled endpoints are tested in this order: Disease Flare, JIA ACR50, JIA ACR30, JIA ACR70, CHAQ Disability Index.</p></td></tr></tbody></table><p>&nbsp;</p><p>In the double-blind phase, each of the components of the JIA ACR response showed greater improvement from the open-label baseline (Day 1) at Week 24, and Week 44 for patients with pJIA treated with tofacitinib oral solution dosed as 5 mg twice daily or weight-based equivalent twice daily compared with those receiving placebo in Study JIA-I.</p><p><strong>&nbsp;</strong></p><p><em>Physical function and health-related quality of life</em></p><p>Changes in physical function in Study JIA-I were measured by the CHAQ Disability Index. The mean change from the double-blind baseline in CHAQ-Disability Index in patients with pJIA was significantly lower in the tofacitinib 5 mg film-coated tablets twice daily or tofacitinib oral solution weight-based equivalent twice daily compared to placebo at Week&nbsp;44 (Table 27). The mean change from the double-blind baseline in CHAQ Disability Index results were favourable to tofacitinib 5 mg twice daily in comparison to placebo across the RF+ polyarthritis, RF- polyarthritis, extended oligoarthritis, and jPsA JIA subtypes and were consistent with those for the overall study population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The PK profile of tofacitinib is characterised by rapid absorption (peak plasma concentrations are reached within 0.5-1&nbsp;hour), rapid elimination (half-life of ~3&nbsp;hours) and dose‑proportional increases in systemic exposure. Steady state concentrations are achieved in 24‑48&nbsp;hours with negligible accumulation after twice daily administration.</p><p>&nbsp;</p><p><u>Absorption and distribution</u></p><p>&nbsp;</p><p>Tofacitinib is well-absorbed, with an oral bioavailability of 74%.<strong><sup> </sup></strong>Coadministration of tofacitinib with a high-fat meal resulted in no changes in AUC while C<sub>max</sub> was reduced by 32%.<strong> </strong>In clinical studies, tofacitinib was administered without regard to meal.</p><p>&nbsp;</p><p>After intravenous administration, the volume of distribution is 87&nbsp;L. Approximately 40% of circulating tofacitinib is bound to plasma proteins. Tofacitinib binds predominantly to albumin and does not appear to bind to a1-acid glycoprotein. Tofacitinib distributes equally between red blood cells and plasma.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>&nbsp;</p><p>Clearance mechanisms for tofacitinib are approximately 70% hepatic metabolism and 30% renal excretion of the parent drug. The metabolism of tofacitinib is primarily mediated by CYP3A4 with minor contribution from CYP2C19. In a human radiolabelled study, more than 65% of the total circulating radioactivity was accounted for by unchanged active substance, with the remaining 35% attributed to 8&nbsp;metabolites, each accounting for less than 8% of total radioactivity. All metabolites have been observed in animal species and are predicted to have less than 10-fold potency than tofacitinib for JAK1/3 inhibition. No evidence of stereo conversion in human samples was detected. The pharmacologic activity of tofacitinib is attributed to the parent molecule. <em>In vitro</em>, tofacitinib is a substrate for MDR1, but not for breast cancer resistance protein (BCRP), OATP1B1/1B3, or OCT1/2.</p><p>&nbsp;</p><p><u>Pharmacokinetics in patients</u></p><p>&nbsp;</p><p>The enzymatic activity of CYP enzymes is reduced in RA patients due to chronic inflammation. In RA patients, the oral clearance of tofacitinib does not vary with time, indicating that treatment with tofacitinib does not normalise CYP enzyme activity.</p><p>&nbsp;</p><p>Population PK analysis in RA patients indicated that systemic exposure (AUC) of tofacitinib in the extremes of body weight (40&nbsp;kg, 140&nbsp;kg) were similar (within 5%) to that of a 70&nbsp;kg patient. Elderly patients 80&nbsp;years of age were estimated to have less than&nbsp;5% higher AUC relative to the mean age of 55&nbsp;years. Women were estimated to have 7% lower AUC compared to men. The available data have also shown that there are no major differences in tofacitinib AUC between White, Black and Asian patients. An approximate linear relationship between body weight and volume of distribution was observed, resulting in higher peak (C<sub>max</sub>) and lower trough (C<sub>min</sub>) concentrations in lighter patients. However, this difference is not considered to be clinically relevant. The between-subject variability (percentage coefficient of variation) in AUC of tofacitinib is estimated to be approximately 27%.</p><p>&nbsp;</p><p>Results from population PK analysis in patients with active PsA, moderate to severe UC or AS were consistent with those in patients with RA.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>Subjects with mild (creatinine clearance 50-80&nbsp;mL/min), moderate (creatinine clearance 30‑49&nbsp;mL/min), and severe (creatinine clearance &lt;&nbsp;30&nbsp;mL/min) renal impairment had 37%, 43% and 123% higher AUC, respectively, compared to subjects with normal renal function (see section&nbsp;4.2)<em>.</em> In subjects with end‑stage renal disease (ESRD), contribution of dialysis to the total clearance of tofacitinib was relatively small. Following a single dose of 10&nbsp;mg, mean AUC in subjects with ESRD based on concentrations measured on a non-dialysis day was approximately 40%&nbsp;(90% confidence intervals: 1.5-95%) higher compared to subjects with normal renal function. In clinical studies, tofacitinib was not evaluated in patients with baseline creatinine clearance values (estimated by Cockcroft-Gault equation) less than 40&nbsp;mL/min (see section&nbsp;4.2).</p><p><em>&nbsp;</em></p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Subjects with mild (Child Pugh A) and moderate (Child Pugh B) hepatic impairment had 3%, and 65% higher AUC, respectively, compared to subjects with normal hepatic function. In clinical studies, tofacitinib was not evaluated in subjects with severe (Child Pugh C) hepatic impairment (see sections&nbsp;4.2 and 4.4), or in patients screened positive for hepatitis B or C.</p><p><strong><u>&nbsp;</u></strong></p><p><u>Interactions</u></p><p><u>&nbsp;</u></p><p>Tofacitinib is not an inhibitor or inducer of CYPs (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and is not an inhibitor of UGTs (UGT1A1, UGT1A4, UGT1A6, UGT1A9, and UGT2B7). Tofacitinib is not an inhibitor of MDR1, OATP1B1/1B3, OCT2, OAT1/3, or MRP at clinically meaningful concentrations.</p><p>&nbsp;</p><p><u>Comparison of PK of prolonged-release and film-coated tablet formulations</u></p><p>&nbsp;</p><p>Tofacitinib 11&nbsp;mg prolonged‑release tablets once daily have demonstrated PK equivalence (AUC and C<sub>max</sub>) to tofacitinib 5&nbsp;mg film‑coated tablets twice daily.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p><em>Pharmacokinetics in paediatric patients with juvenile idiopathic arthritis</em></p><p>Population PK analysis based on results from both tofacitinib 5 mg film-coated tablets twice daily and tofacitinib oral solution weight-based equivalent twice daily indicated that tofacitinib clearance and volume of distribution both decreased with decreasing body weight in JIA patients. The available data indicated that there were no clinically relevant differences in tofacitinib exposure (AUC), based on age, race, gender, patient type or baseline disease severity. The between-subject variability (%&nbsp;coefficient of variation) in (AUC) was estimated to be approximately 24%.</p><p><strong><u>&nbsp;</u></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In non-clinical studies, effects were observed on the immune and haematopoietic systems that were attributed to the pharmacological properties (JAK inhibition) of tofacitinib. Secondary effects from immunosuppression, such as bacterial and viral infections and lymphoma were observed at clinically relevant doses. Lymphoma was observed in 3 of 8&nbsp;adult monkeys at 6&nbsp;or 3 times the clinical tofacitinib exposure level (unbound AUC in humans at a dose of 5&nbsp;mg or 10&nbsp;mg twice daily), and 0 of 14&nbsp;juvenile monkeys at 5 or 2.5 times the clinical exposure level of 5&nbsp;mg or 10&nbsp;mg twice daily. Exposure in monkeys at the no observed adverse effect level (NOAEL) for the lymphomas was approximately 1 or 0.5 times the clinical exposure level of 5&nbsp;mg or 10&nbsp;mg twice daily. Other findings at doses exceeding human exposures included effects on the hepatic and gastrointestinal systems.</p><p><em>&nbsp;</em></p><p>Tofacitinib is not mutagenic or genotoxic based on the results of a series of <em>in vitro</em> and <em>in vivo</em> tests for gene mutations and chromosomal aberrations.</p><p>&nbsp;</p><p>The carcinogenic potential of tofacitinib was assessed in 6-month rasH2 transgenic mouse carcinogenicity and 2-year rat carcinogenicity studies. Tofacitinib was not carcinogenic in mice at exposures up to 38 or 19&nbsp;times the clinical exposure level at 5&nbsp;mg or 10&nbsp;mg twice daily. Benign testicular interstitial (Leydig) cell tumours were observed in rats: benign Leydig cell tumours in rats are not associated with a risk of Leydig cell tumours in humans. Hibernomas (malignancy of brown adipose tissue) were observed in female rats at exposures greater than or equal to 83 or 41&nbsp;times the clinical exposure level at 5&nbsp;mg or 10&nbsp;mg twice daily. Benign thymomas were observed in female rats at 187 or 94 times the clinical exposure level at 5&nbsp;mg or 10&nbsp;mg twice daily.</p><p><em>&nbsp;</em></p><p>Tofacitinib was shown to be teratogenic in rats and rabbits, and have effects in rats on female fertility (decreased pregnancy rate; decreases in the numbers of corpora lutea, implantation sites, and viable foetuses; and an increase in early resorptions), parturition, and peri/postnatal development. Tofacitinib had no effects on male fertility, sperm motility or sperm concentration. Tofacitinib was secreted in milk of lactating rats at concentrations approximately 2-fold those in serum from 1 to 8&nbsp;hours postdose.</p><p>&nbsp;</p><p>No tofacitinib-related findings were observed in juvenile animal studies that indicate a higher sensitivity of paediatric populations compared with adults. In the juvenile rat fertility study, there was no evidence of developmental toxicity, no effects on sexual maturation, and no evidence of reproductive toxicity (mating and fertility) was noted after sexual maturity. In 1-month juvenile rat and 39-week juvenile monkey studies tofacitinib-related effects on immune and haematology parameters consistent with JAK1/3 and JAK2 inhibition were observed. These effects were reversible and consistent with those also observed in adult animals at similar exposures.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>&nbsp;</p><p>microcrystalline cellulose</p><p>lactose monohydrate</p><p>croscarmellose sodium</p><p>magnesium stearate</p><p>&nbsp;</p><p><u>Film coat</u></p><p>&nbsp;</p><p>hypromellose 6cP (E464)</p><p>titanium dioxide (E171)</p><p>lactose monohydrate</p><p>macrogol 3350</p><p>triacetin</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life: 4 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>XELJANZ 5&nbsp;mg film‑coated tablets</u></p><p>&nbsp;</p><p>HDPE bottles with silica gel desiccant and child-resistant polypropylene closure containing 60 film-coated tablets.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Pfizer Inc. USA

Manufactured by:
Pfizer Manufacturing Deutschland GmbH 
(Betriebsstätte Freiburg)
Freiburg, Germany.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                March 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>